APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 11
November 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 11

November 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 11
November 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
JOHNSON AND JOHNSON PHARMACEUTICAL (JOHNSON AND JOHNSON)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
MCNEIL PEDIATRICS (MCNEIL PED)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO BIOTECH PRODUCTS LP (ORTHO BIOTECH)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC (ORTHO MCNEIL JANSSEN)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC (ORTHO MCNEIL JANSSEN)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
PADDOCK LABORATORIES INC (PADDOCK LABS)	PADDOCK LABORATORIES LLC (PADDOCK LLC)
SHIONOGI PHARMA INC (SHIONOGI PHARMA)	SHIONOGI INC (SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001

LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838	14029	14309	14271	
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)	2452 (17.2%)	
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)	11743 (82.3%)	
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)	11573 (81.1%)	
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)	170 (1.2%)	
EXCEPTIONS[1]	89 (0.6%)	89 (0.6%)	89 (0.6%)	76 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	8	6	8	6	
NUMBER OF APPLICANTS	752	768	784	801	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The

application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL
ZYTIGA

+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr	NEWA
+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Aug	CAHN

ACARBOSE

TABLET; ORAL
ACARBOSE

AB	STRIDES ARCOLAB LTD	25MG	A090912	001	Jul 27, 2011	Jul	NEWA
AB		50MG	A090912	002	Jul 27, 2011	Jul	NEWA
AB		100MG	A090912	003	Jul 27, 2011	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN

	NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Aug	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB	+ WATSON LABS INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Oct	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN

TABLET; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	@ WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC
AA	VINTAGE PHARMS	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011	Oct	NEWA

SUSPENSION; ORAL
CAPITAL AND CODEINE

	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ WATSON LABS	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
	@	300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
	@	300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
	@ WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003	Jul	DISC
	@	300MG;30MG	A040443	002	Jan 22, 2003	Jul	DISC
	@	300MG;60MG	A040443	003	Jan 22, 2003	Jul	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		BOCA PHARMA	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Jul	NEWA
>D>	AA		KV PHARM	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Nov	CAHN
>D>		+	MALLINCKRODT	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003	Nov	DISC
>A>		@	MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003	Nov	DISC
	AA	+	MIKART	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Jul	CTEC
>A>	AA		NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Nov	CAHN

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
	AB			300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
	AA			300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
	AB			300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
	AA			300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
	AB			300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
	AA	+	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
	AA			300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
	AA	+		300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
	AA	+		300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC
		@	RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007	May	DISC
		@		500MG;10MG	A040824	001	Aug 16, 2007	May	DISC
		@	RANBAXY LABS LTD	325MG;10MG	A040826	001	Aug 16, 2007	May	DISC
		@		750MG;7.5MG	A040822	001	Aug 16, 2007	May	DISC
>D>	AA		WATSON LABS	325MG;10MG	A040248	002	Apr 28, 2000	Nov	DISC
>A>		@		325MG;10MG	A040248	002	Apr 28, 2000	Nov	DISC
		@		500MG;2.5MG	A040123	003	Mar 04, 1996	Aug	DISC
		@		500MG;7.5MG	A040123	004	Mar 04, 1996	Aug	DISC
		@		650MG;7.5MG	A040123	001	Mar 04, 1996	Aug	DISC
		@		650MG;10MG	A040123	002	Mar 04, 1996	Aug	DISC
		@	WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003	Jul	DISC
		@		750MG;7.5MG	A040494	001	May 28, 2003	Jul	DISC

LORTAB

	AA		UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

		@	ACTAVIS TOTOWA	500MG;5MG	A040199	001	Dec 30, 1998	Jul	DISC

SOLUTION; ORAL
OXYCODONE AND ACETAMINOPHEN

>D>									
>D>	AA		MALLINCKRODT	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Nov	DISC
>A>		@	MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Nov	DISC

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

		@	ACTAVIS TOTOWA	325MG;5MG	A040203	001	Mar 15, 1999	Jul	DISC

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

		@	MYLAN	650MG;65MG	A083978	001		Aug	DISC
		@	VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

	@ XANODYNE PHARM	650MG;100MG	N017122	002			Jan	DISC

DARVOCET-N 50

	@ XANODYNE PHARM	325MG;50MG	N017122	001			Jan	DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004		Mar	DISC
	@	500MG;100MG	A076750	001	Jun 28, 2004		Mar	DISC
	@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008		Apr	DISC
AB		650MG;100MG	A077821	001	Feb 11, 2008		Mar	CAHN
+	MYLAN	650MG;100MG	A070145	001	Jun 12, 1985		Aug	CRLD
	@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994		Mar	DISC
	@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001		Mar	DISC
	@	650MG;100MG	A074843	001	Feb 12, 1997		Mar	DISC
	@ WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007		Aug	DISC
	@	650MG;100MG	A077677	002	Mar 16, 2007		Aug	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011		Oct	CAHN
AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011		Jul	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

	@ ACTAVIS MID ATLANTIC	2%	A087146	001			Aug	DISC

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993		Jun	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997		Aug	DISC
AB	MYLAN	200MG	A074977	001	Apr 13, 1998		Feb	CAHN

CREAM; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N021478	001	Dec 30, 2002		Jul	CAHN

OINTMENT; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N018604	001	Mar 29, 1982		Jul	CAHN

TABLET; ORAL

ACYCLOVIR

	@ ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997		Aug	DISC
	@	800MG	A074870	002	Jun 05, 1997		Aug	DISC
AB	MYLAN	400MG	A074976	001	Apr 13, 1998		Feb	CAHN
AB		800MG	A074976	002	Apr 13, 1998		Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

		ACYCLOVIR SODIUM							
AP	+	APP PHARMS	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Aug	CRLD
	@	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997	Aug	DISC
	@		EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
		ZOVIRAX						
	@	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N018603	001	Oct 22, 1982	Aug	DISC
	@		EQ 1GM BASE/VIAL	N018603	002	Jun 29, 1989	Aug	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

	XERESE							
+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May	CTNA
+	VALEANT INTL	5%;1%	N022436	001	Jul 31, 2009	Aug	CAHN

ADENOSINE

INJECTABLE; INJECTION

	ADENOSINE							
@	BAXTER HLTHCARE	3MG/ML	A076501	001	Jun 16, 2004	Sep	DISC

ALBENDAZOLE

TABLET; ORAL

	ALBENZA							
+	COREPHARMA	200MG	N020666	001	Jun 11, 1996	Jun	CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE							
@	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995	Aug	DISC
AN	RITEDOSE CORP	EQ 0.083% BASE	A077839	001	Dec 16, 2008	Jul	CAHN
AN	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Aug	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SPRAY, METERED; INHALATION

	COMBIVENT RESPIMAT							
+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011	Oct	NEWA

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

	LASTACAFT							
+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

		ACLOVATE							
>A>	AB	+	FOUGERA PHARMS	0.05%	N018702	001	Dec 14, 1982	Nov	CAHN
>D>	AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Nov	CAHN
	AB	+		0.05%	N018702	001	Dec 14, 1982	Mar	CAHN

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

	ALCOHOL 5% IN D5-W							
@	HOSPIRA	5ML/100ML;5GM/100ML	A083263	001		Aug	DISC

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@ SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	10MG	A079013	001	Jul 18, 2011	Jul	NEWA
AB	MYLAN	10MG	A079014	001	Jul 18, 2011	Jul	NEWA
AB	SUN PHARMA GLOBAL	10MG	A079057	001	Jul 18, 2011	Jul	NEWA
AB	TEVA PHARMS	10MG	A079056	001	Jul 18, 2011	Jul	NEWA
AB	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011	Jul	NEWA

UROXATRAL

AB	+ SANOFI AVENTIS US	10MG	N021287	001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM

AP	+ MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Jul	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Sep	NEWA
AB		1MG	A078469	002	Sep 29, 2011	Sep	NEWA
AB		2MG	A078469	003	Sep 29, 2011	Sep	NEWA
AB		3MG	A078469	004	Sep 29, 2011	Sep	NEWA
AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May	NEWA
AB		1MG	A090871	002	Jun 07, 2011	May	NEWA
AB		2MG	A090871	003	Jun 07, 2011	May	NEWA
AB		3MG	A090871	004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL
MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	May	CAHN
		0.25MG	N020700	002	Nov 19, 1996	May	CAHN
		0.5MG	N020700	003	Nov 19, 1996	May	CAHN
	+	1MG	N020700	004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

@ ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006	Jul	DISC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997	Aug	DISC

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 11.4%

@ HOSPIRA	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982	Aug	DISC

NOVAMINE 15%

@ HOSPIRA	15% (15GM/100ML)	N017957	004	Nov 28, 1986	Aug	DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988	Aug	DISC

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988	Aug	DISC

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988	Aug	DISC

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988	Aug	DISC

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988	Aug	DISC

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988	Aug	DISC

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988	Aug	DISC

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988	Aug	DISC

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988	Aug	DISC

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988	Aug	DISC

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988	Aug	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

NEXTERONE

AP	BAXTER HLTHCARE	50MG/ML	N022325	001	Dec 24, 2008	Oct	CAHN
+		150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010	Oct	CAHN
+		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010	Oct	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN
	@ GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007	Jul	DISC
	@	EQ 5MG BASE	A077333	002	Jul 17, 2007	Jul	DISC
	@	EQ 10MG BASE	A077333	003	Jul 17, 2007	Jul	DISC
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771	002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771	003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131	002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131	003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752	001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011	Jun	NEWA
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	Jun	NEWA
AB	MYLAN	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Jun	NEWA
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun	NEWA
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011	Jun	NEWA

LOTREL

AB	NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG
AB +		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR
AB		500MG	A062058	002		Feb	CDFR

FOR SUSPENSION; ORAL

AMOXIL

AB	DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Sep	CMFD
AB		400MG/5ML	N050760	002	Apr 15, 1999	Sep	CMFD

TABLET; ORAL

AMOXIL

AB	DR REDDYS LABS INC	500MG	N050754	002	Jul 10, 1998	Sep	CMFD
AB		875MG	N050754	001	Jul 10, 1998	Sep	CMFD

TABLET, CHEWABLE; ORAL
AMOXIL

AB	DR REDDYS LABS INC	125MG	N050542	002		Sep	CMFD
AB		200MG	N050761	001	Apr 15, 1999	Sep	CMFD
AB		250MG	N050542	001		Sep	CMFD
AB		400MG	N050761	002	Apr 15, 1999	Sep	CMFD

TABLET, EXTENDED RELEASE; ORAL
MOXATAG

+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008	Aug	CAHN

TABLET, FOR SUSPENSION; ORAL
DISPERMOX

@	RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003	Aug	DISC
@		400MG	A065080	001	Aug 11, 2003	Aug	DISC

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Sep	CAHN

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Sep	CMFD

AUGMENTIN '250'

AB	+	DR REDDYS LABS INC	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	Sep	CAHN

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Sep	CMFD

AUGMENTIN ES-600

AB	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Sep	CMFD

TABLET; ORAL
AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Sep	CAHN

AUGMENTIN '500'

AB	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Sep	CAHN

AUGMENTIN '875'

AB	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Sep	CAHN

TABLET, CHEWABLE; ORAL
AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Sep	CMFD

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Sep	CMFD

AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Sep	CMFD

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Sep	CMFD

TABLET, EXTENDED RELEASE; ORAL
AUGMENTIN XR

AB	+	DR REDDYS LABS INC	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Sep	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Sep	DISC

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@	MALLINCKRODT INC	1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Sep	DISC
	@		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Sep	DISC
	@		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Sep	DISC
	@		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Sep	DISC
	@		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Sep	DISC
	@		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Sep	DISC

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	+	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD

FUNGIZONE

	@	APOTHECON	50MG/VIAL	A060517	001		Jun	DISC

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

	+	ALDOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Jul	CAHN
	+		100MG/VIAL	N050729	002	Nov 22, 1996	Jul	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

		DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul	CTEC

PRINCIPEN

	@	APOTHECON	EQ 125MG BASE/5ML	A061394	002		Jul	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN
AB		SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Jul	NEWA
	@	SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010	Jul	DISC

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

>D>	@	IPSEN BIOPHARM LTD	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004	Nov	CAHN
>D>	+		30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Nov	CAHN
>A>	@	US WORLDMEDS	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004	Nov	CAHN
>A>	+		30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Nov	CAHN

ARGATROBAN

INJECTABLE; IV (INFUSION)
ARGATROBAN IN SODIUM CHLORIDE

	+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Jun	NEWA
	+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)
ARGATROBAN IN DEXTROSE

	@	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	May	DISC

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS

>D>	+	MERCK SHARP DOHME	EQ 10MG BASE	N022117	002	Aug 13, 2009	Nov	CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN
>A>	+	ORGANON USA INC	EQ 10MG BASE	N022117	002	Aug 13, 2009	Nov	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
FIORINAL

AA	+	WATSON LABS INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Oct	CAHN

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	@	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983	Aug	DISC
	@	PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983	Jun	CAHN

FIORINAL

	@	WATSON LABS INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Oct	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORINAL W/CODEINE

AB	+	WATSON LABS INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Oct	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

AB		MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA		COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA
AA		WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126	001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	10MG	A078940	001	Aug 30, 2010	Aug	DISC
	@	18MG	A078940	002	Aug 30, 2010	Aug	DISC
	@	25MG	A078940	003	Aug 30, 2010	Aug	DISC
	@	40MG	A078940	004	Aug 30, 2010	Aug	DISC
	@	60MG	A078940	005	Aug 30, 2010	Aug	DISC
	@	80MG	A078940	006	Aug 30, 2010	Aug	DISC
	@	100MG	A078940	007	Aug 30, 2010	Aug	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>A>								
>A>	AB	RANBAXY LABS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Nov	NEWA
>A>	AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Nov	NEWA
>A>	AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Nov	NEWA
>A>	AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Nov	NEWA

LIPITOR

>D>		PFIZER	EQ 10MG BASE	N020702	001	Dec 17, 1996	Nov	CFTG
>A>	AB		EQ 10MG BASE	N020702	001	Dec 17, 1996	Nov	CFTG
>D>			EQ 20MG BASE	N020702	002	Dec 17, 1996	Nov	CFTG
>A>	AB		EQ 20MG BASE	N020702	002	Dec 17, 1996	Nov	CFTG
>D>			EQ 40MG BASE	N020702	003	Dec 17, 1996	Nov	CFTG
>A>	AB		EQ 40MG BASE	N020702	003	Dec 17, 1996	Nov	CFTG
>D>		+	EQ 80MG BASE	N020702	004	Apr 07, 2000	Nov	CFTG
>A>	AB	+	EQ 80MG BASE	N020702	004	Apr 07, 2000	Nov	CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

ATROPINE

INJECTABLE; INJECTION

ATROPINE

	@ SOLVAY	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Jul	CAHN

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

	@ MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Oct	DISC
	+	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Oct	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

@	MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Aug	DISC

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

AB	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Jul	NEWA
AB		EQ 500MG BASE	A065509	001	Jul 13, 2011	Jul	NEWA
AB		EQ 600MG BASE	A065508	001	Jul 13, 2011	Jul	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
AP		2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
+	NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC

INJECTABLE; INTRATHECAL

GABLOFEN

AP		CNS THERAPS INC	0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB		PRINSTON INC	5MG	A076118	001	Feb 11, 2004	Aug	CAHN
AB			10MG	A076118	002	Feb 11, 2004	Aug	CAHN
AB			20MG	A076118	003	Feb 11, 2004	Aug	CAHN
AB			40MG	A076118	004	Feb 11, 2004	Aug	CAHN
AB		PRINSTON PHARM LLC	5MG	A076118	001	Feb 11, 2004	May	CAHN
AB			10MG	A076118	002	Feb 11, 2004	May	CAHN
AB			20MG	A076118	003	Feb 11, 2004	May	CAHN
AB			40MG	A076118	004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>D>	AA	KV PHARM	100MG	A040795	001	Oct 31, 2007	Nov	CAHN
>D>	AA		200MG	A040795	002	Oct 31, 2007	Nov	CAHN
>A>	AA	NESHER PHARMS	100MG	A040795	001	Oct 31, 2007	Nov	CAHN
>A>	AA		200MG	A040795	002	Oct 31, 2007	Nov	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

	@	ACTAVIS TOTOWA	0.5MG	A040699	001	Feb 14, 2008	Jul	DISC
	@		1MG	A040705	001	Feb 14, 2008	Jul	DISC
	@		2MG	A040706	001	Feb 14, 2008	Jul	DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB		STI PHARMA LLC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Apr	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

	@ ACTAVIS TOTOWA	5MG	A040552	001	Oct 28, 2004	Jul	DISC
	@	10MG	A040553	001	Oct 28, 2004	Jul	DISC
	@	25MG	A040554	001	Oct 28, 2004	Jul	DISC

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

AB	ROXANE	50MG	A078285	001	Mar 24, 2011	Mar	NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL
PYLERA

+	APTALIS PHARMA US	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Oct	CAHN
+	AXCAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jun	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672	001	Sep 25, 2000	Oct	DISC
	@	5MG;6.25MG	A075672	002	Sep 25, 2000	Oct	DISC
	@	10MG;6.25MG	A075672	003	Sep 25, 2000	Oct	DISC

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

+	SCHERING	200MG	N202258	001	May 13, 2011	May	NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

	@ HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986	Jun	DISC

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	200MG/100ML	N019121	002	Apr 29, 1986	Aug	CTEC
+		400MG/100ML	N019121	003	Apr 29, 1986	Aug	CTEC
	@ HOSPIRA	200MG/100ML	N019008	002	Apr 29, 1986	Aug	DISC
	@	400MG/100ML	N019008	003	Apr 29, 1986	Aug	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

>D>	AT	TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004	Nov	DISC
>A>		@	0.2%	A076372	001	Sep 10, 2004	Nov	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMDAY

+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD

BROMFENAC SODIUM

	COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA

XIBROM

	@ ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB		MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA

ENTOCORT EC

AB	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Oct	NEWA
	+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		SAGENT STRIDES	0.25%	A091503	001	Oct 18, 2011	Oct	NEWA
AP			0.5%	A091503	002	Oct 18, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		SAGENT STRIDES	0.25%	A091487	002	Oct 18, 2011	Oct	NEWA
AP			0.5%	A091487	001	Oct 18, 2011	Oct	NEWA
AP			0.75%	A091487	003	Oct 18, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

	@	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

		VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
	+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
			522MG	N022108	003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA
AB1			150MG	A091459	002	Jun 09, 2011	May	NEWA
AB2			150MG	A091520	001	Jun 09, 2011	May	NEWA
AB1			200MG	A091459	003	Jun 09, 2011	May	NEWA
AB1		WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN
AB2			150MG	A079094	001	Mar 24, 2009	May	CAHN
AB1			150MG	A079095	002	Mar 24, 2009	May	CAHN
AB1			200MG	A079095	003	Mar 24, 2009	May	CAHN

FORFIVO XL

>A>								
>A>	+	INTELGENX CORP	450MG	N022497	001	Nov 10, 2011	Nov	NEWA

WELLBUTRIN XL

AB3	+	VALEANT INTL	150MG	N021515	001	Aug 28, 2003	Jul	CAHN
AB3			300MG	N021515	002	Aug 28, 2003	Jul	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

			@ BRISTOL MYERS SQUIBB	5MG	N018731	001	Sep 29, 1986	Aug	DISC

BUSPIRONE HYDROCHLORIDE

			@ ACTAVIS TOTOWA	5MG	A075388	001	May 09, 2002	Jul	DISC
			@	10MG	A075388	002	May 09, 2002	Jul	DISC
			@	15MG	A075388	003	May 09, 2002	Jul	DISC
			@	30MG	A078302	001	Dec 17, 2007	Jul	DISC
>D>	AB		IVAX SUB TEVA PHARMS	5MG	A075385	001	Mar 01, 2002	Nov	DISC
>A>			@	5MG	A075385	001	Mar 01, 2002	Nov	DISC
>D>	AB			10MG	A075385	002	Mar 01, 2002	Nov	DISC
>A>			@	10MG	A075385	002	Mar 01, 2002	Nov	DISC
>D>	AB	+		15MG	A075385	003	Mar 01, 2002	Nov	DISC
>A>			@	15MG	A075385	003	Mar 01, 2002	Nov	DISC
>D>	AB		KV PHARM	5MG	A075572	001	Feb 27, 2002	Nov	CAHN
>D>	AB			10MG	A075572	002	Feb 27, 2002	Nov	CAHN
>D>	AB			15MG	A075572	003	Feb 27, 2002	Nov	CAHN
>A>	AB		NESHER PHARMS	5MG	A075572	001	Feb 27, 2002	Nov	CAHN
>A>	AB			10MG	A075572	002	Feb 27, 2002	Nov	CAHN
>A>	AB			15MG	A075572	003	Feb 27, 2002	Nov	CAHN
>D>	AB		TEVA	15MG	A075022	003	Feb 28, 2002	Nov	CRLD
>A>	AB	+		15MG	A075022	003	Feb 28, 2002	Nov	CRLD

BUSULFAN

TABLET; ORAL

MYLERAN

		+	ASPEN GLOBAL	2MG	N009386	001		Oct	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

	AT		G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

		+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CALCIUM ACETATE

	AB		PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA

ELIPHOS

	AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	AB		PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Aug	CAHN
	AB			25MG	A074477	002	Feb 13, 1996	Aug	CAHN
	AB			50MG	A074477	003	Feb 13, 1996	Aug	CAHN
	AB			100MG	A074477	004	Feb 13, 1996	Aug	CAHN
	AB		PRINSTON PHARM LLC	12.5MG	A074477	001	Feb 13, 1996	May	CAHN
	AB			25MG	A074477	002	Feb 13, 1996	May	CAHN
	AB			50MG	A074477	003	Feb 13, 1996	May	CAHN
	AB			100MG	A074477	004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	APOTEX INC	100MG	A078986	001	Nov 25, 2011	Nov	NEWA
>A>	AB		200MG	A078986	002	Nov 25, 2011	Nov	NEWA
>A>	AB		300MG	A078986	003	Nov 25, 2011	Nov	NEWA
	AB	NOSTRUM	100MG	A076697	001	May 20, 2011	May	NEWA
	AB		200MG	A076697	002	May 20, 2011	May	NEWA
	AB		300MG	A076697	003	May 20, 2011	May	NEWA

CARBATROL

	AB	SHIRE	100MG	N020712	003	Sep 30, 1997	May	CFTG
	AB		200MG	N020712	001	Sep 30, 1997	May	CFTG
	AB	+	300MG	N020712	002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

		@ JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

	AB	MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
	AB		25MG;100MG	N017555	003		Jan	CAHN
	AB	+	25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

	AB	MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
	AB	+	50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

	AA	RIVERS EDGE PHARMS	4MG	A090756	001	May 27, 2011	May	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

	AP	ONCO THERAPIES LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	Oct	NEWA
	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	Oct	NEWA
	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	Oct	NEWA
	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	Oct	NEWA
>A>		+	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Nov	NEWA
		@ SAGENT PHARMS	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Sep	CAHN
		@	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Sep	CAHN
		@	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Sep	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	AA	MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
	AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

		@ FACTA FARMA	EQ 125MG BASE/5ML	A062206	001		Aug	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

	@ FACTA FARMA	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988	Aug	CAHN
	@	EQ 250MG BASE/5ML	A062206	002		Aug	CAHN
	@	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL
CEFACLOR

+	TEVA	EQ 500MG BASE	A065058	002	Sep 04, 2002	Jul	CRLD
	@ WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN
AP	STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991	Jul	CMFD
AP		EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

MAXIPIME

AP	+ HOSPIRA INC	EQ 500MG BASE/VIAL	N050679	001	Jan 18, 1996	Aug	CAHN
AP	+	EQ 1GM BASE/VIAL	N050679	002	Jan 18, 1996	Aug	CAHN
AP	+	EQ 2GM BASE/VIAL	N050679	003	Jan 18, 1996	Aug	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTETAN

AP	+ APP PHARMS	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Oct	CTEC
AP	+	EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Oct	CTEC
AP	+	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007	Oct	CTEC
AP	WEST-WARD PHARM CORP	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011	Oct	NEWA
AP		EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011	Oct	NEWA
AP		EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011	Oct	NEWA

CEFOXITIN

INJECTABLE; INJECTION
CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	Aug	NEWA

	INJECTABLE; INJECTION							
	CEFOXITIN							
AP	ANTIBIOTICOS BRASIL	EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	Aug	NEWA	

CEFOXITIN SODIUM

	INJECTABLE; INJECTION							
	CEFOXITIN							
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN	
AP		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN	
AP		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN	
	MEFOXIN							
	@ MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517	001		Aug	CAHN	
	@	EQ 2GM BASE/VIAL	N050517	002		Aug	CAHN	
	@	EQ 10GM BASE/VIAL	N050517	003		Aug	CAHN	

CEFPODOXIME PROXETIL

	TABLET; ORAL							
	CEFPODOXIME PROXETIL							
AB	+ SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD	
	VANTIN							
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC	
	@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC	

CEFTAZIDIME

	INJECTABLE; INJECTION							
	CEFTAZIDIME IN DEXTROSE CONTAINER							
	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jun	NEWA	
	+	EQ 2GM BASE	N050823	002	Jun 13, 2011	Jun	NEWA	

CEFTRIAXONE SODIUM

	INJECTABLE; IM-IV							
	CEFTRIAXONE							
AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN	
AP		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN	
AP		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN	
AP		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN	
	INJECTABLE; INJECTION							
	CEFTRIAXONE							
AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Jan	CAHN	
AP		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Jan	CAHN	
AP		EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	CAHN	
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168	001	May 17, 2005	Jan	CRLD	

CEFUROXIME AXETIL

	TABLET; ORAL							
	CEFUROXIME AXETIL							
AB	ALKEM LABS LTD	EQ 250MG BASE	A065496	001	Jun 07, 2010	May	CAHN	
AB		EQ 500MG BASE	A065496	002	Jun 07, 2010	May	CAHN	
AB	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Jun	CAHN	
AB		EQ 500MG BASE	A065069	002	Oct 02, 2002	Jun	CAHN	

CEFUROXIME SODIUM

	INJECTABLE; IM-IV							
	CEFUROXIME SODIUM							
AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC	
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Jan	CAHN	

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	FACTA FARMA	EQ 250MG BASE	A062118	001		Aug	CAHN
AB		EQ 500MG BASE	A062118	002		Aug	CAHN

KEFLEX

AB	SHIONOGI INC	EQ 250MG BASE	N050405	002		Aug	CAHN
	@	EQ 333MG BASE	N050405	004	May 12, 2006	Aug	CAHN
AB		EQ 500MG BASE	N050405	003		Aug	CAHN
	+	EQ 750MG BASE	N050405	005	May 12, 2006	Aug	CAHN

FOR SUSPENSION; ORAL
CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117	001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117	002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117	003		Jan	CAHN
	@ FACTA FARMA	EQ 100MG BASE/ML	A062117	001		Aug	CAHN
AB		EQ 125MG BASE/5ML	A062117	002		Aug	CAHN
AB	+	EQ 250MG BASE/5ML	A062117	003		Aug	CAHN

TABLET, FOR SUSPENSION; ORAL
PANIXINE DISPERDOSE

	@ RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003	Aug	DISC
	@	EQ 250MG BASE	A065100	001	Sep 11, 2003	Aug	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Aug	DISC
AA	PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008	Aug	CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
CEVIMELINE

AB	APOTEX INC	30MG	A091260	001	Aug 25, 2011	Aug	NEWA

EVOXAC

AB	+ DAIICHI SANKYO CO	30MG	N020989	002	Jan 11, 2000	Aug	CFTG

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291	001	Dec 28, 1995	Feb	CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612	001	Jan 21, 2011	Jan	NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
CHLOROTHIAZIDE SODIUM

AP		SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jul	NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
ZUTRIPRO

	+	CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439	001	Jun 08, 2011	Jun	NEWA

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

	@	ACTAVIS TOTOWA	250MG	A088928	001	May 08, 1987	Jul	DISC
	@		500MG	A040113	001	Sep 29, 1995	Jul	DISC
	@	OHM LABS	250MG	A081298	001	Dec 29, 1993	Aug	DISC
	@		500MG	A081299	001	Dec 29, 1993	Aug	DISC

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD

CHOLESTYRAMINE LIGHT

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD

QUESTRAN

	@	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
	@		EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC

QUESTRAN LIGHT

	@	BRISTOL MYERS	EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
	@		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX

AT		TARO	1%	A090269	001	Feb 23, 2011	Feb	NEWA

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
IMIPENEM AND CILASTATIN

>A>								
>A>	AP	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825	001	Nov 16, 2011	Nov	NEWA
>A>	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A091007	001	Nov 16, 2011	Nov	NEWA
>A>	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A090825	002	Nov 16, 2011	Nov	NEWA

PRIMAXIN

>D>	+	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	N050587	001	Nov 26, 1985	Nov	CFTG
>A>	AP +		EQ 250MG BASE/VIAL;250MG/VIAL	N050587	001	Nov 26, 1985	Nov	CFTG
>D>	+		EQ 500MG BASE/VIAL;500MG/VIAL	N050587	002	Nov 26, 1985	Nov	CFTG
>A>	AP +		EQ 500MG BASE/VIAL;500MG/VIAL	N050587	002	Nov 26, 1985	Nov	CFTG

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

	@	ACTAVIS TOTOWA	100MG	A077028	002	Nov 26, 2004	Jul	DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994	Aug	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008	Aug	DISC
@		400MG/200ML	A077138	002	Mar 18, 2008	Aug	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROQUIN XR

@	DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005	May	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE

AB	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Jun	CMFD
AB		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION
PLATINOL

@	BRISTOL MYERS	50MG/VIAL	N018057	002		Jun	DISC
@	CORDEN PHARMA	10MG/VIAL	N018057	001		Oct	CAHN
@		50MG/VIAL	N018057	002		Oct	CAHN

PLATINOL-AQ

@	CORDEN PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Oct	CAHN
@		1MG/ML	N018057	004	Nov 08, 1988	Oct	CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042	001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042	002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042	003	Nov 05, 2004	Apr	CAHN

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE

AP	ONCO THERAPIES LTD	1MG/ML	A200510	001	Oct 06, 2011	Sep	NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

@	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993	Aug	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 75MG BASE	A091225	001	May 31, 2011	May	NEWA
AB		EQ 150MG BASE	A091225	002	May 31, 2011	May	NEWA
AB		EQ 300MG BASE	A091225	003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

	GEL; TOPICAL							
	CLINDAGEL							
BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000	Mar		CRLD
	INJECTABLE; INJECTION							
	CLINDAMYCIN PHOSPHATE							
AP	SAGENT STRIDES	EQ 150MG BASE/ML	A090108	001	Sep 30, 2011	Sep		NEWA
AP		EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Sep		NEWA
	SOLUTION; TOPICAL							
	CLINDAMYCIN PHOSPHATE							
	@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Aug		DISC
	@ COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr		CAHN

CLOBAZAM

	TABLET; ORAL							
	ONFI							
	LUNDBECK INC	5MG	N202067	001	Oct 21, 2011	Oct		NEWA
		10MG	N202067	002	Oct 21, 2011	Oct		NEWA
	+	20MG	N202067	003	Oct 21, 2011	Oct		NEWA

CLOBETASOL PROPIONATE

	AEROSOL, FOAM; TOPICAL							
	OLUX							
AB	+ STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	May		CAHN
	CREAM; TOPICAL							
	CLOBETASOL PROPIONATE							
	@ ACTAVIS MID ATLANTIC	0.05%	A074139	001	Aug 03, 1994	Aug		DISC
	@ COREPHARMA	0.05%	A075338	001	Feb 09, 2001	Apr		CAHN
	CLOBETASOL PROPIONATE (EMOLLIENT)							
	@ COREPHARMA	0.05%	A075733	001	Aug 22, 2001	Apr		CAHN
	TEMOVATE							
AB1	+ NYCOMED US	0.05%	N019322	001	Dec 27, 1985	Aug		CAHN
	GEL; TOPICAL							
	TEMOVATE							
AB	+ NYCOMED US	0.05%	N020337	001	Apr 29, 1994	Aug		CAHN
	OINTMENT; TOPICAL							
	CLOBETASOL PROPIONATE							
	@ ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994	Aug		DISC
	@ COREPHARMA	0.05%	A075057	001	Aug 12, 1998	Apr		CAHN
	TEMOVATE							
AB	+ NYCOMED US	0.05%	N019323	001	Dec 27, 1985	Aug		CAHN
	SHAMPOO; TOPICAL							
	CLOBETASOL PROPIONATE							
AB	ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011	May		NEWA
	CLOBEX							
AB	+ GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004	May		CFTG
	SOLUTION; TOPICAL							
	CLOBETASOL PROPIONATE							
	@ ACTAVIS MID ATLANTIC	0.05%	A074331	001	Dec 15, 1995	Aug		DISC
AT	NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr		CAHN
	TEMOVATE							
AT	+ NYCOMED US	0.05%	N019966	001	Feb 22, 1990	Aug		CAHN
	SPRAY; TOPICAL							
	CLOBETASOL PROPIONATE							
AT	PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May		NEWA

		SPRAY; TOPICAL							
		CLOBEX							
	AT	+ GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC	
		+	0.05%	N021835	001	Oct 27, 2005	May	CFTG	
		CLOCORTOLONE PIVALATE							
		CREAM; TOPICAL							
		CLODERM							
		+ PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN	
		CLOMIPRAMINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		ANAFRANIL							
	AB	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Aug	CAHN	
	AB	+	50MG	N019906	002	Dec 29, 1989	Aug	CAHN	
	AB		75MG	N019906	003	Dec 29, 1989	Aug	CAHN	
		CLONIDINE							
		SUSPENSION, EXTENDED RELEASE; ORAL							
		CLONIDINE							
		@ TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009	Sep	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
		CLONIDINE							
		@ TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Sep	DISC	
		@	EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Sep	DISC	
		CLONIDINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		CLONIDINE HYDROCHLORIDE							
	AP	APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA	
	AP		5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA	
	AP	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jul	CAHN	
	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jul	CAHN	
	AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA	
	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA	
		TABLET; ORAL							
		CLONIDINE HYDROCHLORIDE							
>A>	AB	ALEMBIC PHARMS LTD	0.1MG	A091368	001	Dec 06, 2011	Nov	NEWA	
>A>	AB		0.2MG	A091368	002	Dec 06, 2011	Nov	NEWA	
>A>	AB		0.3MG	A091368	003	Dec 06, 2011	Nov	NEWA	
		TABLET, EXTENDED RELEASE; ORAL							
>D>		JENLOGA							
>D>		SHIONOGI INC	0.1MG	N022331	001	Sep 30, 2009	Nov	DISC	
>A>		@	0.1MG	N022331	001	Sep 30, 2009	Nov	DISC	
>D>		+	0.2MG	N022331	002	May 25, 2010	Nov	DISC	
>A>		@	0.2MG	N022331	002	May 25, 2010	Nov	DISC	
		KAPVAY							
>D>		SHIONOGI INC	0.1MG	N022331	003	Sep 28, 2010	Nov	CRLD	
>A>		+	0.1MG	N022331	003	Sep 28, 2010	Nov	CRLD	
>D>			0.2MG	N022331	004	Sep 28, 2010	Nov	DISC	
>A>		@	0.2MG	N022331	004	Sep 28, 2010	Nov	DISC	
		CODEINE SULFATE							
		SOLUTION; ORAL							
		CODEINE SULFATE							
		+ ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA	

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID AND COLCHICINE

AB		MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN

CRIZOTINIB

CAPSULE; ORAL
XALKORI

		PFIZER	200MG	N202570	001	Aug 26, 2011	Aug	NEWA
	+		250MG	N202570	002	Aug 26, 2011	Aug	NEWA

CROMOLYN SODIUM

CONCENTRATE; ORAL
CROMOLYN SODIUM

AA		PACK PHARMS LLC	100MG/5ML	A202583	001	Oct 27, 2011	Oct	NEWA

GASTROCROM

AA	+	AZUR PHARMA	100MG/5ML	N020479	001	Feb 29, 1996	Oct	CTEC

SOLUTION; INHALATION
CROMOLYN SODIUM

		@ ACTAVIS MID ATLANTIC	10MG/ML	A075067	001	Jul 19, 1999	Aug	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB		ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
AB	+		30MG	N021777	002	Feb 01, 2007	Apr	CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
AB			30MG	A090738	002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB		JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB			10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB		KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB			10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

AP	+	BAXTER HLTHCARE	500MG/VIAL	A040745	001	May 21, 2008	Aug	CRLD
AP	+		1GM/VIAL	A040745	002	May 21, 2008	Aug	CRLD
AP	+		2GM/VIAL	A040745	003	May 21, 2008	Aug	CRLD

CYTOXAN

AP		BAXTER HLTHCARE	500MG/VIAL	N012142	003		Aug	CRLD
AP			1GM/VIAL	N012142	004	Aug 30, 1982	Aug	CRLD
AP			2GM/VIAL	N012142	005	Aug 30, 1982	Aug	CRLD

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>A>	AP	ONCO THERAPIES LTD	20MG/ML	A200916	001	Dec 13, 2011	Nov	NEWA
>A>	AP		20MG/ML	A200914	001	Dec 13, 2011	Nov	NEWA
>A>	AP		20MG/ML	A200915	001	Dec 13, 2011	Nov	NEWA

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

		@ ACTAVIS TOTOWA	25MG	A076686	001	Oct 24, 2005	Jul	DISC
		@	50MG	A076686	002	Oct 24, 2005	Jul	DISC
		@	100MG	A076686	003	Oct 24, 2005	Jul	DISC

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

REV-EYES

		@ FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Oct	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	May	CAHN
	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

		@ TIBOTEC	EQ 300MG BASE	N021976	001	Jun 23, 2006	May	DISC

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

	+	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	Jun	CAHN

DEFERIPRONE

TABLET; ORAL

FERRIPROX

	+	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	Oct	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

		@ COREPHARMA	75MG	N050261	001		May	CAHN
AB			150MG	N050261	002		May	CAHN
AB	+		300MG	N050261	003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB		VERSAPHARM	150MG	A065389	001	Dec 01, 2008	May	CAHN
AB			300MG	A065389	002	Dec 01, 2008	May	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	50MG	A071588	001	Jun 05, 1987	Aug	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

AB		DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB		DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

		@ CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994	May	DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
EMOQUETTE

AB		VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL
DESOXIMETASONE

AB		VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

OINTMENT; TOPICAL
TOPICORT

	+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA		LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
AA		VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA

TABLET; ORAL
DEXAMETHASONE

BP		PAR PHARM	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
BP			0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
BP			1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
BP			4MG	A088238	001	Apr 28, 1983	Aug	CMFD
BP	+		6MG	A088481	001	Nov 28, 1983	Sep	CRLD
BP			6MG	A088481	001	Nov 28, 1983	Aug	CMFD
BP		ROXANE	0.5MG	A084611	001		Aug	CTEC
BP			0.75MG	A084613	001		Aug	CTEC
BP			1MG	A088306	001	Sep 15, 1983	Aug	CTEC
BP			2MG	A087916	001	Aug 26, 1982	Aug	CTEC
BP			4MG	A084612	001		Aug	CTEC
BP	+		6MG	A088316	001	Sep 15, 1983	Aug	CTEC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP		PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
AP			EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@ TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug		DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb		CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan		CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	25MG	N021802	008	Apr 21, 2011	May		NEWA
		35MG	N021802	007	Apr 21, 2011	May		NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Oct		NEWA
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Oct		NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	COREPHARMA	5MG	N017078	001		Jun		CAHN
AB		10MG	N017078	002		Jun		CAHN
AB	+	15MG	N017078	003		Jun		CAHN

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>D> AA	KV PHARM	5MG	A040365	001	Oct 31, 2002	Nov		CAHN
>D> AA		10MG	A040367	001	Oct 31, 2002	Nov		CAHN
	MIKART	2.5MG	A090533	001	Oct 25, 2011	Oct		NEWA
AA		5MG	A090533	002	Oct 25, 2011	Oct		NEWA
		7.5MG	A090533	003	Oct 25, 2011	Oct		NEWA
AA		10MG	A090533	004	Oct 25, 2011	Oct		NEWA
		15MG	A090533	005	Oct 25, 2011	Oct		NEWA
		20MG	A090533	006	Oct 25, 2011	Oct		NEWA
		30MG	A090533	007	Oct 25, 2011	Oct		NEWA
>A> AA	NESHER PHARMS	5MG	A040365	001	Oct 31, 2002	Nov		CAHN
>A> AA		10MG	A040367	001	Oct 31, 2002	Nov		CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan		NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004		Jun		CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634	001		Jun		CAHN

		INJECTABLE; INJECTION							
		DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003			Jun	CAHN
		DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634	002			Jun	CAHN
		DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS							
		INJECTABLE; INJECTION							
		IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986		Aug	DISC
		DIAZEPAM							
		TABLET; ORAL							
		DIAZEPAM							
		@ ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986		Aug	DISC
		@	5MG	A070706	001	Mar 19, 1986		Aug	DISC
		@	10MG	A070707	001	Mar 19, 1986		Aug	DISC
		DICLOFENAC SODIUM							
		GEL; TOPICAL							
		SOLARAZE							
>A>	+	FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000		Nov	CAHN
>D>	+	NYCOMED US	3%	N021005	001	Oct 16, 2000		Nov	CAHN
		TABLET, EXTENDED RELEASE; ORAL							
		DICLOFENAC SODIUM							
AB		VALEANT INTL	100MG	A075492	001	Feb 11, 2000		Apr	CAHN
		DICYCLOMINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		BENTYL							
AB	+	APTALIS PHARMA US	10MG	N007409	003	Oct 15, 1984		Oct	CAHN
		INJECTABLE; INJECTION							
		BENTYL							
AP	+	APTALIS PHARMA US	10MG/ML	N008370	001	Oct 15, 1984		Oct	CAHN
		BENTYL PRESERVATIVE FREE							
AP	+	APTALIS PHARMA US	10MG/ML	N008370	002	Oct 15, 1984		Oct	CAHN
		SYRUP; ORAL							
		BENTYL							
AA	+	APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984		Oct	CAHN
		TABLET; ORAL							
		BENTYL							
AB	+	APTALIS PHARMA US	20MG	N007409	001	Oct 15, 1984		Oct	CAHN
		DIETHYLPROPION HYDROCHLORIDE							
		TABLET; ORAL							
		DIETHYLPROPION HYDROCHLORIDE							
AA		LANNETT HOLDINGS INC	25MG	A200177	001	Jul 18, 2011		Jul	NEWA
		TABLET, EXTENDED RELEASE; ORAL							
		DIETHYLPROPION HYDROCHLORIDE							
AB		LANNETT HOLDINGS INC	75MG	A091680	001	Oct 24, 2011		Oct	NEWA
		TENUATE DOSPAN							
AB	+	WATSON PHARMS	75MG	N012546	001			Oct	CFTG

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+	ALCON PHARMS LTD	0.05%		N022212	001	Jun 23, 2008	May	CAHN

DIGOXIN

TABLET; ORAL

DIGOXIN

	@	ACTAVIS TOTOWA	0.125MG		A040282	001	Dec 23, 1999	Jul	DISC
	@		0.25MG		A040282	002	Dec 23, 1999	Jul	DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

	AB3	VALEANT INTL	120MG		N020062	001	Aug 10, 1992	Jun	CAHN
	AB3		180MG		N020062	002	Dec 27, 1991	Jun	CAHN
	AB3		240MG		N020062	003	Dec 27, 1991	Jun	CAHN
	AB3		300MG		N020062	004	Dec 27, 1991	Oct	CRLD
	AB3	+	300MG		N020062	004	Dec 27, 1991	Jun	CAHN
	AB3	+	360MG		N020062	005	Aug 24, 1999	Oct	CTEC
	BC	+	360MG		N020062	005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

>D>	AB4	KV PHARM	120MG		A076563	002	Sep 12, 2006	Nov	CAHN
>D>	AB4		180MG		A076563	003	Sep 12, 2006	Nov	CAHN
>D>	AB4		240MG		A076563	004	Sep 12, 2006	Nov	CAHN
>D>	AB4		300MG		A076563	005	Sep 12, 2006	Nov	CAHN
>D>	AB4		360MG		A076563	006	Sep 12, 2006	Nov	CAHN
>A>	AB4	NESHER PHARMS	120MG		A076563	002	Sep 12, 2006	Nov	CAHN
>A>	AB4		180MG		A076563	003	Sep 12, 2006	Nov	CAHN
>A>	AB4		240MG		A076563	004	Sep 12, 2006	Nov	CAHN
>A>	AB4		300MG		A076563	005	Sep 12, 2006	Nov	CAHN
>A>	AB4		360MG		A076563	006	Sep 12, 2006	Nov	CAHN
	AB3	SUN PHARMA GLOBAL	120MG		A090492	001	Oct 28, 2011	Oct	NEWA
	AB3		180MG		A090492	002	Oct 28, 2011	Oct	NEWA
	AB3		240MG		A090492	003	Oct 28, 2011	Oct	NEWA
	AB3		300MG		A090492	004	Oct 28, 2011	Oct	NEWA
	AB3		360MG		A090492	005	Oct 28, 2011	Oct	NEWA
	AB3	VALEANT INTL	120MG		A075116	001	Dec 23, 1999	Apr	CAHN
	AB3		180MG		A075116	002	Dec 23, 1999	Apr	CAHN
	AB3		240MG		A075116	003	Dec 23, 1999	Apr	CAHN
	AB3		300MG		A075116	004	Dec 23, 1999	Apr	CAHN

TIAZAC

	AB4	VALEANT INTL	120MG		N020401	001	Sep 11, 1995	Jun	CAHN
	AB4		180MG		N020401	002	Sep 11, 1995	Jun	CAHN
	AB4		240MG		N020401	003	Sep 11, 1995	Jun	CAHN
	AB4		300MG		N020401	004	Sep 11, 1995	Jun	CAHN
	AB4		360MG		N020401	005	Sep 11, 1995	Jun	CAHN
	AB4	+	420MG		N020401	006	Oct 16, 1998	Jun	CAHN

TABLET; ORAL

CARDIZEM

	AB	VALEANT INTL	30MG		N018602	001	Nov 05, 1982	Jun	CAHN
	AB		60MG		N018602	002	Nov 05, 1982	Jun	CAHN
	AB		90MG		N018602	003	Dec 08, 1986	Jun	CAHN
	AB	+	120MG		N018602	004	Dec 08, 1986	Jun	CAHN

TABLET; ORAL
DILTIAZEM HYDROCHLORIDE

AB		MYLAN	30MG	A072838	004	Nov 05, 1992	Aug	CMS1
AB			60MG	A072838	003	Nov 05, 1992	Aug	CMS1
AB			90MG	A072838	002	Nov 05, 1992	Aug	CMS1

TABLET, EXTENDED RELEASE; ORAL
CARDIZEM LA

AB		VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
AB			180MG	N021392	002	Feb 06, 2003	Jun	CAHN
AB			240MG	N021392	003	Feb 06, 2003	Jun	CAHN
AB			300MG	N021392	004	Feb 06, 2003	Jun	CAHN
AB			360MG	N021392	005	Feb 06, 2003	Jun	CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

		@ HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997	Aug	DISC

TABLET; ORAL
DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

>D>	AB	KV PHARM	EQ 150MG BASE	A071200	001	Dec 15, 1987	Nov	CAHN
>A>	AB	NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987	Nov	CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

AB		ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
AB	+		500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB		SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
AB			500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DIVALPROEX SODIUM

AB		MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB		AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr	NEWA
AB			EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr	NEWA
AB			EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr	NEWA
AB		UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
AB			EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
AB			EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA
AB		WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	+	HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Aug	CRLD
	@	TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993	Aug	DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

	+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	May	NEWA
	+		80MG/VIAL	N022534	002	May 03, 2011	May	NEWA

DOCETAXEL

		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun	NEWA
			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun	NEWA
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA
AP		SANDOZ	20MG/2ML (10MG/ML)	N201525	001	Jun 29, 2011	Jun	NEWA
AP			160MG/16ML (10MG/ML)	N201525	003	Jun 29, 2011	Jun	NEWA
AP		SANDOZ INC	80MG/8ML (10MG/ML)	N201525	002	Jun 29, 2011	Jun	NEWA

TAXOTERE

	@	SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB		ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Aug	NEWA
AB			10MG	A201335	002	Aug 29, 2011	Aug	NEWA
AB		ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	May	NEWA
AB			10MG	A090551	002	May 31, 2011	May	NEWA
AB		APOTEX	5MG	A078841	001	Jun 02, 2011	May	NEWA
AB			10MG	A078841	002	Jun 02, 2011	May	NEWA
AB		AUROBINDO	5MG	A090056	001	May 31, 2011	May	NEWA
AB			10MG	A090056	002	May 31, 2011	May	NEWA
AB		CIPLA LTD	5MG	A077518	001	May 31, 2011	May	NEWA
AB			10MG	A077518	002	May 31, 2011	May	NEWA
AB		DR REDDYS LABS LTD	5MG	A201001	001	May 31, 2011	May	NEWA
AB			10MG	A201001	002	May 31, 2011	May	NEWA
AB		HIKMA PHARMS	5MG	A090247	001	May 31, 2011	May	NEWA
AB			10MG	A090247	002	May 31, 2011	May	NEWA
AB		HUAHAI US INC	5MG	A200292	001	May 31, 2011	May	NEWA
AB			10MG	A200292	002	May 31, 2011	May	NEWA
AB		JUBILANT LIFE	5MG	A090768	001	May 31, 2011	May	NEWA
AB			10MG	A090768	002	May 31, 2011	May	NEWA
AB		MATRIX LABS LTD	5MG	A090521	001	May 31, 2011	May	NEWA
AB			10MG	A090521	002	May 31, 2011	May	NEWA
AB		PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	May	NEWA
AB			10MG	A090425	002	May 31, 2011	May	NEWA
AB		ROXANE	5MG	A078662	001	May 31, 2011	May	NEWA
AB			10MG	A078662	002	May 31, 2011	May	NEWA
AB		SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
AB			10MG	A090290	002	May 31, 2011	May	NEWA

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB		SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
AB			10MG	A090493	002	May 31, 2011	May	NEWA
AB		TEVA	5MG	A077344	001	May 31, 2011	May	NEWA
AB			10MG	A077344	002	May 31, 2011	May	NEWA
AB		TORRENT PHARMS	5MG	A090686	001	May 31, 2011	May	NEWA
AB			10MG	A090686	002	May 31, 2011	May	NEWA
AB		WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
AB			10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

		@ MUTUAL PHARM	5MG	A077975	002	Dec 11, 2009	Sep	DISC
		@	10MG	A077975	001	Dec 11, 2009	Sep	DISC
AB		SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB			10MG	A091198	002	May 10, 2011	Apr	NEWA
AB		ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB			10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

		@ ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
		@	EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
		@	EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
		@	EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC
>D>	AB	KV PHARM	EQ 1MG BASE	A075609	001	Oct 18, 2000	Nov	CAHN
>D>	AB		EQ 2MG BASE	A075609	002	Oct 18, 2000	Nov	CAHN
>D>	AB		EQ 4MG BASE	A075609	003	Oct 18, 2000	Nov	CAHN
>D>	AB		EQ 8MG BASE	A075609	004	Oct 18, 2000	Nov	CAHN
>A>	AB	NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000	Nov	CAHN
>A>	AB		EQ 2MG BASE	A075609	002	Oct 18, 2000	Nov	CAHN
>A>	AB		EQ 4MG BASE	A075609	003	Oct 18, 2000	Nov	CAHN
>A>	AB		EQ 8MG BASE	A075609	004	Oct 18, 2000	Nov	CAHN

DOXERCALCIFEROL

CAPSULE; ORAL
DOXERCALCIFEROL

AB		ROXANE	0.5MCG	A091433	001	Sep 23, 2011	Sep	NEWA

HECTOROL

AB		GENZYME CORP	0.5MCG	N020862	002	Apr 23, 2004	Sep	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP		ONCO THERAPIES LTD	10MG/VIAL	A200170	001	Oct 28, 2011	Oct	NEWA
AP			50MG/VIAL	A200170	002	Oct 28, 2011	Oct	NEWA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB		MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

		TABLET; ORAL						
		DOXYCYCLINE						
		@ MUTUAL PHARM	EQ 50MG BASE	A065471	001	Apr 17, 2009	Sep	DISC
		@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Sep	DISC
		@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Sep	DISC
	DOXYCYCLINE HYCLATE							
		CAPSULE; ORAL						
		DOXYCYCLINE HYCLATE						
	AB	WATSON LABS FLORIDA	EQ 50MG BASE	A062031	002	Oct 13, 1982	May	CAHN
	AB		EQ 100MG BASE	A062031	001		May	CAHN
	DRONABINOL							
		CAPSULE; ORAL						
		DRONABINOL						
	AB	INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011	Aug	NEWA
	AB		5MG	A078501	002	Aug 19, 2011	Aug	NEWA
	AB		10MG	A078501	003	Aug 19, 2011	Aug	NEWA
	DROSPIRENONE; ETHINYL ESTRADIOL							
		TABLET; ORAL						
		DROSPIRENONE AND ETHINYL ESTRADIOL						
>A>	AB	WATSON LABS	3MG;0.02MG	A078833	001	Nov 28, 2011	Nov	NEWA
		LORYNA						
	AB	SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA
		TABLET; ORAL-28						
		SYEDA						
	AB	SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA
	ECONAZOLE NITRATE							
		CREAM; TOPICAL						
		SPECTAZOLE						
		@ ORTHO JANSSEN	1%	N018751	001	Dec 23, 1982	Jul	CAHN
	EDROPHONIUM CHLORIDE							
		INJECTABLE; INJECTION						
		EDROPHONIUM CHLORIDE						
		@ HOSPIRA	10MG/ML	A040131	001	Feb 24, 1998	Aug	DISC
	ELTROMBOPAG OLAMINE							
		TABLET; ORAL						
		PROMACTA						
		GLAXOSMITHKLINE	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Oct	NEWA
	EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE							
		TABLET; ORAL						
		COMPLERA						
	+	GILEAD SCIENCES INC	200MG;25MG;300MG	N202123	001	Aug 10, 2011	Aug	NEWA
	ENALAPRIL MALEATE							
		TABLET; ORAL						
		VASOTEC						
	AB	VALEANT INTL	2.5MG	N018998	005	Jul 26, 1988	Jun	CAHN
	AB		5MG	N018998	001	Dec 24, 1985	Jun	CAHN
	AB		10MG	N018998	002	Dec 24, 1985	Jun	CAHN
	AB	+	20MG	N018998	003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

AB		VALEANT INTL	5MG;12.5MG	N019221	003	Jul 12, 1995	Jun	CAHN
AB	+		10MG;25MG	N019221	001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

>A>		SANDOZ INC	300MG/3ML (100MG/ML)	A078660	001	Nov 28, 2011	Nov	NEWA
		LOVENOX						
>D>		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Nov	CFTG
>A>	AB		300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Nov	CFTG
			300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

INJECTABLE; SUBCUTANEOUS
ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	30MG/0.3ML (100MG/ML)	A076684	001	Sep 19, 2011	Sep	NEWA
AP			40MG/0.4ML (100MG/ML)	A076684	002	Sep 19, 2011	Sep	NEWA
AP			60MG/0.6ML (100MG/ML)	A076684	003	Sep 19, 2011	Sep	NEWA
AP			80MG/0.8ML (100MG/ML)	A076684	004	Sep 19, 2011	Sep	NEWA
AP			100MG/ML (100MG/ML)	A076684	005	Sep 19, 2011	Sep	NEWA
AP			120MG/0.8ML (150MG/ML)	A076684	006	Sep 19, 2011	Sep	NEWA
AP			150MG/ML (150MG/ML)	A076684	007	Sep 19, 2011	Sep	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG
		EPINASTINE HYDROCHLORIDE						
AT		APOTEX	0.05%	A090919	001	Oct 31, 2011	Oct	NEWA
AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA
AT		PHARMAFORCE	0.05%	A090951	001	Oct 31, 2011	Oct	NEWA
AT		SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Oct	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST FORTE DENTAL

AP	+	DENTSPLY PHARM	0.005MG/ML;4%	N021383	001		Aug	CFTG

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	0.005MG/ML;4%	A078959	001	Aug 30, 2011	Aug	NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Apr	NEWA
AP			200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Apr	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
VELETRI

	+	ACTELION	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Aug	CTNA

EPROSARTAN MESYLATE

TABLET; ORAL

>A>		EPROSARTAN MESYLATE							
>A>	AB	MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011	Nov	NEWA	
>A>	AB		EQ 600MG BASE	A202012	002	Nov 16, 2011	Nov	NEWA	
		TEVETEN							
>D>		ABBOTT	EQ 400MG BASE	N020738	005	Dec 22, 1997	Nov	CFTG	
>A>	AB		EQ 400MG BASE	N020738	005	Dec 22, 1997	Nov	CFTG	
>D>	+		EQ 600MG BASE	N020738	006	May 27, 1999	Nov	CFTG	
>A>	AB +		EQ 600MG BASE	N020738	006	May 27, 1999	Nov	CFTG	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

		ERYTHROMYCIN							
AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN	

GEL; TOPICAL

		E-GLADES							
AT		COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr	CAHN	

OINTMENT; OPHTHALMIC

		ERYTHROMYCIN							
AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN	
AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN	

SOLUTION; TOPICAL

		ERYDERM							
		@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN	
		ERYTHROMYCIN							
		@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr	CAHN	

SWAB; TOPICAL

		ERYCETTE							
		@ ORTHO JANSSEN	2%	N050594	001	Feb 15, 1985	Jul	CAHN	
		ERYTHROMYCIN							
		@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr	CAHN	

TABLET; ORAL

		ERYTHROMYCIN							
		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN	
	+		500MG	A061621	002		Jan	CAHN	

TABLET, COATED PARTICLES; ORAL

		PCE							
		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN	
	+		500MG	N050611	002	Aug 22, 1990	Jan	CAHN	

TABLET, DELAYED RELEASE; ORAL

		E-MYCIN							
		@ ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN	
		@	333MG	A060272	002		Jan	CAHN	
		ERY-TAB							
	+	ARBOR PHARMS INC	250MG	A062298	001		Jan	CAHN	
	+		333MG	A062298	003	Mar 29, 1982	Jan	CAHN	
	+		500MG	A062298	002		Jan	CAHN	

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

		E.E.S.							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan	CAHN	
		ERYPED							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan	CAHN	

	GRANULE; ORAL							
	ERYPED							
+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	N050207	002		Jan	CAHN	
	SUSPENSION; ORAL							
	E.E.S. 200							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan	CAHN	
	E.E.S. 400							
AB +	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan	CAHN	
	PEDIAMYCIN							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan	CAHN	
	PEDIAMYCIN 400							
AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002		Jan	CAHN	
	TABLET; ORAL							
	E.E.S. 400							
	@ ARBOR PHARMS INC	EQ 400MG BASE	A061905	001		Jan	CAHN	
BX +		EQ 400MG BASE	A061905	002	Aug 12, 1982	Jan	CAHN	
	ERYTHROMYCIN ETHYLSUCCINATE							
BX +	ARBOR PHARMS INC	EQ 400MG BASE	A061904	001		Jan	CAHN	
	TABLET, CHEWABLE; ORAL							
	E.E.S.							
	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	002		Jan	CAHN	
	ERYPED							
	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	003	Jul 05, 1988	Jan	CAHN	
	ERYTHROMYCIN STEARATE							
	TABLET; ORAL							
	ERYTHROCIN STEARATE							
	@ ARBOR PHARMS INC	EQ 125MG BASE	A060359	002		Jan	CAHN	
+		EQ 250MG BASE	A060359	001		Aug	CRLD	
		EQ 250MG BASE	A060359	001		Jan	CAHN	
	@	EQ 500MG BASE	A060359	003		Aug	DISC	
+		EQ 500MG BASE	A060359	003		Jan	CAHN	
	ESTRADIOL							
	TABLET; ORAL							
	ESTRACE							
	@ BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993	Aug	DISC	
	ESTRADIOL; NORETHINDRONE ACETATE							
	TABLET; ORAL							
	ACTIVELLA							
AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Mar	CTEC	
	ESTRADIOL AND NORETHINDRONE ACETATE							
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324	002	Jun 09, 2011	May	NEWA	
	ESTROPIPATE							
	CREAM; VAGINAL							
	OGEN							
	@ PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001		Apr	DISC	
	ESZOPICLONE							
	TABLET; ORAL							
	ESZOPICLONE							
	@ LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Oct	DISC	
AB		1MG	A091124	001	Sep 13, 2011	Aug	NEWA	
	@	2MG	A091124	002	Sep 13, 2011	Oct	DISC	

		TABLET; ORAL							
		ESZOPICLONE							
	AB	LUPIN LTD	2MG	A091124	002	Sep 13, 2011	Aug	NEWA	
		@	3MG	A091124	003	Sep 13, 2011	Oct	DISC	
	AB		3MG	A091124	003	Sep 13, 2011	Aug	NEWA	
		@ TEVA	1MG	A091169	001	May 23, 2011	Jun	DISC	
	AB		1MG	A091169	001	May 23, 2011	May	NEWA	
		@	2MG	A091169	002	May 23, 2011	Jun	DISC	
	AB		2MG	A091169	002	May 23, 2011	May	NEWA	
		@	3MG	A091169	003	May 23, 2011	Jun	DISC	
	AB		3MG	A091169	003	May 23, 2011	May	NEWA	
		@ WOCKHARDT LTD	1MG	A091165	001	Jul 14, 2011	Jul	NEWA	
		@	2MG	A091165	002	Jul 14, 2011	Jul	NEWA	
		@	3MG	A091165	003	Jul 14, 2011	Jul	NEWA	
		LUNESTA							
		SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Oct	CTEC	
	AB		1MG	N021476	001	Dec 15, 2004	Aug	CTEC	
			1MG	N021476	001	Dec 15, 2004	Jun	CTEC	
	AB		1MG	N021476	001	Dec 15, 2004	May	CFTG	
			2MG	N021476	002	Dec 15, 2004	Oct	CTEC	
	AB		2MG	N021476	002	Dec 15, 2004	Aug	CTEC	
			2MG	N021476	002	Dec 15, 2004	Jun	CTEC	
	AB		2MG	N021476	002	Dec 15, 2004	May	CFTG	
		+	3MG	N021476	003	Dec 15, 2004	Oct	CTEC	
	AB	+	3MG	N021476	003	Dec 15, 2004	Aug	CTEC	
		+	3MG	N021476	003	Dec 15, 2004	Jun	CTEC	
	AB	+	3MG	N021476	003	Dec 15, 2004	May	CFTG	
		ETHINYL ESTRADIOL; LEVONORGESTREL							
		TABLET; ORAL							
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
	AB	LUPIN LTD	0.02MG,0.01MG;0.1MG,N/A	A091674	001	Oct 26, 2011	Oct	NEWA	
>A>	AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	Nov	NEWA	
	AB	WATSON LABS	0.02MG,0.01MG;0.1MG,N/A	A200407	001	Oct 25, 2011	Oct	NEWA	
	AB		0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	NEWA	
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	May	NEWA	
		LOSEASONIQUE							
	AB	TEVA WOMENS	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Oct	CFTG	
			0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Aug	CAHN	
		LYBREL							
	AB +	WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	CFTG	
		SEASONIQUE							
	AB +	TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	May	CFTG	
		TABLET; ORAL-21							
		ALESSE							
		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Jul	CAHN	
		@ WYETH PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Aug	CAHN	
		TRIPHASIL-21							
		@ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N019192	001	Nov 01, 1984	Aug	CAHN	
		TABLET; ORAL-28							
		ALESSE							
		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Jul	CAHN	
		@ WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Aug	CAHN	

	TABLET; ORAL-28							
	ORSYTHIA							
AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr	NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET; ORAL-28							
	BRIELLYN							
AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar	NEWA	
	TABLET, CHEWABLE; ORAL							
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CRLD	
AB	WATSON LABS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep	NEWA	
+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL							
	LO LOESTRIN FE							
+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD	
	TABLET; ORAL-28							
	GILDESS FE 1.5/30							
AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA	
	GILDESS FE 1/20							
AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA	

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL							
	NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA	
	TABLET; ORAL-28							
	NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA	

ETHINYL ESTRADIOL; NORGESTREL

	TABLET; ORAL-21							
	OVRAL							
	@ WYETH PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN	
	TABLET; ORAL-28							
	LO/OVRAL-28							
AB	WYETH PHARMS	0.03MG;0.3MG	N017802	001		Aug	CAHN	
	OVRAL-28							
	@ WYETH PHARMS	0.05MG;0.5MG	N016806	001		Aug	CAHN	

ETHOSUXIMIDE

	CAPSULE; ORAL							
	ETHOSUXIMIDE							
AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN	

ETODOLAC

	CAPSULE; ORAL							
	ETODOLAC							
	@ MYLAN	200MG	A075071	001	Sep 30, 1998	Feb	CAHN	
	@	300MG	A075071	002	Sep 30, 1998	Feb	CAHN	

TABLET; ORAL
ETODOLAC

	@ ACTAVIS ELIZABETH	400MG	A074819	001	Feb 28, 1997	Aug	DISC
	@	500MG	A074819	002	Apr 28, 1998	Sep	NEWA
	@ MYLAN	400MG	A075012	001	Sep 30, 1998	Feb	CAHN
	@	500MG	A075012	002	Sep 30, 1998	Feb	CAHN

ETONOGESTREL

IMPLANT; IMPLANTATION
NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011	May	NEWA

ETRAVIRINE

TABLET; ORAL
INTELENCE

	TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD
+		200MG	N022187	002	Dec 22, 2010	Jan	NEWA

EXEMESTANE

TABLET; ORAL
AROMASIN

AB	+ PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG

EXEMESTANE

AB	ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL
VYTORIN

	MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Oct	CAHN
		10MG;20MG	N021687	002	Jul 23, 2004	Oct	CAHN
		10MG;40MG	N021687	003	Jul 23, 2004	Oct	CAHN
+		10MG;80MG	N021687	004	Jul 23, 2004	Oct	CAHN

EZOGABINE

TABLET; ORAL
POTIGA

	VALEANT PHARMS	50MG	N022345	001	Jun 10, 2011	Jun	NEWA
		200MG	N022345	002	Jun 10, 2011	Jun	NEWA
		300MG	N022345	003	Jun 10, 2011	Jun	NEWA
+		400MG	N022345	004	Jun 10, 2011	Jun	NEWA

FAMCICLOVIR

TABLET; ORAL
FAMCICLOVIR

AB	APOTEX	125MG	A091480	001	Jul 22, 2011	Jul	NEWA
AB		250MG	A091480	002	Jul 22, 2011	Jul	NEWA
AB		500MG	A091480	003	Jul 22, 2011	Jul	NEWA
AB	AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A091114	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A091114	003	Mar 21, 2011	Mar	NEWA
AB	MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
AB		250MG	A201333	002	Mar 24, 2011	Mar	NEWA
AB		500MG	A201333	003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A090128	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128	003	Mar 21, 2011	Mar	NEWA

TABLET; ORAL
FAMCICLOVIR

AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

	@ HOSPIRA	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN

PEPCID

	@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE

	@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

	@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL
FAMOTIDINE

	@ ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001	Aug	DISC
	@	40MG	A075650	002	Sep 14, 2001	Aug	DISC
AB	ALEMBIC PHARMS LTD	20MG	A078916	001	May 22, 2009	Jul	CAHN
AB		40MG	A078916	002	May 22, 2009	Jul	CAHN
AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL
DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr	NEWA

FELBAMATE

TABLET; ORAL
FELBAMATE

AB	AMNEAL PHARMS	400MG	A201680	001	Sep 13, 2011	Aug	NEWA
AB		600MG	A201680	002	Sep 13, 2011	Aug	NEWA

FELBATOL

AB	MEDA PHARMS	400MG	N020189	001	Jul 29, 1993	Aug	CFTG
AB +		600MG	N020189	002	Jul 29, 1993	Aug	CFTG

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	ENDO PHARMS	2.5MG	A200815	001	Oct 28, 2011	Oct	NEWA
AB		5MG	A200815	002	Oct 28, 2011	Oct	NEWA
AB		10MG	A200815	003	Oct 28, 2011	Oct	NEWA
>A> AB	TORRENT PHARMS LTD	2.5MG	A202170	001	Nov 28, 2011	Nov	NEWA
>A> AB		5MG	A202170	002	Nov 28, 2011	Nov	NEWA
>A> AB		10MG	A202170	003	Nov 28, 2011	Nov	NEWA

FENOFIBRATE

CAPSULE; ORAL
LIPOFEN

	@ CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006	Sep	DISC

TABLET; ORAL
FENOGLIDE

		SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
	+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

	AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA

FENTANYL-25

	AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA

FENTANYL-50

	AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA

FENTANYL-75

	AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL
LAZANDA

		ARCHIMEDES	100MCG	N022569	001	Jun 30, 2011	Jun	NEWA
	+		400MCG	N022569	002	Jun 30, 2011	Jun	NEWA

TABLET; SUBLINGUAL
ABSTRAL

		PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA
			EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA
			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA
	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA
			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA
			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Jan	NEWA

FIDAXOMICIN

TABLET; ORAL
DIFICID

	+	OPTIMER PHARMS	200MG	N201699	001	May 27, 2011	May	NEWA

FINASTERIDE

TABLET; ORAL
FINASTERIDE

	AB	SUN PHARMA GLOBAL	1MG	A090508	001	Oct 03, 2011	Sep	NEWA
	AB		5MG	A090507	001	Aug 16, 2011	Aug	NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL
FLAVOXATE HYDROCHLORIDE

>D>	AB	PADDOCK LLC	100MG	A076831	001	Dec 16, 2004	Nov	CRLD
>A>	AB	+	100MG	A076831	001	Dec 16, 2004	Nov	CRLD

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE

	AB	AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Feb	NEWA
	AB		100MG	A078423	002	Mar 07, 2011	Feb	NEWA
	AB		150MG	A078423	003	Mar 07, 2011	Feb	NEWA
	AB		200MG	A078423	004	Mar 07, 2011	Feb	NEWA
	AB	MYLAN	50MG	A076042	001	Jul 29, 2004	Feb	CAHN
	AB		100MG	A076042	002	Jul 29, 2004	Feb	CAHN

TABLET; ORAL
FLUCONAZOLE

AB		MYLAN	150MG	A076042	003	Jul 29, 2004	Feb	CAHN
AB			200MG	A076042	004	Jul 29, 2004	Feb	CAHN

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

AB		VALEANT	250MG	N017001	001		Jun	CFTG
AB	+		500MG	N017001	002		Jun	CFTG

FLUCYTOSINE

AB		SIGMAPHARM LABS LLC	250MG	A201566	001	Jun 28, 2011	Jun	NEWA
AB			500MG	A201566	002	Jun 28, 2011	Jun	NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL
OFORTA

	+	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	Apr	CMFD
	@		10MG	N022273	001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLUDROCORTISONE ACETATE

AB		WEST-WARD PHARM CORP	0.1MG	A091302	001	Jul 22, 2011	Jul	NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP		PFIZER	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	May	CAHN
AP			1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	May	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

>D>		@ G AND W LABS	0.01%	A089526	001	Jul 26, 1988	Nov	CMFD
>A>	AT		0.01%	A089526	001	Jul 26, 1988	Nov	CMFD
	AT		0.025%	A089525	001	Jul 26, 1988	Oct	CMFD

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787	004		Jun	CAHN
AT	+		0.025%	N012787	005		Jun	CAHN
AT	+		0.025%	N012787	002		Jun	CAHN

SYNALAR-HP

	@	MEDIMETRIKS PHARMS	0.2%	N016161	002		Jun	CAHN

OIL; TOPICAL
DERMA-SMOOTHE/FS

AT	+	HILL DERMAC	0.01%	N019452	002	Nov 09, 2005	Oct	CFTG
AT	+		0.01%	N019452	001	Feb 03, 1988	Oct	CFTG

FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A201759	001	Oct 17, 2011	Oct	NEWA
AT			0.01%	A201764	001	Oct 17, 2011	Oct	NEWA

		OIL/DROPS; OTIC							
		DERMOTIC							
AT	+	HILL DERMAC	0.01%	N019452	003	Nov 09, 2005	Oct		CFTG
		FLUOCINOLONE ACETONIDE							
AT		IDENTI PHARMS INC	0.1%	A091306	001	Oct 17, 2011	Oct		NEWA
		OINTMENT; TOPICAL							
		FLUOCINOLONE ACETONIDE							
AT		G AND W LABS	0.025%	A089524	001	Jul 26, 1988	Oct		CMFD
		SYNALAR							
AT	+	MEDIMETRIKS PHARMS	0.025%	N013960	001		Jun		CAHN
		SOLUTION; TOPICAL							
		SYNALAR							
AT	+	MEDIMETRIKS PHARMS	0.01%	N015296	001		Jun		CAHN
		FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE							
		CREAM; TOPICAL							
		NEO-SYNALAR							
		@ MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Aug		CAHN
		FLUOROURACIL							
		INJECTABLE; INJECTION							
		FLUOROURACIL							
AP		SANDOZ	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Apr		NEWA
AP			2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Apr		NEWA
		@ VALEANT	500MG/10ML (50MG/ML)	N012209	001		Mar		DISC
		FLUOXETINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		FLUOXETINE HYDROCHLORIDE							
AB1		ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009	Apr		CAHN
AB1			EQ 20MG BASE	A090223	002	Mar 19, 2009	Apr		CAHN
AB			EQ 40MG BASE	A090223	003	Mar 19, 2009	Apr		CAHN
		TABLET; ORAL							
		FLUOXETINE HYDROCHLORIDE							
		EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Oct		NEWA
		FLURANDRENOLIDE							
		CREAM; TOPICAL							
		CORDRAN SP							
		WATSON PHARMS	0.025%	N012806	003		Oct		CMFD
		@	0.025%	N012806	003		Jul		DISC
		@	0.05%	N012806	002		Jul		DISC
		OINTMENT; TOPICAL							
		CORDRAN							
		@ WATSON PHARMS	0.025%	N012806	004		Jun		DISC
		@	0.05%	N012806	001		Jun		DISC
		FLURAZEPAM HYDROCHLORIDE							
		CAPSULE; ORAL							
		DALMANE							
		@ VALEANT PHARM INTL	15MG	N016721	001		Oct		DISC
		@	30MG	N016721	002		Oct		DISC
		FLURAZEPAM HYDROCHLORIDE							
>D> AB		MYLAN	30MG	A070345	001	Nov 27, 1985	Nov		CRLD
>A> AB	+	MYLAN PHARMS INC	30MG	A070345	001	Nov 27, 1985	Nov		CRLD

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

AB			MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL
FLUTICASONE PROPIONATE

>D>	AB		KV PHARM	0.05%	A076865	001	Sep 10, 2004	Nov	CAHN
>A>	AB		NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004	Nov	CAHN

LOTION; TOPICAL
CUTIVATE

>A>	AB	+	FOUGERA PHARMS	0.05%	N021152	001	Mar 31, 2005	Nov	CAHN
>D>	AB	+	NYCOMED US	0.05%	N021152	001	Mar 31, 2005	Nov	CAHN
	AB	+		0.05%	N021152	001	Mar 31, 2005	Apr	CFTG

FLUTICASONE PROPIONATE

	AB		GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Apr	NEWA

OINTMENT; TOPICAL
CUTIVATE

>D>	AB	+	ALTANA	0.005%	N019957	001	Dec 14, 1990	Nov	CAHN
>A>	AB	+	FOUGERA PHARMS	0.005%	N019957	001	Dec 14, 1990	Nov	CAHN

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

			@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
			@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL
FOLIC ACID

	AA	+	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
	AA		JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN
			@ MUTUAL PHARM	1MG	A040582	001	Jul 18, 2005	Sep	DISC

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS
ARIXTRA

	AP	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
	AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
	AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
	AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG

FONDAPARINUX SODIUM

	AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jun	NEWA
	AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jun	NEWA
	AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jun	NEWA
	AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jun	NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION
FORADIL CERTIHALER

			@ NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
AB			20MG	A091163	002	Mar 30, 2011	Mar	NEWA
AB			40MG	A091163	003	Mar 30, 2011	Mar	NEWA

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS USA	10MG;12.5MG	A079025	001	Sep 17, 2010	Jul	CAHN
AB			20MG;12.5MG	A079025	002	Sep 17, 2010	Jul	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
AP		PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB		MARKSANS PHARMA	100MG	A090007	001	Jul 21, 2011	Jul	NEWA
AB			300MG	A090007	002	Jul 21, 2011	Jul	NEWA
AB			400MG	A090007	003	Jul 21, 2011	Jul	NEWA
AB		MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
AB			300MG	A090158	002	Feb 14, 2011	Jan	NEWA
AB			400MG	A090158	003	Feb 14, 2011	Jan	NEWA
AB		MYLAN	100MG	A090158	001	Feb 14, 2011	May	CAHN
AB			300MG	A090158	002	Feb 14, 2011	May	CAHN
AB			400MG	A090158	003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL
GABAPENTIN

AA		HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL
GABAPENTIN

AB		AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Sep	NEWA
AB			800MG	A200651	002	Oct 06, 2011	Sep	NEWA
AB		HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jul	NEWA
AB			800MG	A078782	002	Jul 21, 2011	Jul	NEWA
AB		ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
AB			800MG	A078926	002	Feb 11, 2011	Jan	NEWA

GRALISE

BX	+	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544	002	Jan 28, 2011	Jan	NEWA
BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011	Jul	CAHN
BX	+		600MG	N022544	002	Jan 28, 2011	Jul	CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL
HORIZANT

	+	GLAXO GRP LTD	600MG	N022399	001	Apr 06, 2011	Apr	NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

RAZADYNE ER

AB	+ JANSSEN PHARMS	EQ 8MG BASE	N021615	001	Apr 01, 2005	Jul	CAHN
AB		EQ 16MG BASE	N021615	002	Apr 01, 2005	Jul	CAHN
AB		EQ 24MG BASE	N021615	003	Apr 01, 2005	Jul	CAHN

SOLUTION; ORAL

RAZADYNE

AA	+ JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	Jul	CAHN

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	@ ACTAVIS ELIZABETH	EQ 4MG BASE	A077585	001	Sep 15, 2009	Aug	DISC
	@	EQ 8MG BASE	A077585	002	Sep 15, 2009	Aug	DISC
	@	EQ 12MG BASE	A077585	003	Sep 15, 2009	Aug	DISC
AB	APOTEX INC	EQ 4MG BASE	A077781	001	Sep 27, 2011	Sep	NEWA
AB		EQ 8MG BASE	A077781	002	Sep 27, 2011	Sep	NEWA
AB		EQ 12MG BASE	A077781	003	Sep 27, 2011	Sep	NEWA
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
AB		EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
AB		EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
AB		EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
AB		EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

RAZADYNE

AB	+ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	Jul	CAHN
AB		EQ 8MG BASE	N021169	002	Feb 28, 2001	Jul	CAHN
AB		EQ 12MG BASE	N021169	003	Feb 28, 2001	Jul	CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT	APOTEX CORP	0.3%	A079084	001	Aug 19, 2011	Aug	NEWA

ZYMAR

AT	+ ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Aug	CFTG

GEFITINIB

TABLET; ORAL

IRESSA

	@ ASTRAZENECA	250MG	N021399	001	May 05, 2003	Sep	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

		GEMCITABINE						
	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Aug	NEWA
	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Aug	NEWA
	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Aug	NEWA
	+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD
		GEMCITABINE HYDROCHLORIDE						
AP		ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Jul	NEWA
AP		ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Jul	NEWA
AP		APP PHARMS	EQ 2GM BASE/VIAL	A090242	003	May 16, 2011	May	NEWA
AP		DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091365	002	Jul 25, 2011	Jul	NEWA
AP		FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	May	NEWA
AP		HOSPIRA	EQ 200MG BASE/VIAL	A078339	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078339	002	Jul 25, 2011	Jul	NEWA
AP	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Jul	CTEC
	+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	May	CTNA
AP		ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Jul	NEWA
AP		SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078433	002	Jul 25, 2011	Jul	NEWA
AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA
AP		WATSON LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul	NEWA
		GEMZAR						
AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

		GEMFIBROZIL						
AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

		GENTAMICIN SULFATE						
AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

		GENTAMICIN SULFATE						
AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL

		GLIMEPIRIDE						
AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN

TABLET; ORAL
GLIMEPIRIDE

AB		MYLAN	4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB		MYLAN	5MG	A074438	001	Jun 20, 1995	Aug	CAHN
AB			10MG	A074438	002	Jun 20, 1995	Aug	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	+	TEVA PHARMS	5MG;500MG	A077270	003	Oct 28, 2005	Aug	CRLD
AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

METAGLIP

	@	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Aug	DISC
	@		2.5MG;500MG	N021460	002	Oct 21, 2002	Aug	DISC
	@		5MG;500MG	N021460	003	Oct 21, 2002	Aug	DISC

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE

	+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	May	CAHN

GLYBURIDE

TABLET; ORAL
GLYBURIDE

	@	ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002	Jul	DISC
	@		3MG	A075947	002	Nov 14, 2002	Jul	DISC
	@		6MG	A075947	003	Nov 14, 2002	Jul	DISC
AB		HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	May	CAHN
AB			2.5MG	A090937	002	Feb 28, 2011	May	CAHN
AB			5MG	A090937	003	Feb 28, 2011	May	CAHN
AB		INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
AB			2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
AB			5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP		HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Sep	NEWA

TABLET; ORAL
GLYCOPYRROLATE

AA		BOCA PHARMA	1MG	A090020	001	Oct 19, 2011	Oct	NEWA
AA			2MG	A090020	002	Oct 19, 2011	Oct	NEWA

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL

>D>		@ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Nov	CAHN
>D>		@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Nov	CAHN
>D>		@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Nov	CAHN
>A>		@ HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Nov	CAHN

	INJECTABLE; INJECTION							
	FACTREL							
>A>	@ HIKMA (MAPLE)	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Nov	CAHN
>A>	@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Nov	CAHN
	GRANISETRON							
	FILM, EXTENDED RELEASE; TRANSDERMAL							
	SANCUSO							
	+ PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN
	GRISEOFULVIN, ULTRAMICROCRYSTALLINE							
	TABLET; ORAL							
	FULVICIN P/G							
	@ ELORAC	125MG	A061996	001		Jan	CAHN
	@	250MG	A061996	002		Jan	CAHN
	FULVICIN P/G 165							
	@ ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN
	FULVICIN P/G 330							
	@ ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN
	HALOBETASOL PROPIONATE							
	OINTMENT; TOPICAL							
	HALOBETASOL PROPIONATE							
	@ ACTAVIS MID ATLANTIC	0.05%	A077109	001	Jun 14, 2005	Aug	DISC
	HALOPERIDOL LACTATE							
	INJECTABLE; INJECTION							
	HALOPERIDOL							
AP	PFIZER	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	May	CAHN
AP	SAGENT PHARMS	EQ 5MG BASE/ML	A200742	001	Sep 02, 2011	Aug	NEWA
AP		EQ 5MG BASE/ML	A091637	001	Sep 02, 2011	Aug	NEWA
	HEPARIN SODIUM							
	INJECTABLE; INJECTION							
	HEPARIN SODIUM							
	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Jul	NEWA
		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Jul	NEWA
		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jul	NEWA
AP	SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091659	001	Jun 08, 2011	May	NEWA
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	May	NEWA
	HEPARIN SODIUM PRESERVATIVE FREE							
	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Jul	NEWA
	HEXAMINOLEVULINATE HYDROCHLORIDE							
	FOR SOLUTION; INTRAVESICAL							
	CYSVIEW KIT							
	+ GE HEALTHCARE	100MG/VIAL	N022555	001	May 28, 2010	May	CAHN
	HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE							
	TABLET; ORAL							
	HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE							
AB	NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Apr	NEWA
	TUSSIGON							
AB	+ KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC

HYALURONIDASE

INJECTABLE; INJECTION
HYDASE

+	AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

AA	HETERO LABS UNIT III	10MG	A040901	001	Sep 12, 2008	Jul	CAHN
AA		25MG	A040901	002	Sep 12, 2008	Jul	CAHN
AA		50MG	A040901	003	Sep 12, 2008	Jul	CAHN
AA		100MG	A040901	004	Sep 12, 2008	Jul	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN
AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL
HYDROCHLOROTHIAZIDE

	@ ACTAVIS ELIZABETH	25MG	A085054	002		Aug	DISC
	@	50MG	A085208	001		Aug	DISC
>D> AB	IVAX SUB TEVA PHARMS	50MG	A083177	002		Nov	CRLD
>A> AB	+	50MG	A083177	002		Nov	CRLD
AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809	002	Sep 04, 2007	Jan	CAHN
>D> AB	+ MYLAN	50MG	A040735	003	Jan 23, 2007	Nov	CRLD
>A> AB	MYLAN PHARMS INC	50MG	A040735	003	Jan 23, 2007	Nov	CRLD

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

	@ SANOFI AVENTIS	12.5MG;75MG	N020758	001	Sep 30, 1997	Jun	CAHN
	+	12.5MG;150MG	N020758	002	Sep 30, 1997	Sep	CRLD
		12.5MG;150MG	N020758	002	Sep 30, 1997	Jun	CAHN
		12.5MG;300MG	N020758	003	Aug 31, 1998	Sep	CRLD
	+	12.5MG;300MG	N020758	003	Aug 31, 1998	Aug	CRLD
		12.5MG;300MG	N020758	003	Aug 31, 1998	Jun	CAHN
	@	25MG;300MG	N020758	004	Mar 15, 2005	Aug	DISC
	+	25MG;300MG	N020758	004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002	Aug	CAHN
AB		12.5MG;20MG	A076230	002	Jul 01, 2002	Aug	CAHN
AB		25MG;20MG	A076230	003	Jul 01, 2002	Aug	CAHN
AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230	001	Jul 01, 2002	May	CAHN
AB		12.5MG;20MG	A076230	002	Jul 01, 2002	May	CAHN
AB		25MG;20MG	A076230	003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356	002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356	003	Apr 20, 2011	Apr	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A> AB	LANNETT HOLDINGS INC	25MG;37.5MG	A201407	001	Dec 09, 2011	Nov	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
REZIRA

+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun	NEWA

HYDROCORTISONE

CREAM; TOPICAL
ALA-CORT

AT	CROWN LABS	1%	A080706	006		Sep	CAHN

LOTION; TOPICAL
ALA-CORT

AT	CROWN LABS	1%	A083201	001		Sep	CAHN

ALA-SCALP

	CROWN LABS	2%	A083231	001		Sep	CAHN

SOLUTION; TOPICAL
TEXACORT

+	STAYMA	2.5%	A081271	001	Apr 17, 1992	Aug	CAHN
+	TIBER LABS	2.5%	A081271	001	Apr 17, 1992	May	CAHN

TABLET; ORAL
HYDROCORTISONE

AB	COREPHARMA	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646	002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE

@	FERA PHARMS	0.5%	A080828	001		Mar	CAHN

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL
PANDEL

>A> +	NYCOMED US	0.1%	N020453	001	Feb 28, 1997	Nov	CAHN
>D> +	SAVAGE LABS	0.1%	N020453	001	Feb 28, 1997	Nov	CAHN

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

@	HOSPIRA	EQ 250MG BASE/VIAL	A085930	001		Aug	DISC

		INJECTABLE; INJECTION							
		A-HYDROCORT							
		@ HOSPIRA	EQ 500MG BASE/VIAL	A085931	001			Aug	DISC
		@	EQ 1GM BASE/VIAL	A085932	001			Aug	DISC
		HYDROFLUMETHIAZIDE							
		TABLET; ORAL							
		HYDROFLUMETHIAZIDE							
		@ PAR PHARM	50MG	A088850	001	May 31, 1985		May	DISC
		HYDROMORPHONE HYDROCHLORIDE							
		TABLET; ORAL							
		HYDROMORPHONE HYDROCHLORIDE							
	AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005		Feb	CAHN
>D>	AB	KV PHARM	2MG	A077311	001	Nov 09, 2005		Nov	CAHN
>D>	AB		4MG	A077311	002	Nov 09, 2005		Nov	CAHN
>D>	AB		8MG	A077311	003	Nov 09, 2005		Nov	CAHN
>A>	AB	NESHER PHARMS	2MG	A077311	001	Nov 09, 2005		Nov	CAHN
>A>	AB		4MG	A077311	002	Nov 09, 2005		Nov	CAHN
>A>	AB		8MG	A077311	003	Nov 09, 2005		Nov	CAHN
		HYDROXOCOBALAMIN							
		INJECTABLE; INJECTION							
		CYANOKIT							
		@ MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006		Sep	DISC
		+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011		Sep	CMFD
		@	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011		Apr	DISC
		HYDROXYAMPHETAMINE HYDROBROMIDE							
		SOLUTION/DROPS; OPHTHALMIC							
		PAREDRINE							
		@ PHARMICS	1%	N000004	004			Jan	CAHN
		HYDROXYPROGESTERONE CAPROATE							
		SOLUTION; INTRAMUSCULAR							
		MAKENA							
		+ KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011		Feb	NEWA
		HYDROXYZINE HYDROCHLORIDE							
		TABLET; ORAL							
		HYDROXYZINE HYDROCHLORIDE							
		@ ACTAVIS TOTOWA	10MG	A040600	001	Dec 28, 2004		Jul	DISC
		@	25MG	A040602	001	Dec 28, 2004		Jul	DISC
		@	50MG	A040604	001	Dec 28, 2004		Jul	DISC
	AB	HETERO LABS UNIT III	10MG	A040805	001	May 29, 2008		Jul	CAHN
	AB		25MG	A040805	002	May 29, 2008		Jul	CAHN
	AB		50MG	A040805	003	May 29, 2008		Jul	CAHN
		IBUPROFEN							
		TABLET; ORAL							
		IBUPROHM							
		@ OHM LABS	400MG	A070469	001	Aug 29, 1985		Aug	DISC

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

		@	FOREST LABS	400MG;5MG	N021378	001	Nov 26, 2004	Aug	DISC

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

>D>	AB	+	ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008	Nov	CRLD
>A>	AB			400MG;5MG	A078769	001	Jan 04, 2008	Nov	CRLD
	AB	+		400MG;5MG	A078769	001	Jan 04, 2008	Aug	CRLD
>D>	AB		BARR	400MG;5MG	A078316	001	Nov 29, 2007	Nov	CRLD
>A>	AB	+	BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007	Nov	CRLD

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

		+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Aug	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

	AP		SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

	AP		BEDFORD LABS	1GM/20ML(50MG/ML)	A076619	001	Jun 29, 2011	Jun	NEWA
	AP			3GM/60ML(50MG/ML)	A076619	002	Jun 29, 2011	Jun	NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

			NOVARTIS	2MG	N022192	002	May 06, 2009	Jan	CAHN
				4MG	N022192	003	May 06, 2009	Jan	CAHN
				6MG	N022192	004	May 06, 2009	Jan	CAHN
				8MG	N022192	005	May 06, 2009	Jan	CAHN
				10MG	N022192	006	May 06, 2009	Jan	CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

		@	ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Jun	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

		@	ACTAVIS TOTOWA	10MG	A040753	001	Feb 28, 2008	Jul	DISC
		@		25MG	A040752	001	Feb 28, 2008	Jul	DISC
		@		50MG	A040751	001	Feb 28, 2008	Jul	DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

	AB		TARO	5%	A200173	001	Apr 15, 2011	Apr	NEWA
	AB		TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	NEWA
	AB		TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

CREAM; TOPICAL
ZYCLARA
\+ GRACEWAY 2.5% N022483 002 Jul 15, 2011 Jul NEWA

INDACATEROL MALEATE

POWDER; INHALATION
ARCAPTA NEOHALER
\+ NOVARTIS EQ 75MCG BASE N022383 001 Jul 01, 2011 Jul NEWA

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
AB HETERO DRUGS LTD 25MG A091240 001 Apr 12, 2011 Mar NEWA
AB 50MG A091240 002 Apr 12, 2011 Mar NEWA
AB HETERO LABS UNIT III 25MG A091240 001 Apr 12, 2011 Jul CAHN
AB 50MG A091240 002 Apr 12, 2011 Jul CAHN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN
AB \+ SANDOZ 75MG A074464 001 May 28, 1998 Jan CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS
DATSCAN
\+ GE HLTHCARE INC 5MCI/2.5ML (2MCI/ML) N022454 001 Jan 14, 2011 Jan NEWA

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200
@ HOSPIRA 41% A074898 001 Dec 30, 1997 Feb DISC
IOPAMIDOL-200 IN PLASTIC CONTAINER
@ HOSPIRA 41% A074636 001 Dec 30, 1997 Feb DISC
IOPAMIDOL-250
@ HOSPIRA 51% A075005 001 Feb 24, 1998 Aug DISC
@ 51% A074898 002 Dec 30, 1997 Feb DISC
IOPAMIDOL-250 IN PLASTIC CONTAINER
@ HOSPIRA 51% A074636 002 Dec 30, 1997 Feb DISC
IOPAMIDOL-300
@ HOSPIRA 61% A075005 002 Feb 24, 1998 Aug DISC
@ 61% A074898 003 Dec 30, 1997 Feb DISC
IOPAMIDOL-300 IN PLASTIC CONTAINER
@ HOSPIRA 61% A074637 001 Apr 03, 1997 Aug DISC
@ 61% A074636 003 Dec 30, 1997 Feb DISC
IOPAMIDOL-370
@ HOSPIRA 76% A075005 003 Feb 24, 1998 Aug DISC
@ 76% A074898 004 Dec 30, 1997 Feb DISC
IOPAMIDOL-370 IN PLASTIC CONTAINER
@ HOSPIRA 76% A074636 004 Dec 30, 1997 Feb DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
@ ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999 Aug DISC
AN RITEDOSE CORP 0.02% A075693 001 Jan 26, 2001 Jul CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA
AP		X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	CAHN
AP			100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER

		LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL

AB		VALEANT INTL	5MG	N012093	007	Jul 29, 1988	Jun	CAHN
AB			10MG	N012093	002	Jul 29, 1988	Jun	CAHN
AB			20MG	N012093	006	Jul 29, 1988	Jun	CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Jun	CAHN
	+		40MG	N012093	001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>D>	AB	KV PHARM	30MG	A075395	001	Mar 16, 2000	Nov	CAHN
>D>	AB		60MG	A075395	002	Mar 16, 2000	Nov	CAHN
>D>	AB		120MG	A075395	003	Mar 16, 2000	Nov	CAHN
>A>	AB	NESHER PHARMS	30MG	A075395	001	Mar 16, 2000	Nov	CAHN
>A>	AB		60MG	A075395	002	Mar 16, 2000	Nov	CAHN
>A>	AB		120MG	A075395	003	Mar 16, 2000	Nov	CAHN
	AB	TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011	May	NEWA
	AB		60MG	A200495	001	Jun 03, 2011	May	NEWA
	AB		120MG	A200495	002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL
ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX

		@ ORTHO MCNEIL JANSSEN	10MG/ML	N020966	001	Mar 30, 1999	May	DISC

TABLET; ORAL
ONMEL

	+	STIEFEL LABS INC	200MG	N022484	001	Apr 29, 2010	May	CTNA

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL
EXTINA

AT	+	STIEFEL LABS INC	2%	N021738	001	Jun 12, 2007	Aug	CFTG

AEROSOL, FOAM; TOPICAL
KETOCONAZOLE

AT	PERRIGO ISRAEL	2%	A091550	001	Aug 25, 2011	Aug	NEWA

GEL; TOPICAL
XOLEGEL

+	AQUA PHARMS	2%	N021946	001	Jul 28, 2006	May	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	PFIZER	15MG/ML	A078299	001	Jul 16, 2007	May	CAHN
AP		30MG/ML	A078299	002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL
SPRIX

+	LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN

LAMIVUDINE

TABLET; ORAL
EPIVIR

>D>		VIIV HLTHCARE	150MG	N020564	001	Nov 17, 1995	Nov	CFTG
>A>	AB		150MG	N020564	001	Nov 17, 1995	Nov	CFTG
>D>	+		300MG	N020564	003	Jun 24, 2002	Nov	CFTG
>A>	AB	+	300MG	N020564	003	Jun 24, 2002	Nov	CFTG

LAMIVUDINE

>A>	AB	APOTEX	150MG	A091606	001	Dec 02, 2011	Nov	NEWA
>A>	AB		300MG	A091606	002	Dec 02, 2011	Nov	NEWA
>A>	AB	AUROBINDO PHARMA LTD	150MG	A202032	001	Nov 17, 2011	Nov	NEWA
>A>	AB		300MG	A202032	002	Nov 17, 2011	Nov	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
COMBIVIR

AB	+	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG

LAMIVUDINE AND ZIDOVUDINE

AB	TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	May	NEWA

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

AB	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB		100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB		150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB		200MG	A078669	004	Apr 08, 2011	Mar	NEWA
AB	ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
AB		100MG	A090607	002	Jan 13, 2011	Jan	NEWA
AB		150MG	A090607	003	Jan 13, 2011	Jan	NEWA
AB		200MG	A090607	004	Jan 13, 2011	Jan	NEWA
AB	ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
AB		100MG	A090607	002	Jan 13, 2011	Apr	CAHN
AB		150MG	A090607	003	Jan 13, 2011	Apr	CAHN
AB		200MG	A090607	004	Jan 13, 2011	Apr	CAHN
AB	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
AB		100MG	A078134	002	Apr 19, 2011	Apr	NEWA
AB		150MG	A078134	003	Apr 19, 2011	Apr	NEWA
AB		200MG	A078134	004	Apr 19, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	25MG	A090170	001	Oct 06, 2011	Sep	NEWA

TABLET; ORAL
LAMOTRIGINE

AB		UNICHEM LABS LTD	100MG	A090170	002	Oct 06, 2011	Sep	NEWA
AB			150MG	A090170	003	Oct 06, 2011	Sep	NEWA
AB			200MG	A090170	004	Oct 06, 2011	Sep	NEWA

TABLET, CHEWABLE; ORAL
LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
LAMICTAL XR

		SMITHKLINE BEECHAM	250MG	N022115	006	Jun 21, 2011	Sep	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

>D>	+	BEAUFOUR IPSEN	EQ 60MG BASE	N022074	001	Aug 30, 2007	Nov	CAHN
>D>	+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Nov	CAHN
>D>	+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Nov	CAHN
>A>	+	IPSEN PHARMS	EQ 60MG BASE	N022074	001	Aug 30, 2007	Nov	CAHN
>A>	+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Nov	CAHN
>A>	+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Nov	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
AT		LUITPOLD	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
AT		PADDOCK LABS	0.005%	A090887	001	Jul 19, 2011	Jul	NEWA
AT		PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LEFLUNOMIDE

TABLET; ORAL
LEFLUNOMIDE

>A>	AB		ALEMBIC PHARMS LTD	10MG	A091369	001	Nov 21, 2011	Nov	NEWA
>A>	AB			20MG	A091369	002	Nov 21, 2011	Nov	NEWA

LETROZOLE

TABLET; ORAL
LETROZOLE

AB		ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
AB		ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Aug	CAHN
AB		AMIDE PHARM	2.5MG	A090292	001	Jul 13, 2011	Jul	NEWA
AB		DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
AB		ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA
AB		FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
AB		IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
AB		INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
AB		KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
AB		NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
AB		ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA

TABLET; ORAL
LETROZOLE

AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
@	SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
AB		2.5MG	A090196	001	Jun 03, 2011	May	NEWA
AB	TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

@	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC

LUPRON DEPOT

+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jun	NEWA

LUPRON DEPOT-PED

+	ABBOTT ENDOCRINE	11.25MG/VIAL	N020263	007	Aug 15, 2011	Aug	NEWA
+		30MG/VIAL	N020263	008	Aug 15, 2011	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug	CAHN
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug	CAHN
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

AP	HIKMA FARMACEUTICA	500MG/5ML(100MG/ML)	A090981	001	Oct 13, 2011	Oct	NEWA
AP	INNOPHARMA LLC	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	NEWA

LEVETIRACETAM IN SODIUM CHLORIDE

>A>	+ HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Nov	NEWA
>A>	+	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Nov	NEWA
>A>	+	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Nov	NEWA

SOLUTION; ORAL
LEVETIRACETAM

AA	APOTEX	100MG/ML	A090187	001	Aug 05, 2011	Jul	NEWA
AA	LUPIN LTD	100MG/ML	A090893	001	Oct 17, 2011	Oct	NEWA

TABLET; ORAL
LEVETIRACETAM

AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA
AB	AJANTA PHARMA	250MG	A201293	001	Jun 14, 2011	May	NEWA
AB		500MG	A201293	002	Jun 14, 2011	May	NEWA
AB		750MG	A201293	003	Jun 14, 2011	May	NEWA
AB		1GM	A201293	004	Jun 14, 2011	May	NEWA
AB	BRECKENRIDGE PHARM	250MG	A090511	001	Aug 18, 2011	Aug	NEWA
AB		500MG	A090511	002	Aug 18, 2011	Aug	NEWA
AB		750MG	A090511	003	Aug 18, 2011	Aug	NEWA
AB		1GM	A090511	004	Aug 18, 2011	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL
KEPPRA XR

AB	UCB INC	500MG	N022285	001	Sep 12, 2008	Aug	CFTG

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

AB	+	UCB INC	750MG	N022285	002	Feb 12, 2009	Aug	CFTG

LEVETIRACETAM

AB		ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091557	002	Sep 12, 2011	Aug	NEWA
AB		ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Sep	NEWA
AB			750MG	A091360	002	Oct 04, 2011	Sep	NEWA
AB		APOTEX INC	500MG	A091261	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091261	002	Sep 12, 2011	Aug	NEWA
AB		LUPIN LTD	500MG	A091399	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091399	002	Sep 12, 2011	Aug	NEWA
AB		MUTUAL PHARM CO INC	500MG	A091285	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091285	002	Sep 12, 2011	Aug	NEWA
AB		PAR PHARM	500MG	A091291	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091291	002	Sep 12, 2011	Aug	NEWA
AB		TEVA PHARMS	500MG	A091430	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091430	002	Sep 12, 2011	Aug	NEWA
AB		WATSON LABS FLORIDA	500MG	A091093	001	Sep 12, 2011	Aug	NEWA
AB			750MG	A091093	002	Sep 12, 2011	Aug	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		SYNTHON PHARMS	2.5MG/5ML	A091263	001	Nov 07, 2011	Oct	NEWA

XYZAL

AA	+	UCB INC	2.5MG/5ML	N022157	001	Jan 28, 2008	Oct	CFTG

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
AB		GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA
AB		TEVA PHARMS	5MG	A090199	001	Aug 22, 2011	Aug	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

AP	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Jun	CFTG

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	CFTG
AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	CFTG

LEVOFLOXACIN

AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Jun	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Jun	NEWA
AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jun	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jun	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jun	NEWA
AP		HIKMA FARMACEUTICA	EQ 250MG/50ML (EQ 5MG/ML)	A091375	001	Sep 16, 2011	Sep	NEWA
AP			EQ 500MG/100ML (EQ5MG/ML)	A091375	002	Sep 16, 2011	Sep	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A091375	003	Sep 16, 2011	Sep	NEWA

	SOLUTION; ORAL							
	LEVAQUIN							
AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004	Jun	CFTG	
	LEVOFLOXACIN							
AA	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Jun	NEWA	
	SOLUTION/DROPS; OPHTHALMIC							
	LEVOFLOXACIN							
AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA	
	TABLET; ORAL							
	LEVAQUIN							
AB	ORTHO MCNEIL JANSSEN	250MG	N020634	001	Dec 20, 1996	Jun	CFTG	
AB		500MG	N020634	002	Dec 20, 1996	Jun	CFTG	
AB	+	750MG	N020634	003	Sep 08, 2000	Jun	CFTG	
	LEVOFLOXACIN							
AB	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Sep	NEWA	
AB		500MG	A090787	002	Sep 29, 2011	Sep	NEWA	
AB		750MG	A090787	003	Sep 29, 2011	Sep	NEWA	
AB	AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A201043	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A201043	003	Jun 20, 2011	Jun	NEWA	
AB	DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A076710	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A076710	003	Jun 20, 2011	Jun	NEWA	
AB	GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A200250	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A200250	003	Jun 20, 2011	Jun	NEWA	
AB	LUPIN	250MG	A078424	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A078424	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A078424	003	Jun 20, 2011	Jun	NEWA	
AB	MYLAN	250MG	A076276	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A076276	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A077097	001	Jun 20, 2011	Jun	NEWA	
AB	SANDOZ	250MG	A077438	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A077438	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A077438	003	Jun 20, 2011	Jun	NEWA	
AB	TEVA	250MG	A076361	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A076361	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A076361	003	Jun 20, 2011	Jun	NEWA	
AB	TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A090722	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A090722	003	Jun 20, 2011	Jun	NEWA	
AB	WOCKHARDT	250MG	A090367	001	Jun 20, 2011	Jun	NEWA	
AB		500MG	A090367	002	Jun 20, 2011	Jun	NEWA	
AB		750MG	A090367	003	Jun 20, 2011	Jun	NEWA	
	LEVOLEUCOVORIN CALCIUM							
	POWDER; IV (INFUSION)							
	FUSILEV							
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA	
	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA	
	SOLUTION; IV (INFUSION)							
	FUSILEV							
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Oct	CMS1	

SOLUTION; IV (INFUSION)
FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Oct	CMS1
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL
PLAN B

AB	+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN
	@	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

	@ VALEANT PHARM INTL	2MG	N008720	001	Dec 19, 1991	Mar	DISC

LEVORPHANOL TARTRATE

	ROXANE	2MG	A074278	001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

+	APP PHARMS	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	NEWA
+		200MCG/VIAL	N202231	002	Jun 24, 2011	Jun	NEWA
+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	NEWA

TABLET; ORAL
LEVO-T

AB1, AB2, AB3	ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC

		TABLET; ORAL							
		LEVO-T							
AB1, AB2, AB3	+	ALARA PHARM	0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC	
		LIDOCAINE							
		OINTMENT; TOPICAL							
		LIDOCAINE							
AT		NOVOCOL INC	5%	A040911	001	May 23, 2011	May	NEWA	
		LIDOCAINE HYDROCHLORIDE							
		JELLY; TOPICAL							
		LIDOCAINE HYDROCHLORIDE							
AT		HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	Mar	NEWA	
		XYLOCAINE							
AT	+	OAK PHARMS	2%	N008816	001		Aug	CAHN	
		SOLUTION; ORAL							
		LIDOCAINE HYDROCHLORIDE VISCOUS							
		@ ACTAVIS MID ATLANTIC	2%	A086578	001		Aug	DISC	
		SOLUTION; TOPICAL							
		PEDIATRIC LTA KIT							
		@ HOSPIRA	2%	A085995	001		Aug	DISC	
		SYSTEM; INTRADERMAL							
		ZINGO							
		@ POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Jun	CAHN	
		LIDOCAINE; PRILOCAINE							
		CREAM; TOPICAL							
		EMLA							
AB	+	OAK PHARMS	2.5%;2.5%	N019941	001	Dec 30, 1992	Aug	CAHN	
		LINAGLIPTIN							
		TABLET; ORAL							
		TRADJENTA							
	+	BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011	May	NEWA	
		LINDANE							
		LOTION; TOPICAL							
		LINDANE							
AT		OLTA PHARMS	1%	A087313	001		Oct	CMFD	
AT	+	WOCKHARDT	1%	A088190	001	Aug 16, 1984	Oct	CTEC	
		LISINOPRIL							
		TABLET; ORAL							
		LISINOPRIL							
AB		PRINSTON INC	2.5MG	A076180	001	Jul 01, 2002	Aug	CAHN	
AB			5MG	A076180	002	Jul 01, 2002	Aug	CAHN	
AB			10MG	A076180	003	Jul 01, 2002	Aug	CAHN	
AB			20MG	A076164	001	Jul 01, 2002	Aug	CAHN	
AB			30MG	A076164	002	Jul 01, 2002	Aug	CAHN	
AB			40MG	A076164	003	Jul 01, 2002	Aug	CAHN	
AB		PRINSTON PHARM LLC	2.5MG	A076180	001	Jul 01, 2002	May	CAHN	
AB			5MG	A076180	002	Jul 01, 2002	May	CAHN	
AB			10MG	A076180	003	Jul 01, 2002	May	CAHN	
AB			20MG	A076164	001	Jul 01, 2002	May	CAHN	

TABLET; ORAL
LISINOPRIL

AB	PRINSTON PHARM LLC	30MG	A076164	002	Jul 01, 2002	May	CAHN
AB		40MG	A076164	003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP	TAYLOR	2MG/ML	A075025	001	Jul 23, 1998	Sep	CMFD

TABLET; ORAL
ATIVAN

AB	VALEANT INTL	0.5MG	N017794	001		Jul	CAHN
AB		1MG	N017794	002		Jul	CAHN
AB +		2MG	N017794	003		Jul	CAHN

LORAZEPAM

	@ MUTUAL PHARM	0.5MG	A072553	001	Mar 29, 1991	Sep	DISC
	@	1MG	A072554	001	Mar 29, 1991	Sep	DISC
	@	2MG	A072555	001	Mar 29, 1991	Sep	DISC

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428	001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428	002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428	003	Oct 06, 2010	Apr	CAHN
AB	HUAHAI US INC	25MG	A091497	001	Jun 06, 2011	May	NEWA
AB		50MG	A091497	002	Jun 06, 2011	May	NEWA
AB		100MG	A091497	003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590	002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590	003	Oct 06, 2010	Jan	NEWA
AB	PRINSTON INC	25MG	A091497	001	Jun 06, 2011	Aug	CAHN
AB		50MG	A091497	002	Jun 06, 2011	Aug	CAHN
AB		100MG	A091497	003	Jun 06, 2011	Aug	CAHN

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011	Apr	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXAPINE SUCCINATE

AB	LANNETT HOLDINGS INC	EQ 5MG BASE	A090695	001	Sep 26, 2011	Sep	NEWA
AB		EQ 10MG BASE	A090695	002	Sep 26, 2011	Sep	NEWA
AB		EQ 25MG BASE	A090695	003	Sep 26, 2011	Sep	NEWA
AB		EQ 50MG BASE	A090695	004	Sep 26, 2011	Sep	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

@	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982	Aug	DISC	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA	
AA		25MG	A201451	002	Feb 23, 2011	Feb	NEWA	
AA		50MG	A201451	003	Feb 23, 2011	Feb	NEWA	
AA	JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN	
AA		25MG	A040659	002	Jun 04, 2010	Jan	CAHN	

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

AB	LUPIN LTD	250MG	A091322	001	Jul 22, 2011	Jul	NEWA	

MELOXICAM

TABLET; ORAL
MELOXICAM

AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN	
AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN	
AB	PURACAP PHARM	7.5MG	A077938	001	Jul 19, 2006	Jun	CAHN	
AB		15MG	A077938	002	Jul 19, 2006	Jun	CAHN	

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE

@	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	May	CAHN	
@		10MG	A090058	002	May 05, 2010	May	CAHN	

MEMANTINE HYDROCHLORIDE

@	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	Oct	NEWA	
@		10MG	A090052	002	Oct 25, 2011	Oct	NEWA	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002	001	Jul 30, 1993	May	CAHN	

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	May	CAHN	
AA		400MG	A090122	002	Feb 18, 2009	May	CAHN	
AA	TARO	200MG	A200998	001	May 23, 2011	May	NEWA	
AA		400MG	A200998	002	May 23, 2011	May	NEWA	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

+	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	May	CAHN	

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Oct	NEWA
AP			1GM/VIAL	A091404	002	Oct 26, 2011	Oct	NEWA
AP		SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
AP			1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA

MERREM

AP	+	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+	MEDA PHARMS	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN

SFROWASA

AB		MEDA PHARMS	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

	+	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN

ASACOL HD

	+	WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008	Jun	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB		APOTEX	500MG	A090666	001	Dec 07, 2011	Nov	NEWA
>A>	AB			850MG	A090666	002	Dec 07, 2011	Nov	NEWA
>A>	AB			1GM	A090666	003	Dec 07, 2011	Nov	NEWA
	AB		MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
	AB			850MG	A075973	002	Jan 25, 2002	Feb	CAHN
	AB			1GM	A075973	003	Jan 25, 2002	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

	AB2		ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Jun	CTEC
	AB	+		1GM	N021574	002	Apr 27, 2004	Jun	CTEC

GLUCOPHAGE XR

	AB1		BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	CTEC

GLUMETZA

>D>	BX		DEPOMED INC	500MG	N021748	001	Jun 03, 2005	Nov	CAHN
>D>	BX	+		1GM	N021748	002	Jun 03, 2005	Nov	CAHN
>A>	BX		SANTARUS	500MG	N021748	001	Jun 03, 2005	Nov	CAHN
>A>	BX	+		1GM	N021748	002	Jun 03, 2005	Nov	CAHN

METFORMIN HYDROCHLORIDE

		@	ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004	Aug	DISC
	AB1			500MG	A076450	001	Oct 01, 2004	Jun	CTEC
		@		750MG	A076878	001	Apr 13, 2005	Aug	DISC
	AB1		ALVOGEN	500MG	A078321	001	Apr 17, 2008	Aug	CAHN
	AB			750MG	A078321	002	Apr 17, 2008	Aug	CAHN
	AB1		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Jun	CTEC
	AB1		APOTEX	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
	AB			750MG	A076706	002	Dec 29, 2005	Jun	CAHN
	AB1		IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Jun	CTEC
	AB2		LUPIN LTD	500MG	A090692	001	Jun 29, 2011	Aug	CAHN
	AB2			500MG	A090692	001	Jun 29, 2011	Jun	NEWA

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB		LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Aug	CAHN
AB			1GM	A090692	002	Jun 29, 2011	Jun	NEWA
AB1		MYLAN	500MG	A076650	001	Sep 13, 2005	Jun	CTEC
AB1		NEUROSCI INC	500MG	A078321	001	Apr 17, 2008	Jun	CTEC
AB1		NOSTRUM	500MG	A076756	001	Jul 26, 2006	Jun	CTEC
AB1		RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
AB1		SANDOZ	500MG	A076873	001	Dec 14, 2004	Jun	CTEC
AB1		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC
AB1		TEVA	500MG	A076269	001	Jun 18, 2004	Jun	CTEC
AB1		TORRENT PHARM	500MG	A090014	001	Dec 30, 2009	Jun	CTEC
AB1		WATSON LABS FLORIDA	500MG	A076172	001	Jun 16, 2004	Jun	CTEC
AB1		WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
AB1		ZYDUS PHARMS USA	500MG	A077060	001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET

AB		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB			850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION
DOLOPHINE HYDROCHLORIDE

	+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Oct	CAHN

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

AB		EMCURE PHARMS USA	5MG	A040734	001	Dec 14, 2007	Jul	CAHN
AB			10MG	A040734	002	Dec 14, 2007	Jul	CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA		AUSTARPHARMA LLC	500MG	A200958	001	Oct 21, 2011	Oct	NEWA
AA			750MG	A200958	002	Oct 21, 2011	Oct	NEWA
AA		LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
AA			750MG	A084756	001		Jun	CAHN
	@	PURACAP PHARM	500MG	A084231	002		Jun	CAHN
	@		750MG	A084471	001		Jun	CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
METHSCOPOLAMINE BROMIDE

>A>	AA	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Nov	NEWA
>A>	AA		5MG	A040642	002	Dec 06, 2011	Nov	NEWA

METHYLERGONOVINE MALEATE

TABLET; ORAL
METHERGINE

AB	+	NOVARTIS	0.2MG	N006035	003		Apr	CTEC

TABLET; ORAL
METHYLERGONOVINE MALEATE

AB		NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	NEWA

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS
RELISTOR

		PROGENICS	8MG/0.4ML	N021964	002	Sep 27, 2010	Oct	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>A>			ACTAVIS	20MG	A078458	001	Dec 01, 2011	Nov	NEWA
>A>	AB			30MG	A078458	002	Dec 01, 2011	Nov	NEWA
>A>	AB			40MG	A078458	003	Dec 01, 2011	Nov	NEWA
			RITALIN LA						
>D>	BX		NOVARTIS	20MG	N021284	001	Jun 05, 2002	Nov	CFTG
>A>	AB			20MG	N021284	001	Jun 05, 2002	Nov	CFTG
>D>	BX			30MG	N021284	002	Jun 05, 2002	Nov	CFTG
>A>	AB			30MG	N021284	002	Jun 05, 2002	Nov	CFTG
>D>	BX	+		40MG	N021284	003	Jun 05, 2002	Nov	CFTG
>A>	AB	+		40MG	N021284	003	Jun 05, 2002	Nov	CFTG

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

		@ ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002	Aug	DISC
		@	10MG	A040321	002	Feb 05, 2002	Aug	DISC
		@	20MG	A040321	003	Feb 05, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

		@ ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001	Aug	DISC

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP		HEMOFARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
AP			EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
		@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC
		METHYLPREDNISOLONE SODIUM SUCCINATE						
AP		MUSTAFA NEVSAT	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jul	NEWA
AP			EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jul	NEWA
AP			EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jul	NEWA
		SOLU-MEDROL						
AP	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856	007	Feb 27, 1985	Jul	CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

	@ HOSPIRA	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991	Aug		DISC

TABLET; ORAL
REGLAN

AB	ANI PHARMS	EQ 5MG BASE	N017854	002	May 05, 1987	Aug		CAHN
AB +		EQ 10MG BASE	N017854	001		Aug		CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
REGLAN ODT

	@ MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005	Aug		CAHN
	@	EQ 10MG BASE	N021793	002	Jun 10, 2005	Aug		CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

>D> AB	KV PHARM	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Nov		CAHN
>D> AB		EQ 50MG TARTRATE	A077176	001	May 14, 2008	Nov		CAHN
>D> AB		EQ 100MG TARTRATE	A076640	002	May 18, 2007	Nov		CAHN
>D> AB		EQ 200MG TARTRATE	A076640	001	May 18, 2007	Nov		CAHN
>A> AB	NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Nov		CAHN
>A> AB		EQ 50MG TARTRATE	A077176	001	May 14, 2008	Nov		CAHN
>A> AB		EQ 100MG TARTRATE	A076640	002	May 18, 2007	Nov		CAHN
>A> AB		EQ 200MG TARTRATE	A076640	001	May 18, 2007	Nov		CAHN

METRONIDAZOLE

GEL; TOPICAL
METROGEL

AB +	GALDERMA LABS LP	1%	N021789	001	Jun 30, 2005	Jul		CTEC

METRONIDAZOLE

AB	G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan		NEWA
AB	TOLMAR	1%	A090903	001	Jul 22, 2011	Jul		NEWA

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP +	PFIZER	500MG/100ML	N018353	002		Jun		CAHN

TABLET; ORAL
METRONIDAZOLE

AB	ALEMBIC PHARMS LTD	250MG	A079067	001	Mar 13, 2009	May		CAHN
AB		500MG	A079067	002	Mar 13, 2009	May		CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

	@ PFIZER	EQ 500MG BASE/VIAL	N018353	001		Jun		DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan		CRLD

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

	@ ORTHO JANSSEN	2%	N017494	001		Jul		CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

		MIDAZOLAM HYDROCHLORIDE						
	@	HOSPIRA	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000	Aug	DISC
		MIDOZALAM HYDROCHLORIDE						
AP		SAGENT STRIDES	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	NEWA
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

		SAVELLA						
	+	CYPRESS BIOSCIENCE	50MG	N022256	003	Jan 14, 2009	Aug	CRLD
			100MG	N022256	004	Jan 14, 2009	Aug	CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION

		MILRINONE LACTATE						
	@	HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

		MINOCYCLINE HYDROCHLORIDE						
AB		PAR PHARM	EQ 50MG BASE	A065131	001	Apr 16, 2003	Oct	CAHN
AB			EQ 75MG BASE	A065131	002	Apr 16, 2003	Oct	CAHN
AB	+		EQ 100MG BASE	A065131	003	Apr 16, 2003	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL

		MINOCYCLINE HYDROCHLORIDE						
>A> AB		LUPIN LTD	EQ 45MG BASE	A091424	001	Nov 30, 2011	Nov	NEWA
>A>	@		EQ 55MG BASE	A091424	002	Nov 30, 2011	Nov	NEWA
>A> AB			EQ 90MG BASE	A091424	003	Nov 30, 2011	Nov	NEWA
>A> AB			EQ 135MG BASE	A091424	004	Nov 30, 2011	Nov	NEWA

MIRTAZAPINE

TABLET; ORAL

		MIRTAZAPINE						
	@	ACTAVIS ELIZABETH	15MG	A076308	001	Jun 20, 2003	Aug	DISC
	@		30MG	A076308	002	Jun 20, 2003	Aug	DISC
	@		45MG	A076308	003	Jun 20, 2003	Aug	DISC
	@	ACTAVIS TOTOWA	15MG	A076241	001	Jun 25, 2003	Jul	DISC
	@		30MG	A076241	002	Jun 25, 2003	Jul	DISC
	@		45MG	A076241	003	Jun 25, 2003	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

		MIRTAZAPINE						
AB		ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA
AB			30MG	A077959	002	Feb 14, 2011	Jan	NEWA
AB			45MG	A077959	003	Feb 14, 2011	Jan	NEWA
	@	ACTAVIS TOTOWA	15MG	A076689	001	Aug 31, 2005	Jul	DISC
	@		30MG	A076689	002	Aug 31, 2005	Jul	DISC
	@		45MG	A076689	003	Aug 31, 2005	Jul	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

		MITOXANTRONE HYDROCHLORIDE						
>D> AP		BIONICHE PHARMA USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Nov	CAHN

			INJECTABLE; INJECTION							
			MITOXANTRONE HYDROCHLORIDE							
>D>	AP		BIONICHE PHARMA USA	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Nov	CAHN
	AP	+	HOSPIRA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871	001	Apr 11, 2006	Aug	CRLD
	AP	+		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871	002	Apr 11, 2006	Aug	CRLD
	AP	+		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871	003	Apr 11, 2006	Aug	CRLD
>A>	AP		MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Nov	CAHN
>A>	AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Nov	CAHN
			NOVANTRONE						
			@ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987	Aug	DISC
			MORPHINE SULFATE						
			CAPSULE, EXTENDED RELEASE; ORAL						
			KADIAN						
	AB		ACTAVIS ELIZABETH	20MG	N020616	001	Jul 03, 1996	Oct	CFTG
	AB			30MG	N020616	004	Mar 09, 2001	Oct	CFTG
	AB			50MG	N020616	002	Jul 03, 1996	Oct	CFTG
	AB			60MG	N020616	005	Mar 09, 2001	Oct	CFTG
	AB			80MG	N020616	006	Oct 27, 2006	Oct	CFTG
	AB	+		100MG	N020616	003	Jul 03, 1996	Oct	CFTG
			MORPHINE SULFATE						
	AB		WATSON LABS	20MG	A200812	001	Nov 10, 2011	Oct	NEWA
	AB			30MG	A200812	002	Nov 10, 2011	Oct	NEWA
	AB			50MG	A200812	003	Nov 10, 2011	Oct	NEWA
	AB			60MG	A200812	004	Nov 10, 2011	Oct	NEWA
	AB			80MG	A200812	005	Nov 10, 2011	Oct	NEWA
	AB			100MG	A200812	006	Nov 10, 2011	Oct	NEWA
			INJECTABLE; INJECTION						
>A>			MORPHINE SULFATE						
>A>		+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Nov	NEWA
>A>		+		4MG/ML	N202515	002	Nov 14, 2011	Nov	NEWA
>A>		+		8MG/ML	N202515	003	Nov 14, 2011	Nov	NEWA
>A>		+		10MG/ML	N202515	004	Nov 14, 2011	Nov	NEWA
>A>		+		15MG/ML	N202515	005	Nov 14, 2011	Nov	NEWA
			INJECTABLE, LIPOSOMAL; EPIDURAL						
			DEPODUR						
		+	EKR THERAP	10MG/ML (10MG/ML)	N021671	001	May 18, 2004	May	CRLD
			@	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004	May	DISC
			SOLUTION; ORAL						
			MORPHINE SULFATE						
			LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011	Jun	NEWA
	AA		MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Jul	NEWA
	AA	+	ROXANE	100MG/5ML	N022195	003	Jan 25, 2010	Aug	CTEC
			TABLET, EXTENDED RELEASE; ORAL						
			MORPHINE SULFATE						
>D>	AB		KV PHARM	15MG	A076733	001	May 19, 2004	Nov	CAHN
>D>	AB			30MG	A076720	002	Dec 23, 2005	Nov	CAHN
>D>	AB			60MG	A076720	001	May 19, 2004	Nov	CAHN
>D>	AB			100MG	A077855	001	Sep 27, 2007	Nov	CAHN
>D>	AB			200MG	A077855	002	Sep 27, 2007	Nov	CAHN
	AB		MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Oct	NEWA
	AB			30MG	A200824	002	Oct 18, 2011	Oct	NEWA

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	MYLAN PHARMS INC	60MG	A200824	003	Oct 18, 2011	Oct	NEWA
AB		100MG	A200824	004	Oct 18, 2011	Oct	NEWA
AB		200MG	A200824	005	Oct 18, 2011	Oct	NEWA
>A> AB	NESHER PHARMS	15MG	A076733	001	May 19, 2004	Nov	CAHN
>A> AB		30MG	A076720	002	Dec 23, 2005	Nov	CAHN
>A> AB		60MG	A076720	001	May 19, 2004	Nov	CAHN
>A> AB		100MG	A077855	001	Sep 27, 2007	Nov	CAHN
>A> AB		200MG	A077855	002	Sep 27, 2007	Nov	CAHN
@	WATSON LABS	100MG	A075656	001	Jan 30, 2001	Aug	DISC

MUPIROCIN

OINTMENT; TOPICAL
MUPIROCIN

AB	GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011	May	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL
BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
MYCOPHENOLATE MOFETIL

AB	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct	NEWA

TABLET; ORAL
MYCOPHENOLATE MOFETIL

AB	ALKEM LABS LTD	500MG	A091249	001	Nov 04, 2011	Oct	NEWA
@	DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010	Oct	DISC

NABUMETONE

TABLET; ORAL
NABUMETONE

@	ACTAVIS ELIZABETH	500MG	A079093	001	Feb 27, 2009	Aug	DISC
@		750MG	A079093	002	Feb 27, 2009	Aug	DISC
AB	LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
AB		750MG	A090445	002	Jan 12, 2011	Jan	NEWA
AB	WATSON LABS	500MG	A091083	001	Jun 13, 2011	May	NEWA
AB		750MG	A091083	002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	ACIC FINE CHEMS	EQ 1GM BASE	A090560	001	Oct 03, 2011	Sep	NEWA
AP		EQ 2GM BASE	A090560	002	Oct 03, 2011	Sep	NEWA
AP	IBI	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Jun	NEWA
AP		EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Jun	NEWA
AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Apr	NEWA
AP +	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A091205	001	Aug 17, 2011	Aug	NEWA
AB	ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	AUROBINDO PHARMA USA	250MG	A200429	001	Nov 08, 2011	Oct	NEWA
AB		375MG	A200429	002	Nov 08, 2011	Oct	NEWA
AB		500MG	A200429	003	Nov 08, 2011	Oct	NEWA
AB	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Aug	NEWA
AB		375MG	A091305	002	Aug 24, 2011	Aug	NEWA
AB		500MG	A091305	003	Aug 24, 2011	Aug	NEWA
AB	MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416	002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416	003	Feb 14, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

	@ ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998	Aug	DISC
	@	500MG	A074936	002	Feb 24, 1998	Aug	DISC
AB	INVAGEN PHARMS	375MG	A091432	001	Sep 19, 2011	Sep	NEWA
AB		500MG	A091432	002	Sep 19, 2011	Sep	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A200629	001	Oct 31, 2011	Oct	NEWA
AB		EQ 500MG BASE	A200629	002	Oct 31, 2011	Oct	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Apr	NEWA
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Apr	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	HERITAGE PHARMS INC	EQ 1MG BASE	A200502	001	Feb 28, 2011	Oct	CAHN
AB		EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Oct	CAHN
AB	INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
AB		EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

	@ EKR THERAP	45MG	N020005	002	Feb 21, 1992	May	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2		VALEANT INTL	30MG	A075289	002	Feb 06, 2001	Apr	CAHN
AB1			30MG	A075269	001	Dec 04, 2000	Apr	CAHN
AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

		NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010	Aug	NEWA

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB	+	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Sep	CRLD
AB		BARR LABS INC	30MG	A077811	001	May 02, 2007	Sep	CRLD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Apr	CFTG

NITROFURANTOIN

AB		AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

	+	PROSTRAKAN INC	0.4%	N021359	001	Jun 21, 2011	Jun	NEWA

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB		GLENMARK GENERICS	150MG	A090618	001	Jul 15, 2011	Jul	NEWA
AB			300MG	A090618	002	Jul 15, 2011	Jul	NEWA
AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NORETHINDRONE

TABLET; ORAL-28
NORETHINDRONE

AB1		LUPIN LTD	0.35MG	A091325	001	Sep 19, 2011	Sep	NEWA

NORGESTREL

TABLET; ORAL
OVRETTE

	@	WYETH PHARMS	0.075MG	N017031	001		Aug	CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
PAMELOR

AB		MALLINCKRODT LLC	EQ 10MG BASE	N018013	001		Aug	CAHN
AB			EQ 25MG BASE	N018013	002		Aug	CAHN
AB			EQ 50MG BASE	N018013	004		Aug	CAHN
AB	+		EQ 75MG BASE	N018013	003		Aug	CAHN

SOLUTION; ORAL
PAMELOR

	@	MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012	001		Sep	DISC
AA			EQ 10MG BASE/5ML	N018012	001		Jul	CAHN

NYSTATIN

CREAM; TOPICAL
MYCOSTATIN

	@	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575	001		Aug	DISC

NYSTATIN

AT		TARO	100,000 UNITS/GM	A064022	001	Jan 29, 1993	Aug	CRLD

POWDER; TOPICAL
MYCOSTATIN

	@	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578	001		Aug	DISC

NYSTATIN

AT	+	COASTAL PHARMS	100,000 UNITS/GM	A065203	001	Jul 15, 2004	Oct	CRLD
AT			100,000 UNITS/GM	A065203	001	Jul 15, 2004	Aug	CRLD
>D> AT		KV PHARM	100,000 UNITS/GM	A065321	001	Aug 18, 2006	Nov	CAHN
>A> AT		NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006	Nov	CAHN

SUSPENSION; ORAL
NYSTATIN

AA		HI TECH PHARMA	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Aug	CAHN
AA		VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYKACET

	@	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Aug	DISC

OINTMENT; TOPICAL
MYKACET

	@	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Aug	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP		WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Apr	NEWA
AP			EQ 1MG BASE/ML	A090986	002	May 11, 2011	Apr	NEWA

	INJECTABLE; INJECTION							
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
AP		EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
AP		EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA
AP	MYLAN INSTITUTIONAL	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Aug	CAHN
AP		EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Aug	CAHN
AP		EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Aug	CAHN
AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Apr	NEWA
AP		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Apr	NEWA
AP		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Apr	NEWA
	OFLOXACIN							
	SOLUTION/DROPS; OPHTHALMIC							
	OFLOXACIN							
AT	FERA PHARMS	0.3%	A076830	001	Aug 31, 2004	Oct	CAHN
	SOLUTION/DROPS; OTIC							
	OFLOXACIN							
AT	FERA PHARMS	0.3%	A090395	001	Aug 11, 2009	Oct	CAHN
	OLANZAPINE							
	INJECTABLE; INTRAMUSCULAR							
	OLANZAPINE							
AP	INNOPHARMA LLC	10MG/VIAL	A201588	001	Oct 24, 2011	Oct	NEWA
	ZYPREXA							
AP +	LILLY	10MG/VIAL	N021253	001	Mar 29, 2004	Oct	CFTG
	TABLET; ORAL							
	OLANZAPINE							
AB	DR REDDYS LABS LTD	20MG	A076133	002	Oct 24, 2011	Oct	NEWA
AB	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Oct	NEWA
AB		5MG	A076000	002	Oct 24, 2011	Oct	NEWA
AB		7.5MG	A076000	003	Oct 24, 2011	Oct	NEWA
AB		10MG	A076000	004	Oct 24, 2011	Oct	NEWA
AB		15MG	A076000	005	Oct 24, 2011	Oct	NEWA
	ZYPREXA							
AB	LILLY	2.5MG	N020592	001	Sep 30, 1996	Oct	CFTG
AB +		5MG	N020592	002	Sep 30, 1996	Oct	CFTG
AB		7.5MG	N020592	003	Sep 30, 1996	Oct	CFTG
AB		10MG	N020592	004	Sep 30, 1996	Oct	CFTG
AB		15MG	N020592	005	Sep 09, 1997	Oct	CFTG
AB		20MG	N020592	006	Sep 09, 1997	Oct	CFTG
	TABLET, ORALLY DISINTEGRATING; ORAL							
	OLANZAPINE							
AB	APOTEX INC	5MG	A091265	001	Oct 24, 2011	Oct	NEWA
AB		10MG	A091265	002	Oct 24, 2011	Oct	NEWA
AB		15MG	A091265	003	Oct 24, 2011	Oct	NEWA
AB		20MG	A091265	004	Oct 24, 2011	Oct	NEWA
AB	DR REDDYS LABS LTD	5MG	A076534	001	Oct 24, 2011	Oct	NEWA
AB		10MG	A076534	002	Oct 24, 2011	Oct	NEWA
AB		15MG	A076534	003	Oct 24, 2011	Oct	NEWA
AB		20MG	A076534	004	Oct 24, 2011	Oct	NEWA
AB	PAR PHARM	5MG	A078109	001	Oct 24, 2011	Oct	NEWA
AB		10MG	A078109	002	Oct 24, 2011	Oct	NEWA
AB		15MG	A078109	003	Oct 24, 2011	Oct	NEWA
AB		20MG	A078109	004	Oct 24, 2011	Oct	NEWA
AB	TORRENT PHARMS LLC	5MG	A091415	001	Oct 25, 2011	Oct	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB		TORRENT PHARMS LLC	10MG	A091415	002	Oct 25, 2011	Oct	NEWA
AB			15MG	A091415	003	Oct 25, 2011	Oct	NEWA
AB			20MG	A091415	004	Oct 25, 2011	Oct	NEWA

ZYPREXA ZYDIS

AB	+	LILLY	5MG	N021086	001	Apr 06, 2000	Oct	CFTG
AB			10MG	N021086	002	Apr 06, 2000	Oct	CFTG
AB			15MG	N021086	003	Apr 06, 2000	Oct	CFTG
AB			20MG	N021086	004	Apr 06, 2000	Oct	CFTG

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

>D> AB		KV PHARM	4MG	A077717	001	Jun 25, 2007	Nov	CAHN
>D> AB			8MG	A077717	002	Jun 25, 2007	Nov	CAHN
>A> AB		NESHER PHARMS	4MG	A077717	001	Jun 25, 2007	Nov	CAHN
>A> AB			8MG	A077717	002	Jun 25, 2007	Nov	CAHN
AB		RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
AB			8MG	A078602	002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

AP		PFIZER	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN
AP		TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD
AP		TEVA PHARMS	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006	Aug	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		PFIZER	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	May	CAHN
AP		TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006	Sep	CMFD

SOLUTION; ORAL
ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
AA		SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL
ONDANSETRON HYDROCHLORIDE

AB		TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
AB			EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
AB			EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
ORPHENADRINE CITRATE

AP		SAGENT PHARMS	30MG/ML	A090585	001	Aug 30, 2011	Aug	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL
TAMIFLU

		ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jun	NEWA
	@		EQ 12MG BASE/ML	N021246	001	Dec 14, 2000	Jul	DISC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>D>	AP	+	HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009	Nov	CRLD
>A>	AP			50MG/VIAL	A078815	001	Sep 30, 2009	Nov	CRLD
>D>	AP	+		100MG/VIAL	A078815	002	Sep 30, 2009	Nov	CRLD
>A>	AP			100MG/VIAL	A078815	002	Sep 30, 2009	Nov	CRLD
	AP		SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
	AP			50MG/VIAL	A090849	001	Apr 28, 2011	Apr	NEWA
	AP			100MG/VIAL	A090849	002	Apr 28, 2011	Apr	NEWA
	AP			100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA
>D>	AP		SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Nov	CRLD
>A>	AP	+		50MG/VIAL	A078818	001	Aug 07, 2009	Nov	CRLD
>D>	AP			100MG/VIAL	A078818	002	Aug 07, 2009	Nov	CRLD
>A>	AP	+		100MG/VIAL	A078818	002	Aug 07, 2009	Nov	CRLD

OXAPROZIN

TABLET; ORAL

OXAPROZIN

		@	ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001	Aug	DISC
	AB		MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN

OXICONAZOLE NITRATE

LOTION; TOPICAL

OXISTAT

>D>		+	ALTANA	EQ 1% BASE	N020209	001	Sep 30, 1992	Nov	CAHN
>A>		+	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Nov	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXECTA

			KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011	Jun	NEWA
				7.5MG	N202080	002	Jun 17, 2011	Jun	NEWA

OXYCODONE HYDROCHLORIDE

	AB		COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
	AB			15MG	A091313	002	Feb 18, 2011	Feb	NEWA
	AB			30MG	A091313	003	Feb 18, 2011	Feb	NEWA
>D>	AB		KV PHARM	5MG	A077290	001	Dec 08, 2005	Nov	CAHN
>D>	AB			10MG	A077290	002	Dec 08, 2005	Nov	CAHN
>D>	AB			15MG	A077290	003	Dec 08, 2005	Nov	CAHN
>D>	AB			20MG	A077290	004	Dec 08, 2005	Nov	CAHN
>D>	AB			30MG	A077290	005	Dec 08, 2005	Nov	CAHN
>A>	AB		NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Nov	CAHN
>A>	AB			10MG	A077290	002	Dec 08, 2005	Nov	CAHN
>A>	AB			15MG	A077290	003	Dec 08, 2005	Nov	CAHN
>A>	AB			20MG	A077290	004	Dec 08, 2005	Nov	CAHN
>A>	AB			30MG	A077290	005	Dec 08, 2005	Nov	CAHN
	AB		RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
	AB			10MG	A091490	002	Mar 09, 2011	Feb	NEWA
	AB			15MG	A091490	003	Mar 09, 2011	Feb	NEWA
	AB			20MG	A091490	004	Mar 09, 2011	Feb	NEWA
	AB			30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL
ANADROL-50

+	MEDA PHARMS	50MG	N016848	001		May	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

	@ ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
	@	15MG	N021610	006	Feb 29, 2008	Feb	DISC

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL

AP	ONCO THERAPIES LTD	6MG/ML	A091540	001	Sep 29, 2011	Sep	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
INVEGA

	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul	CAHN
		3MG	N021999	001	Dec 19, 2006	Jul	CAHN
+		6MG	N021999	002	Dec 19, 2006	Jul	CAHN
		9MG	N021999	003	Dec 19, 2006	Jul	CAHN
	@	12MG	N021999	004	Dec 19, 2006	Jul	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CAHN
		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CAHN
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Aug	CRLD
		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CAHN
		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CAHN
		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Aug	CRLD
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

	@ NOVARTIS	90MG/VIAL	N020036	004	May 06, 1993	Oct	DISC

PAMIDRONATE DISODIUM

AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May	CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May	CAHN
AP	PFIZER	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Aug	CAHN
AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Aug	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
PANCREAZE

	JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010	Jun	CAHN

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

	JANSSEN PHARMS	43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010	Jun	CAHN
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010	Jun	CAHN
+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003	Apr 12, 2010	Jun	CAHN

ZENPEP

	APTALIS PHARMA US	27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009	Oct	CAHN
		55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009	Oct	CAHN
		82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009	Oct	CAHN
+		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Oct	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA
AB	JUBILANT ORGANOSYS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Aug	NEWA
AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Aug	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

AP	SANDOZ CANADA INC	0.002MG/ML	A091108	001	Jul 27, 2011	Jul	NEWA
AP		0.005MG/ML	A091108	002	Jul 27, 2011	Jul	NEWA

ZEMPLAR

AP	+ ABBOTT	0.002MG/ML	N020819	002	Feb 01, 2000	Jul	CFTG
AP	+	0.005MG/ML	N020819	001	Apr 17, 1998	Jul	CFTG

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

	@ KING PFIZER	EQ 250MG BASE	A062310	001		Aug	CAHN
	@ MONARCH PHARMS	EQ 250MG BASE	A062310	001		May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	EQ 10MG BASE	A076968	001	Jun 21, 2010	Aug	DISC
	@	EQ 20MG BASE	A076968	002	Jun 21, 2010	Aug	DISC
	@	EQ 30MG BASE	A076968	003	Jun 21, 2010	Aug	DISC
	@	EQ 40MG BASE	A076968	004	Jun 21, 2010	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB		MYLAN	EQ 37.5MG BASE	A091427	001	Apr 14, 2011	Apr	NEWA

PAXIL CR

AB	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB		VALEANT INTL	400MG	A075028	001	Jul 20, 1998	Apr	CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA		EMCURE PHARMS USA	35MG	A040762	001	Jan 28, 2008	Jul	CAHN
AA		MIKAH PHARMA	35MG	A040762	001	Jan 28, 2008	Aug	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	15MG	A040460	001	Jan 14, 2003	Jul	DISC
		@	30MG	A040448	001	Jan 22, 2003	Jul	DISC
		@	30MG	A040227	001	Jun 18, 1997	Jul	DISC
		@	37.5MG	A040228	001	Jun 19, 1997	Jul	DISC
AA		LANNETT HOLDINGS INC	37.5MG	A201961	001	Jul 20, 2011	Jul	NEWA

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	37.5MG	A040190	001	May 30, 1997	Jul	DISC
AA		ELITE LABS	37.5MG	A200272	001	Jan 31, 2011	May	CAHN
AA		EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

		CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	NEWA
	+		30MG	N202088	002	Jun 13, 2011	Jun	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

		LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jul	NEWA
			EQ 30MG BASE	A040872	002	Jul 28, 2011	Jul	NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
ORAVERSE

	+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008	Aug	CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP		X-GEN PHARMS	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON

		@ BIOVAIL TECHNOLOGIES	1MG/0.5ML	N012223	002		Aug	CAHN
		@	10MG/ML	N012223	001		Aug	CAHN

TABLET; ORAL
MEPHYTON
\+ BIOVAIL TECHNOLOGIES 5MG N010104 003 Aug CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
ISOPTO CARPINE
ALCON RES 1% N200890 001 Jun 22, 2010 May CTNA
2% N200890 002 Jun 22, 2010 May CTNA
\+ 4% N200890 003 Jun 22, 2010 May CTNA

PIMECROLIMUS

CREAM; TOPICAL
ELIDEL
\+ VALEANT INTL 1% N021302 001 Dec 13, 2001 Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM
AP AUROBINDO PHARMA LTD EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A065498 001 May 23, 2011 May NEWA
AP EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A065498 002 May 23, 2011 May NEWA
AP EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A065498 003 May 23, 2011 May NEWA
AP HOSPIRA INC EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A065386 001 Sep 15, 2009 Jan CAHN
AP EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A065386 002 Sep 15, 2009 Jan CAHN
AP EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A065386 003 Sep 15, 2009 Jan CAHN
AP EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A065446 001 Sep 15, 2009 Jan CAHN
AP INSTITUTO BIOCHEMICO EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A065523 001 May 31, 2011 May NEWA
AP EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A065523 002 May 31, 2011 May NEWA
AP EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A065523 003 May 31, 2011 May NEWA
AP EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A090498 001 May 31, 2011 May NEWA

PIROXICAM

CAPSULE; ORAL
PIROXICAM
@ MYLAN 10MG A074043 001 Sep 22, 1992 Feb CAHN
@ 20MG A074043 002 Sep 22, 1992 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL
LIVALO
KOWA CO EQ 1MG BASE N022363 001 Aug 03, 2009 Jul CAHN
EQ 2MG BASE N022363 002 Aug 03, 2009 Jul CAHN
\+ EQ 4MG BASE N022363 003 Aug 03, 2009 Jul CAHN

PODOFILOX

SOLUTION; TOPICAL
PODOFILOX
AT PRECISION DERMAT 0.5% A090184 001 Jul 21, 2010 Jun CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA		KREMERS URBAN PHARMS	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	Sep	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

		@ MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jun	CAHN
		@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	DISC
AA	+		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jun	CAHN
			227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jun	CAHN
AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jun	CAHN
		@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jun	CAHN

COLYTE WITH FLAVOR PACKS

AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jun	CAHN

COLYTE-FLAVORED

AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jun	CAHN
AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jun	CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP		SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Jun	NEWA

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

		PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Aug	CMFD
		@	75MG/VIAL	N020451	001	Dec 27, 1995	Jun	DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

AB		NESHER PHARMS	8MEQ	N018238	001		Aug	CAHN

MICRO-K 10

AB		NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Aug	CAHN

POTASSIUM CHLORIDE

>D>		@ KV PHARM	10MEQ	A070980	001	Feb 17, 1987	Nov	CAHN
>A>		@ NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987	Nov	CAHN
AB		PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA
AB			10MEQ	A200185	002	May 18, 2011	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

BC	+	UPSHER-SMITH LABS	10MEQ	N019123	002	Apr 17, 1986	Oct	CRLD

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

>D>	AB		KV PHARM	20MEQ	A076044	001	Apr 05, 2002	Nov	CAHN
>A>	AB		NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Nov	CAHN

POTASSIUM CITRATE

FOR SOLUTION; ORAL
POTASSIUM CITRATE

			@ UNIV TX SW MEDCTR	10MEQ/PACKET	N019647	002	Oct 13, 1988	Oct	CAHN
			@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Oct	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER

			BOEHRINGER INGELHEIM	2.25MG	N022421	006	Jun 17, 2011	Jun	NEWA
				3.75MG	N022421	007	Jun 17, 2011	Jun	NEWA

PRAZIQUANTEL

TABLET; ORAL
BILTRICIDE

		+	BAYER PHARMA AG	600MG	N018714	001	Dec 29, 1982	Sep	CAHN

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

>D>	AA	+	KV PHARM	5MG/5ML	A040423	001	Oct 22, 2001	Nov	CAHN
>D>	AA	+		15MG/5ML	A040364	001	Apr 10, 2002	Nov	CAHN
>A>	AA	+	NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001	Nov	CAHN
>A>	AA	+		15MG/5ML	A040364	001	Apr 10, 2002	Nov	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

>D>	AA		KV PHARM	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Nov	CAHN
>D>	AA			EQ 15MG BASE/5ML	A076988	001	May 24, 2005	Nov	CAHN
>A>	AA		NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Nov	CAHN
>A>	AA			EQ 15MG BASE/5ML	A076988	001	May 24, 2005	Nov	CAHN
			@ VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC

PREDNISONE

TABLET; ORAL
PREDNISONE

	AB		JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
	AB			5MG	A040362	002	Aug 29, 2001	Jan	CAHN
	AB			10MG	A040362	001	Aug 29, 2001	Jan	CAHN
	AB			20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PREGABALIN

CAPSULE; ORAL
LYRICA

			CPPI CV	25MG	N021446	001	Dec 30, 2004	Sep	CAHN
				50MG	N021446	002	Dec 30, 2004	Sep	CAHN
				75MG	N021446	003	Dec 30, 2004	Sep	CAHN
				100MG	N021446	004	Dec 30, 2004	Sep	CAHN
				150MG	N021446	005	Dec 30, 2004	Sep	CAHN
				225MG	N021446	007	Dec 30, 2004	Sep	CAHN

		CAPSULE; ORAL							
		LYRICA							
	+	CPPI CV	300MG	N021446	008	Dec 30, 2004	Sep	CAHN	
		SOLUTION; ORAL							
		LYRICA							
	+	CPPI CV	20MG/ML	N022488	001	Jan 04, 2010	Sep	CAHN	
		PRIMIDONE							
		SUSPENSION; ORAL							
		MYSOLINE							
		@ NURO PHARMA	250MG/5ML	N010401	001		Oct	CAHN	
		PROCHLORPERAZINE MALEATE							
		TABLET; ORAL							
		PROCOMP							
	AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN	
	AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN	
		PROGESTERONE							
		CAPSULE; ORAL							
		PROMETRIUM							
>A>		ABBOTT LABS	100MG	N019781	001	May 14, 1998	Nov	CAHN	
>A>	+		200MG	N019781	002	Oct 15, 1999	Nov	CAHN	
>A>	@		300MG	N019781	003	Oct 15, 1999	Nov	CAHN	
>D>		ABBOTT PRODS	100MG	N019781	001	May 14, 1998	Nov	CAHN	
>D>	+		200MG	N019781	002	Oct 15, 1999	Nov	CAHN	
>D>	@		300MG	N019781	003	Oct 15, 1999	Nov	CAHN	
		PROMETHAZINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		PROMETHAZINE HYDROCHLORIDE							
	AP	X-GEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	May	CAHN	
	AP		50MG/ML	A040737	002	Apr 24, 2008	May	CAHN	
		SUPPOSITORY; RECTAL							
		PHENERGAN							
		@ SHIONOGI INC	12.5MG	N010926	002		Aug	CAHN	
		@	25MG	N010926	001		Aug	CAHN	
		@	50MG	N011689	001		Aug	CAHN	
		TABLET; ORAL							
		PROMETHAZINE HYDROCHLORIDE							
	AB	EMCURE PHARMS USA	12.5MG	A040673	001	Mar 05, 2008	Jul	CAHN	
	AB		25MG	A040673	002	Mar 05, 2008	Jul	CAHN	
	AB		50MG	A040673	003	Mar 05, 2008	Jul	CAHN	
	AB	MYLAN	12.5MG	A091054	001	Aug 30, 2011	Aug	NEWA	
	AB		25MG	A091054	002	Aug 30, 2011	Aug	NEWA	
	AB		50MG	A091054	003	Aug 30, 2011	Aug	NEWA	
		PROPAFENONE HYDROCHLORIDE							
		TABLET; ORAL							
		PROPAFENONE HYDROCHLORIDE							
>D>	AB	KV PHARM	150MG	A076193	001	Feb 07, 2002	Nov	CAHN	
>D>	AB		225MG	A076193	002	Feb 07, 2002	Nov	CAHN	
>D>	AB		300MG	A076193	003	Feb 07, 2002	Nov	CAHN	
>A>	AB	NESHER PHARMS	150MG	A076193	001	Feb 07, 2002	Nov	CAHN	
>A>	AB		225MG	A076193	002	Feb 07, 2002	Nov	CAHN	
>A>	AB		300MG	A076193	003	Feb 07, 2002	Nov	CAHN	

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927	002		Jan	CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

@	XANODYNE PHARM	65MG	N010997	003		Jan	DISC

DOLENE

@	HERITAGE PHARMS INC	65MG	A080530	001		Aug	DISC

PROPOXYPHENE HYDROCHLORIDE

@	MYLAN	65MG	A040569	001	Dec 16, 2004	Aug	DISC
@	TEVA	65MG	A088615	001	Oct 22, 1984	Mar	DISC
@	VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009	Mar	DISC
@	WEST WARD	65MG	A083501	001		Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

@	XANODYNE PHARM	100MG	N016862	002		Jan	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	GLAXOSMITHKLINE	60MG	A078703	001	Jul 15, 2011	Jul	NEWA
AB		80MG	A078703	002	Jul 15, 2011	Jul	NEWA
AB		120MG	A078703	003	Jul 15, 2011	Jul	NEWA
AB		160MG	A078703	004	Jul 15, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	60MG	A090321	001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321	002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321	003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321	004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213	005	Apr 08, 2011	Mar	NEWA

PYRIMETHAMINE

TABLET; ORAL
DARAPRIM

+	COREPHARMA	25MG	N008578	001		Jun	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

@	ACTAVIS TOTOWA	EQ 5MG BASE	A076459	001	Dec 22, 2004	Jul	DISC
@		EQ 10MG BASE	A076459	002	Dec 22, 2004	Jul	DISC
@		EQ 20MG BASE	A076459	003	Dec 22, 2004	Jul	DISC
@		EQ 40MG BASE	A076459	004	Dec 22, 2004	Jul	DISC
AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

@	ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008	Aug	DISC
@		2.5MG	A077513	002	Jun 18, 2008	Aug	DISC
@		5MG	A077513	003	Jun 18, 2008	Aug	DISC
@		10MG	A077513	004	Jun 18, 2008	Aug	DISC
AB	AUROBINDO PHARMA LTD	1.25MG	A091604	001	Jun 08, 2011	May	NEWA
AB		2.5MG	A091604	002	Jun 08, 2011	May	NEWA
AB		5MG	A091604	003	Jun 08, 2011	May	NEWA
AB		10MG	A091604	004	Jun 08, 2011	May	NEWA

TABLET; ORAL
RAMIPRIL

AB	MATRIX LABS LTD	1.25MG	A090650	001	Jun 30, 2011	Jun	NEWA
AB		2.5MG	A090650	002	Jun 30, 2011	Jun	NEWA
AB		5MG	A090650	003	Jun 30, 2011	Jun	NEWA
AB		10MG	A090650	004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007	Sep	CAHN
AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	Mar	NEWA
AA	SUN PHARM INDS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Sep	NEWA
AA	TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May	NEWA

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023	002	Aug 22, 1997	Feb	CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA

	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996	Oct	CAHN
		EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996	Oct	CAHN
+		EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996	Oct	CAHN

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

@	ACTAVIS TOTOWA	300MG	N050429	001		Jul	DISC

INJECTABLE; INJECTION
RIFAMPIN

>D>	AP	COVENANT PHARMA INC	600MG/VIAL	A065502	001	Sep 21, 2010	Nov	CAHN
	AP	PFIZER	600MG/VIAL	A065421	001	May 22, 2008	May	CAHN
>A>	AP	VERSAPHARM INC	600MG/VIAL	A065502	001	Sep 21, 2010	Nov	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN

+	SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

+	TIBOTEC	EQ 25MG BASE	N202022	001	May 20, 2011	May	NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A076375	001	Jan 14, 2003	Jul	DISC

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jun	CAHN
+		25MG/VIAL	N021346	001	Oct 29, 2003	Jun	CAHN
		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jun	CAHN
		50MG/VIAL	N021346	003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL
RISPERDAL

AA	+ JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996	Jun	CAHN

RISPERIDONE

AA	AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011	May	NEWA
AA	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL
RISPERDAL

AB	JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999	Jun	CAHN
AB		0.5MG	N020272	007	Jan 27, 1999	Jun	CAHN
AB	+	1MG	N020272	001	Dec 29, 1993	Jun	CAHN
AB		2MG	N020272	002	Dec 29, 1993	Jun	CAHN
AB		3MG	N020272	003	Dec 29, 1993	Jun	CAHN
AB		4MG	N020272	004	Dec 29, 1993	Jun	CAHN
	@	5MG	N020272	005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

	@ ACTAVIS TOTOWA	0.25MG	A078071	001	Jun 17, 2009	Jul	DISC
	@	0.5MG	A078071	002	Jun 17, 2009	Jul	DISC
	@	1MG	A078071	003	Jun 17, 2009	Jul	DISC
	@	2MG	A078071	004	Jun 17, 2009	Jul	DISC
	@	3MG	A078071	005	Jun 17, 2009	Jul	DISC
	@	4MG	A078071	006	Jun 17, 2009	Jul	DISC
AB	AJANTA PHARMA LTD	0.25MG	A201003	001	Aug 24, 2011	Aug	NEWA
AB		0.5MG	A201003	002	Aug 24, 2011	Aug	NEWA
AB		1MG	A201003	003	Aug 24, 2011	Aug	NEWA
AB		2MG	A201003	004	Aug 24, 2011	Aug	NEWA
AB		3MG	A201003	005	Aug 24, 2011	Aug	NEWA
AB		4MG	A201003	006	Aug 24, 2011	Aug	NEWA
	@ CADISTA PHARMS	0.25MG	A078828	001	Mar 23, 2009	Sep	DISC
	@	0.5MG	A078828	002	Mar 23, 2009	Sep	DISC
	@	1MG	A078828	003	Mar 23, 2009	Sep	DISC
	@	2MG	A078828	004	Mar 23, 2009	Sep	DISC
	@	3MG	A078828	005	Mar 23, 2009	Sep	DISC
	@	4MG	A078828	006	Mar 23, 2009	Sep	DISC
AB	CIPLA	0.25MG	A077543	001	May 18, 2011	May	NEWA
AB		0.5MG	A077543	002	May 18, 2011	May	NEWA
AB		1MG	A077543	003	May 18, 2011	May	NEWA
AB		2MG	A077543	004	May 18, 2011	May	NEWA

TABLET; ORAL
RISPERIDONE

AB	CIPLA	3MG	A077543	005	May 18, 2011	May	NEWA
AB		4MG	A077543	006	May 18, 2011	May	NEWA
>A> AB	PRINSTON INC	0.25MG	A077493	001	Nov 29, 2011	Nov	NEWA
>A> AB		0.5MG	A077493	002	Nov 29, 2011	Nov	NEWA
>A> AB		1MG	A077493	003	Nov 29, 2011	Nov	NEWA
>A> AB		2MG	A077493	004	Nov 29, 2011	Nov	NEWA
>A> AB		3MG	A077493	005	Nov 29, 2011	Nov	NEWA
>A> AB		4MG	A077493	006	Nov 29, 2011	Nov	NEWA
@	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
@		0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
@		1MG	A077784	003	Jun 08, 2010	Feb	DISC
@		2MG	A077784	004	Jun 08, 2010	Feb	DISC
@		3MG	A077784	005	Jun 08, 2010	Feb	DISC
@		4MG	A077784	006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

AB	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Jul	CAHN
AB +		1MG	N021444	002	Apr 02, 2003	Jul	CAHN
AB		2MG	N021444	003	Apr 02, 2003	Jul	CAHN
AB		3MG	N021444	004	Dec 23, 2004	Jul	CAHN
AB		4MG	N021444	005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

AB	JUBILANT ORGANOSYS	0.5MG	A090839	001	Nov 04, 2011	Oct	NEWA
AB		1MG	A090839	002	Nov 04, 2011	Oct	NEWA
AB		2MG	A090839	003	Nov 04, 2011	Oct	NEWA
AB		3MG	A090839	004	Nov 04, 2011	Oct	NEWA
AB		4MG	A090839	005	Nov 04, 2011	Oct	NEWA
AB	MYLAN	0.5MG	A091537	001	Mar 30, 2011	Mar	NEWA
AB		1MG	A091537	002	Mar 30, 2011	Mar	NEWA
AB		2MG	A091537	003	Mar 30, 2011	Mar	NEWA
AB		3MG	A091537	004	Mar 30, 2011	Mar	NEWA
AB		4MG	A091537	005	Mar 30, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	0.5MG	A076996	001	Apr 19, 2011	Apr	NEWA
AB		1MG	A076996	002	Apr 19, 2011	Apr	NEWA
AB		2MG	A076996	003	Apr 19, 2011	Apr	NEWA
AB		3MG	A076996	004	Apr 19, 2011	Apr	NEWA
AB		4MG	A076996	005	Apr 19, 2011	Apr	NEWA

RIVAROXABAN

TABLET; ORAL
XARELTO

>A>	JANSSEN PHARMS	15MG	N202439	001	Nov 04, 2011	Nov	NEWA
>A> +		20MG	N202439	002	Nov 04, 2011	Nov	NEWA
+	JOHNSON AND JOHNSON	10MG	N022406	001	Jul 01, 2011	Jul	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Aug	CAHN
AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	Aug	CAHN
AB		EQ 1MG BASE	A078110	003	May 05, 2008	Aug	CAHN
AB		EQ 2MG BASE	A078110	004	May 05, 2008	Aug	CAHN
AB		EQ 3MG BASE	A078110	005	May 05, 2008	Aug	CAHN
AB		EQ 4MG BASE	A078110	006	May 05, 2008	Aug	CAHN
AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110	001	May 05, 2008	May	CAHN
AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	May	CAHN
AB		EQ 1MG BASE	A078110	003	May 05, 2008	May	CAHN
AB		EQ 2MG BASE	A078110	004	May 05, 2008	May	CAHN
AB		EQ 3MG BASE	A078110	005	May 05, 2008	May	CAHN
AB		EQ 4MG BASE	A078110	006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Mar	NEWA

>A> RUXOLITINIB PHOSPHATE

>A> TABLET; ORAL

>A> JAKAFI

>A>	INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011	Nov	NEWA
>A>		EQ 10MG BASE	N202192	002	Nov 16, 2011	Nov	NEWA
>A>		EQ 15MG BASE	N202192	003	Nov 16, 2011	Nov	NEWA
>A>		EQ 20MG BASE	N202192	004	Nov 16, 2011	Nov	NEWA
>A>	+	EQ 25MG BASE	N202192	005	Nov 16, 2011	Nov	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101	002	Oct 03, 1983	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

@	ACTAVIS MID ATLANTIC	2.5%	A084394	001		Aug	DISC

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	ORTHO JANSSEN	2%	N021385	001	Dec 10, 2003	Jul	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	EQ 25MG BASE	A078175	001	Jul 21, 2010	Jul	DISC
		@	EQ 50MG BASE	A078175	002	Jul 21, 2010	Jul	DISC
		@	EQ 100MG BASE	A078175	003	Jul 21, 2010	Jul	DISC
		@ IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
		@	EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
		@	EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
	AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
	AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
		@ PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299	001	Feb 06, 2007	Jul	DISC
		@	EQ 50MG BASE	A077299	002	Feb 06, 2007	Jul	DISC
		@	EQ 100MG BASE	A077299	003	Feb 06, 2007	Jul	DISC
		@ ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
		@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
		@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

		@ ACTAVIS TOTOWA	5MG	A078735	001	Aug 30, 2010	Jul	DISC
		@	10MG	A078735	002	Aug 30, 2010	Jul	DISC
		@	20MG	A078735	003	Aug 30, 2010	Jul	DISC
		@	40MG	A078735	004	Aug 30, 2010	Jul	DISC
		@	80MG	A078735	005	Aug 30, 2010	Jul	DISC
>A>	AB	BLU CARIBE	5MG	A078034	001	Dec 20, 2006	Nov	CAHN
>A>	AB		10MG	A078034	002	Dec 20, 2006	Nov	CAHN
>A>	AB		20MG	A078034	003	Dec 20, 2006	Nov	CAHN
>A>	AB		40MG	A078034	004	Dec 20, 2006	Nov	CAHN
>A>	AB		80MG	A078034	005	Dec 20, 2006	Nov	CAHN
>A>	AB	DR REDDYS LABS INC	5MG	A077752	005	Jan 23, 2008	Nov	NEWA
	AB	MICRO LABS LTD	5MG	A090383	001	Sep 16, 2011	Sep	NEWA
	AB		10MG	A090383	002	Sep 16, 2011	Sep	NEWA
	AB		20MG	A090383	003	Sep 16, 2011	Sep	NEWA
	AB		40MG	A090383	004	Sep 16, 2011	Sep	NEWA
	AB		80MG	A090383	005	Sep 16, 2011	Sep	NEWA
>D>	AB	PERRIGO R AND D	5MG	A078034	001	Dec 20, 2006	Nov	CAHN
>D>	AB		10MG	A078034	002	Dec 20, 2006	Nov	CAHN
>D>	AB		20MG	A078034	003	Dec 20, 2006	Nov	CAHN
>D>	AB		40MG	A078034	004	Dec 20, 2006	Nov	CAHN
>D>	AB		80MG	A078034	005	Dec 20, 2006	Nov	CAHN

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL
JUVISYNC

		MERCK SHARP DOHME	10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Oct	NEWA
			20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Oct	NEWA
+			40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Oct	NEWA

SINECATECHINS

OINTMENT; TOPICAL
VEREGEN

+		MEDIGENE AG	15%	N021902	001	Oct 31, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@	MALLINCKRODT LLC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985	Aug	CAHN	

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	HOSPIRA	450MG/100ML	N018380	001		Aug	DISC	
@		450MG/100ML	N017670	001		Aug	DISC	

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

@		NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
+			10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+		HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA

SODIUM NITRITE

+		HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA

SODIUM PHENYLBUTYRATE

TABLET; ORAL

BUPHENYL

>D>		+	MEDICIS	500MG	N020572	001	May 13, 1996	Nov	CFTG
>A>	AB	+		500MG	N020572	001	May 13, 1996	Nov	CFTG
>A>			SODIUM PHENYLBUTYRATE						
>A>	AB		AMPOLGEN	500MG	A090910	001	Nov 18, 2011	Nov	NEWA

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590	001	May 13, 2011	May	NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@		PFIZER	EQ 2GM BASE/VIAL	N050347	001		Jun	DISC
@			EQ 4GM BASE/VIAL	N050347	002		Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

	@	PFIZER	EQ 1GM BASE/2.5ML	A060111	001		Jul	DISC

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

	+	APTALIS PHARMA US	1GM/10ML	N019183	001	Dec 16, 1993	Oct	CAHN

TABLET; ORAL

CARAFATE

AB	+	APTALIS PHARMA US	1GM	N018333	001		Oct	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

	+	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Aug	CAHN

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Jun	CFTG

SUMATRIPTAN SUCCINATE

AB		SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	NEWA
	@	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009	Aug	DISC
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009	Aug	DISC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

	@	ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
	@		EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
	@		EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

	@	SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993	Jun	DISC
	@		EQ 20MG BASE	N020070	002	Sep 09, 1993	Jun	DISC
	@		EQ 30MG BASE	N020070	003	Sep 09, 1993	Jun	DISC
	@		EQ 40MG BASE	N020070	004	Sep 09, 1993	Jun	DISC

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB		ACCORD HLTHCARE	0.5MG	A091195	001	Aug 31, 2011	Aug	NEWA
AB			1MG	A091195	002	Aug 31, 2011	Aug	NEWA
AB			5MG	A091195	003	Aug 31, 2011	Aug	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

AB		APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Sep	NEWA
AB			EQ 20MG BASE	A090878	002	Sep 23, 2011	Sep	NEWA

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL
NUCYNTA

>A>		JANSSEN PHARMS	EQ 50MG BASE	N022304	001	Nov 20, 2008	Nov	CAHN
>A>			EQ 75MG BASE	N022304	002	Nov 20, 2008	Nov	CAHN
>A>	+		EQ 100MG BASE	N022304	003	Nov 20, 2008	Nov	CAHN
>D>		ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N022304	001	Nov 20, 2008	Nov	CAHN
>D>			EQ 75MG BASE	N022304	002	Nov 20, 2008	Nov	CAHN
>D>	+		EQ 100MG BASE	N022304	003	Nov 20, 2008	Nov	CAHN

TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER

>A>		JANSSEN PHARMS	EQ 50MG BASE	N200533	001	Aug 25, 2011	Nov	CAHN
>A>			EQ 100MG BASE	N200533	002	Aug 25, 2011	Nov	CAHN
>A>			EQ 150MG BASE	N200533	003	Aug 25, 2011	Nov	CAHN
>A>			EQ 200MG BASE	N200533	004	Aug 25, 2011	Nov	CAHN
>A>	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	Nov	CAHN
>D>		ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N200533	001	Aug 25, 2011	Nov	CAHN
			EQ 50MG BASE	N200533	001	Aug 25, 2011	Aug	NEWA
>D>			EQ 100MG BASE	N200533	002	Aug 25, 2011	Nov	CAHN
			EQ 100MG BASE	N200533	002	Aug 25, 2011	Aug	NEWA
>D>			EQ 150MG BASE	N200533	003	Aug 25, 2011	Nov	CAHN
			EQ 150MG BASE	N200533	003	Aug 25, 2011	Aug	NEWA
>D>			EQ 200MG BASE	N200533	004	Aug 25, 2011	Nov	CAHN
			EQ 200MG BASE	N200533	004	Aug 25, 2011	Aug	NEWA
>D>	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	Nov	CAHN
	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	Aug	NEWA

TELAPREVIR

TABLET; ORAL
INCIVEK

	+	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	May	NEWA

TELBIVUDINE

SOLUTION; ORAL
TYZEKA

		@ NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009	Jun	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB		JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
AB			EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
AB			EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
AB			EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB		MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

	@	ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

	+	WATSON LABS	2MG/24HR	N020489	003	Oct 20, 2011	Oct	NEWA
	@		2.5MG/24HR	N020489	001	Sep 29, 1995	Oct	DISC
	+		4MG/24HR	N020489	004	Oct 20, 2011	Oct	NEWA
	@		5MG/24HR	N020489	002	May 02, 1997	Oct	DISC

GEL; TRANSDERMAL
ANDROGEL

		ABBOTT LABS	1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000	Aug	CAHN
BX	+		1% (5GM/PACKET)	N021015	002	Feb 28, 2000	Aug	CAHN

GEL, METERED; TRANSDERMAL
ANDROGEL

	+	ABBOTT LABS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003	Aug	CAHN
	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Aug	CAHN
	+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA

FORTESTA

	+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT

TABLET, EXTENDED RELEASE; BUCCAL
STRIANT

	+	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN

TETRABENAZINE

TABLET; ORAL
XENAZINE

		VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
	+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

	@	SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN

SUSPENSION; ORAL
SUMYCIN

	@	PAR PHARM	125MG/5ML	A060400	001		Jul	DISC

TABLET; ORAL
SUMYCIN

	@	PAR PHARM	250MG	A061147	001		Jul	DISC
	@		500MG	A061147	004		Jul	DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEO-24

>D>	BC	ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	Nov	CAHN
	BC		100MG	A087942	001	Aug 22, 1983	Jun	CAHN
>D>	BC		200MG	A087943	001	Aug 22, 1983	Nov	CAHN
	BC		200MG	A087943	001	Aug 22, 1983	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL
THEO-24

>D>	BC	ACTIENT PHARMS	300MG	A087944	001	Aug 22, 1983	Nov	CAHN
	BC		300MG	A087944	001	Aug 22, 1983	Jun	CAHN
>D>			400MG	A081034	001	Feb 28, 1992	Nov	CAHN
			400MG	A081034	001	Feb 28, 1992	Jun	CAHN
>A>	BC	UCB INC	100MG	A087942	001	Aug 22, 1983	Nov	CAHN
>A>	BC		200MG	A087943	001	Aug 22, 1983	Nov	CAHN
>A>	BC		300MG	A087944	001	Aug 22, 1983	Nov	CAHN
>A>			400MG	A081034	001	Feb 28, 1992	Nov	CAHN

INJECTABLE; INJECTION
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	80MG/100ML	N019211	002	Dec 14, 1984	Aug	DISC
@		200MG/100ML	N019211	004	Dec 14, 1984	Aug	DISC
@		400MG/100ML	N019211	005	Dec 14, 1984	Aug	DISC

SOLUTION; ORAL
THEOPHYLLINE

+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

@	HOSPIRA	100MG/ML	A040079	001	May 03, 1996	May	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL

AB	CEPHALON	2MG	N020646	005	Apr 16, 1999	Oct	CFTG
AB	+	4MG	N020646	001	Sep 30, 1997	Oct	CFTG

TIAGABINE HYDROCHLORIDE

AB	SUN PHARM INDS	2MG	A077555	001	Nov 04, 2011	Oct	NEWA
AB		4MG	A077555	002	Nov 04, 2011	Oct	NEWA

TICAGRELOR

TABLET; ORAL
BRILINTA

+	ASTRAZENECA LP	90MG	N022433	001	Jul 20, 2011	Jul	NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999	Aug	DISC
AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN
AT		EQ 0.5% BASE	A075412	001	Sep 08, 2000	Sep	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
@		EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
@	ACTAVIS TOTOWA	EQ 2MG BASE	A076281	001	Oct 20, 2003	Jul	DISC

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	EQ 4MG BASE	A076281	002	Oct 20, 2003	Jul	DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT		FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

	@	HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
AP	+		EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD

TOLCAPONE

TABLET; ORAL
TASMAR

	+	VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998	Jun	CRLD
	@		200MG	N020697	002	Jan 29, 1998	Jun	DISC

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

	@	ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP		DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
AP		SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

AP		HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
		SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
			EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB		VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar	NEWA
AB			10MG	A090613	002	Mar 22, 2011	Mar	NEWA
AB			20MG	A090613	003	Mar 22, 2011	Mar	NEWA
AB			100MG	A090613	004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONZIP

	+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010	Aug	CTNA
			150MG	N022370	004	Aug 01, 2011	Aug	NEWA
			200MG	N022370	002	May 07, 2010	Aug	CTNA
			300MG	N022370	003	May 07, 2010	Aug	CTNA

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002	Aug	DISC

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

>A>	AB		ALVOGEN	50MG	A202075	001	Nov 28, 2011	Nov	NEWA
	AB		ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
TRAMADOL HYDROCHLORIDE

	AB		LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Aug	NEWA
	AB			200MG	A200503	002	Aug 29, 2011	Aug	NEWA
	AB			300MG	A200503	003	Aug 29, 2011	Aug	NEWA
	AB		PAR PHARM	300MG	A078783	003	Sep 20, 2011	Sep	NEWA
>A>	AB		SUN PHARMA GLOBAL	100MG	A201384	001	Dec 07, 2011	Nov	NEWA
>A>	AB			200MG	A201384	002	Dec 07, 2011	Nov	NEWA
>A>	AB			300MG	A201384	003	Dec 07, 2011	Nov	NEWA

ULTRAM ER

	AB	+	VALEANT INTL	100MG	N021692	001	Sep 08, 2005	Jun	CAHN
	AB			200MG	N021692	002	Sep 08, 2005	Jun	CAHN
	AB			300MG	N021692	003	Sep 08, 2005	Aug	CTEC
	BC			300MG	N021692	003	Sep 08, 2005	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE

		+	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Aug	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION
CYKLOKAPRON

	AP	+	PHARMACIA AND UPJOHN	100MG/ML	N019281	001	Dec 30, 1986	Aug	CFTG

TRANEXAMIC ACID

>D>	AP		BIONICHE PHARMA	100MG/ML	A091657	001	Nov 03, 2011	Nov	CAHN
	AP			100MG/ML	A091657	001	Nov 03, 2011	Oct	NEWA
>A>	AP		MYLAN INSTITUTIONAL	100MG/ML	A091657	001	Nov 03, 2011	Nov	CAHN
	AP		PHARMAFORCE	100MG/ML	A201885	001	Aug 10, 2011	Aug	NEWA
>A>	AP		VERSAPHARM INC	100MG/ML	A202373	001	Nov 17, 2011	Nov	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

			@ ALCON	0.004%	N021257	001	Mar 16, 2001	May	DISC

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OLEPTRO

		+	ANGELINI LABOPHARM	150MG	N022411	001	Feb 02, 2010	Jun	CAHN
				300MG	N022411	002	Feb 02, 2010	May	CAHN
		+	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	Aug	CAHN
				300MG	N022411	002	Feb 02, 2010	Aug	CAHN

TRETINOIN

CREAM; TOPICAL
RENOVA

		+	ORTHO JANSSEN	0.02%	N021108	001	Aug 31, 2000	Jul	CAHN
	AB2	+		0.05%	N019963	001	Dec 29, 1995	Jul	CAHN

RETIN-A

	AB	+	ORTHO JANSSEN	0.025%	N019049	001	Sep 16, 1988	Jul	CAHN
	AB1	+		0.05%	N017522	001		Jul	CAHN
	AB	+		0.1%	N017340	001		Jul	CAHN

GEL; TOPICAL
RETIN-A

AB	+	ORTHO JANSSEN	0.01%	N017955	001			Jul	CAHN
AB	+		0.025%	N017579	002			Jul	CAHN

SOLUTION; TOPICAL
RETIN-A

AT	+	ORTHO JANSSEN	0.05%	N016921	001			Jul	CAHN

SWAB; TOPICAL
RETIN-A

	@	ORTHO JANSSEN	0.05%	N016921	002			Jul	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

	@	ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982		Aug	DISC

TRIDERM

AT		CROWN LABS	0.1%	A088042	001	Mar 19, 1984		Sep	CAHN

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

	@	ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982		Aug	DISC

PASTE; DENTAL
TRIAMCINOLONE ACETONIDE

AT	+	TARO	0.1%	A070730	001	Oct 01, 1986		Aug	CTNA

SPRAY, METERED; NASAL
TRIAMCINOLONE ACETONIDE

AB		TEVA BRANDED PHARM	0.055MG/SPRAY	A078104	001	Jul 30, 2009		Aug	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011		May	CAHN
AP		PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011		Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP		LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011		May	CAHN
AP		PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011		Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM

AB		NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011		May	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB		MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006		Feb	CAHN
AB			EQ 50MG BASE	A077361	002	Aug 02, 2006		Feb	CAHN
AB			EQ 100MG BASE	A077361	003	Aug 02, 2006		Feb	CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR
TRELSTAR

	+	WATSON LABS	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000		Sep	CTNA
	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001		Sep	CTNA

TROSPIUM CHLORIDE

TABLET; ORAL
TROSPIUM CHLORIDE

>A>	AB	APOTEX	20MG	A091513	001	Dec 06, 2011	Nov	NEWA

URSODIOL

TABLET; ORAL
URSO 250

	AB	APTALIS PHARMA US	250MG	N020675	001	Dec 10, 1997	Oct	CAHN

URSO FORTE

	AB	+ APTALIS PHARMA US	500MG	N020675	002	Jul 21, 2004	Oct	CAHN

URSODIOL

	AB	GLENMARK GENERICS	250MG	A090801	001	Jul 12, 2011	Jul	NEWA
	AB		500MG	A090801	002	Jul 12, 2011	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

	AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
	AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

	AP	PFIZER	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	May	CAHN
	AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	May	CAHN
	AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	May	CAHN
	AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Jun	NEWA
	AP	STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Sep	NEWA

VANDETANIB

TABLET; ORAL
VANDETANIB

		IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
	+		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

	AP	PFIZER	10MG/VIAL	A090243	001	May 11, 2010	May	CAHN
	AP		20MG/VIAL	A090243	002	May 11, 2010	May	CAHN

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)
VPRIV

		@ SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010	Oct	DISC

VEMURAFENIB

TABLET; ORAL
ZELBORAF

	+	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011	Aug	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011	Apr	NEWA
AB			EQ 75MG BASE	A200834	002	Apr 14, 2011	Apr	NEWA
AB			EQ 150MG BASE	A200834	003	Apr 14, 2011	Apr	NEWA
AB		DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011	Apr	NEWA
AB			EQ 75MG BASE	A078421	002	May 06, 2011	Apr	NEWA
AB			EQ 150MG BASE	A078421	003	May 06, 2011	Apr	NEWA
AB		MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	May	NEWA
AB			EQ 75MG BASE	A078789	002	Jun 01, 2011	May	NEWA
AB			EQ 150MG BASE	A078789	003	Jun 01, 2011	May	NEWA
AB		ORCHID HLTHCARE	EQ 37.5MG BASE	A091123	001	Jul 11, 2011	Jun	NEWA
AB			EQ 75MG BASE	A091123	002	Jul 11, 2011	Jun	NEWA
AB			EQ 150MG BASE	A091123	003	Jul 11, 2011	Jun	NEWA
AB		TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	May	NEWA
AB			EQ 75MG BASE	A090899	002	Jun 01, 2011	May	NEWA
AB			EQ 150MG BASE	A090899	003	Jun 01, 2011	May	NEWA
AB		VALEANT INTL	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Apr	NEWA
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Apr	NEWA
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Apr	NEWA
AB		WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Apr	NEWA
AB			EQ 75MG BASE	A078865	002	Apr 14, 2011	Apr	NEWA
AB			EQ 150MG BASE	A078865	003	Apr 14, 2011	Apr	NEWA
AB		ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011	Apr	NEWA
AB			EQ 75MG BASE	A090174	002	Apr 14, 2011	Apr	NEWA
AB			EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

EFFEXOR

	@	WYETH PHARMS INC	EQ 25MG BASE	N020151	002	Dec 28, 1993	Aug	DISC
	@		EQ 37.5MG BASE	N020151	006	Dec 28, 1993	Aug	DISC
	@		EQ 50MG BASE	N020151	003	Dec 28, 1993	Aug	DISC
	@		EQ 75MG BASE	N020151	004	Dec 28, 1993	Aug	DISC
	@		EQ 100MG BASE	N020151	005	Dec 28, 1993	Aug	DISC

VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932	001	Dec 14, 2010	Jul	CAHN
AB			EQ 37.5MG BASE	A078932	002	Dec 14, 2010	Jul	CAHN
AB			EQ 50MG BASE	A078932	003	Dec 14, 2010	Jul	CAHN
AB			EQ 75MG BASE	A078932	004	Dec 14, 2010	Jul	CAHN
AB			EQ 100MG BASE	A078932	005	Dec 14, 2010	Jul	CAHN
	@	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008	Aug	DISC
	@		EQ 37.5MG BASE	A078517	002	Jun 13, 2008	Aug	DISC
	@		EQ 50MG BASE	A078517	003	Jun 13, 2008	Aug	DISC
	@		EQ 75MG BASE	A078517	004	Jun 13, 2008	Aug	DISC
	@		EQ 100MG BASE	A078517	005	Jun 13, 2008	Aug	DISC
AB	+	TEVA	EQ 50MG BASE	A076690	003	Aug 03, 2006	Aug	CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB		ALKERMES GAINESVILLE	120MG	N019614	001	May 29, 1990	Sep	CAHN
AB			180MG	N019614	003	Jan 09, 1992	Sep	CAHN
AB			240MG	N019614	002	May 29, 1990	Sep	CAHN
	+		360MG	N019614	004	May 10, 1996	Sep	CAHN

			INJECTABLE; INJECTION							
			VERAPAMIL HYDROCHLORIDE							
			@ HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987	Aug	DISC	
			TABLET; ORAL							
			VERAPAMIL HYDROCHLORIDE							
			@ ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986	Aug	DISC	
			@	120MG	A070468	001	Sep 24, 1986	Aug	DISC	
			TABLET, EXTENDED RELEASE; ORAL							
			ISOPTIN SR							
>A>	AB	+	PFIZER	120MG	N019152	003	Mar 06, 1991	Nov	CAHN	
>A>	AB	+		180MG	N019152	002	Dec 15, 1989	Nov	CAHN	
>A>	AB	+		240MG	N019152	001	Dec 16, 1986	Nov	CAHN	
>D>	AB	+	RANBAXY	120MG	N019152	003	Mar 06, 1991	Nov	CAHN	
>D>	AB	+		180MG	N019152	002	Dec 15, 1989	Nov	CAHN	
>D>	AB	+		240MG	N019152	001	Dec 16, 1986	Nov	CAHN	
			VERAPAMIL HYDROCHLORIDE							
	AB		GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Jul	NEWA	
	AB			180MG	A090700	002	Aug 03, 2011	Jul	NEWA	
			VILAZODONE HYDROCHLORIDE							
			TABLET; ORAL							
			VIIBRYD							
			FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	May	CAHN	
				20MG	N022567	002	Jan 21, 2011	May	CAHN	
		+		40MG	N022567	003	Jan 21, 2011	May	CAHN	
			TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA	
				20MG	N022567	002	Jan 21, 2011	Jan	NEWA	
		+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA	
			VINCRISTINE SULFATE							
			INJECTABLE; INJECTION							
			VINCRISTINE SULFATE							
			@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC	
			VINCRISTINE SULFATE PFS							
	AP	+	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Sep	CRLD	
			WARFARIN SODIUM							
			TABLET; ORAL							
			WARFARIN SODIUM							
	AB		INVAGEN PHARMS	1MG	A090935	001	May 25, 2011	May	NEWA	
	AB			2MG	A090935	002	May 25, 2011	May	NEWA	
	AB			2.5MG	A090935	003	May 25, 2011	May	NEWA	
	AB			3MG	A090935	004	May 25, 2011	May	NEWA	
	AB			4MG	A090935	005	May 25, 2011	May	NEWA	
	AB			5MG	A090935	006	May 25, 2011	May	NEWA	
	AB			6MG	A090935	007	May 25, 2011	May	NEWA	
	AB			7.5MG	A090935	008	May 25, 2011	May	NEWA	
	AB			10MG	A090935	009	May 25, 2011	May	NEWA	
>D>			ZICONOTIDE							
>D>			INJECTABLE; INTRATHECAL							
>D>			PRIALT							
>D>		+	AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Nov	CAIN	
>D>		+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Nov	CAIN	
>D>		+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Nov	CAIN	

>A>	ZICONOTIDE ACETATE							
>A>	INJECTABLE; INTRATHECAL							
>A>	PRIALT							
>A>	+ AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Nov	CAIN	
>A>	+	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Nov	CAIN	
>A>	+	500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Nov	CAIN	
	ZIDOVUDINE							
	INJECTABLE; INJECTION							
	ZIDOVUDINE							
AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN	
	TABLET; ORAL							
	ZIDOVUDINE							
AB	HEC PHARM INC	300MG	A202058	001	Oct 07, 2011	Sep	NEWA	
	@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA	
	ZOLEDRONIC ACID							
	INJECTABLE; IV (INFUSION)							
	ZOMETA							
	+ NOVARTIS	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Jun	NEWA	
	ZOLPIDEM TARTRATE							
	TABLET; ORAL							
	ZOLPIDEM TARTRATE							
AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN	
AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN	
	TABLET; SUBLINGUAL							
>A>	INTERMEZZO							
>A>	TRANSCEPT PHARMS	1.75MG	N022328	001	Nov 23, 2011	Nov	NEWA	
>A>	+	3.5MG	N022328	002	Nov 23, 2011	Nov	NEWA	
	TABLET, EXTENDED RELEASE; ORAL							
	ZOLPIDEM TARTRATE							
AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	Apr	NEWA	
AB	SANDOZ	6.25MG	A090107	001	Jul 01, 2011	Jun	NEWA	
AB		12.5MG	A090107	002	Jul 01, 2011	Jun	NEWA	
AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	NEWA	
AB		12.5MG	A078483	002	Jun 06, 2011	Jul	NEWA	
	ZOLPIDEM TATRATE							
AB	ACTAVIS S ATLANTIC	12.5MG	A078179	001	Jun 06, 2011	Sep	NEWA	

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL									
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY									
@ ACTAVIS MID ATLANTIC		5MG/5ML		A090378	002	May 09, 2008	Aug	DISC
SILARX		5MG/5ML		A091130	001	Apr 22, 2011	Apr	NEWA
SUN PHARM INDS INC		5MG/5ML		A091327	001	Oct 17, 2011	Oct	NEWA
TARO		5MG/5ML		A201546	001	May 20, 2011	May	NEWA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
@ ACTAVIS MID ATLANTIC		5MG/5ML		A090378	001	May 09, 2008	Aug	DISC
SILARX		5MG/5ML		A091130	002	Apr 22, 2011	Apr	NEWA
SUN PHARM INDS INC		5MG/5ML		A091327	002	Oct 17, 2011	Oct	NEWA
TARO		5MG/5ML		A201546	002	May 20, 2011	May	NEWA
TABLET, CHEWABLE; ORAL									
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY									
SUN PHARMA GLOBAL		5MG		A090142	001	Aug 30, 2011	Aug	NEWA
		10MG		A090142	002	Aug 30, 2011	Aug	NEWA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
SUN PHARMA GLOBAL		5MG		A090142	003	Aug 30, 2011	Aug	NEWA
		10MG		A090142	004	Aug 30, 2011	Aug	NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL									
HIBICLENS									
>A>	+	MOLNLYCKE HLTH	4%	N017768	001		Nov	CAHN
>D>	+	REGENT	4%	N017768	001		Nov	CAHN
HIBISTAT									
>A>	+	MOLNLYCKE HLTH	0.5%	N018300	001		Nov	CAHN
>D>	+	REGENT	0.5%	N018300	001		Nov	CAHN
SPONGE; TOPICAL									
PHARMASEAL SCRUB CARE									
+		CAREFUSION	4%	N019793	001	Dec 02, 1988	Aug	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL									
CHLORAPREP ONE-STEP SEPP									
+		CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
CHLORAPREP SINGLE SWABSTICK									
+		CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
CHLORAPREP TRIPLE SWABSTICK									
+		CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
CHLORASCRUB MAXI SWABSTICK									
>A>	+	3M INFECTION	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Nov	CAHN
>D>	+	SOLUMED	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Nov	CAHN
CHLORASCRUB SWAB									
>A>	+	3M INFECTION	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Nov	CAHN
>D>	+	SOLUMED	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Nov	CAHN
CHLORASCRUB SWABSTICK									
>A>	+	3M INFECTION	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Nov	CAHN
>D>	+	SOLUMED	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Nov	CAHN

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998	Sep	CMFD
		200MG	A074948	002	Jul 26, 2002	Sep	CMFD

CROMOLYN SODIUM

SPRAY, METERED; NASAL
CROMOLYN SODIUM

	@ ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL
ADVIL PM

>A>	+ PFIZER CONS HLTHCARE	38MG;200MG	N021394	001	Dec 21, 2005	Nov	CAHN
>D>	+ WYETH CONS	38MG;200MG	N021394	001	Dec 21, 2005	Nov	CAHN

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

	MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL
ALLEGRA ALLERGY

	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
	MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	NEWA
	TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
	MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	NEWA
	TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502	008	Apr 12, 2011	Mar	NEWA
MYLAN	60MG	A077081	006	Jul 21, 2011	Jul	NEWA
	180MG	A077081	008	Jul 21, 2011	Jul	NEWA
TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
	180MG	A076447	008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
	180MG	A076502	009	Apr 12, 2011	Mar	NEWA
MYLAN	60MG	A077081	007	Jul 21, 2011	Jul	NEWA
	180MG	A077081	009	Jul 21, 2011	Jul	NEWA
TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
	180MG	A076447	009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011	Jun	NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL
>A> GUAIFENESIN

>A> PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011	Nov	NEWA

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Aug	NEWA

TABLET; ORAL
IBUPROFEN

ADVENT PHARMS	200MG	A076460	001	Nov 26, 2003	Jul	CAHN
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	Aug	CAHN
	200MG	A076460	001	Nov 26, 2003	May	CAHN
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
	200MG	A091239	001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
	200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL
PLAN B

+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL
LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	May	NEWA

LORATADINE

TABLET; ORAL
LORATADINE

MYLAN	10MG	A078447	001	Aug 12, 2011	Aug	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK

@ ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997	Aug	DISC

MINOXIDIL

AEROSOL, FOAM; TOPICAL
MINOXIDIL

PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Apr	NEWA

SOLUTION; TOPICAL
THEROXIDIL

EI INC	2%	A078176	001	Nov 09, 2007	Oct	CAHN
	5%	A076239	001	Aug 24, 2004	Oct	CAHN

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011	Sep	NEWA
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA
RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	May	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	A091349	001	Jul 20, 2011	Jul	NEWA
	EQ 4MG BASE	A091354	001	Jul 20, 2011	Jul	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
ZEGERID OTC

+ MSD CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009	Sep	CAHN

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE

+ BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000	Aug	CAHN

POTASSIUM IODIDE

TABLET; ORAL
IOSAT

ANBEX	65MG	N018664	002	May 12, 2011	Apr	NEWA

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011	Sep	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011	Apr	NEWA
	EQ 150MG BASE	A091429	002	May 11, 2011	Apr	NEWA
SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jun	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2011

NO NOVEMBER 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE - ZYTIGA							
N202379	001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
ADAPALENE - DIFFERIN							
N021753	001	7868044	Mar 12, 2023	U-1078			
ADAPALENE - DIFFERIN							
N022502	001	7998467	May 31, 2028	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N022320	001	7964202	Sep 01, 2024	DP U-1078			
		>A> 8071644	Jul 18, 2027	DP U-1078			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N021747	001	5405084	Apr 11, 2012	DP		NP	Oct 07, 2014
		5472143	Sep 29, 2013	DP			
		5497944	Mar 12, 2013	DP			
		5662271	Sep 02, 2014	DP			
		5911851	Sep 29, 2013	DP			
		5964416	Oct 04, 2016	DP			
		6007676	Sep 29, 2013	DP			
		6149054	Dec 19, 2016	DP			
		6176442	Oct 04, 2016	DP			
		6453795	Dec 05, 2016	DP			
		6503362	Sep 29, 2013	DP			
		6726124	Oct 04, 2016	DP			
		6846413	Aug 28, 2018	DP			
		6977042	Aug 28, 2018	DP			
		6988496	Feb 23, 2020	DP			
		7104470	Oct 04, 2016	DP			
		7246615	May 31, 2016	DP			
		7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP			
		7802568	Feb 26, 2019	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		>A> 7988001	Aug 04, 2021	DP			
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D							
N021762	001	5994329	Jul 17, 2018	U-647	Y		
ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE							
A079013	001					>A> PC	Jan 14, 2012
ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE							
A079014	001					>A> PC	Jan 14, 2012
ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE							
A079054	001					>A> PC	Jan 14, 2012
ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE							
A079056	001					>A> PC	Jan 14, 2012
ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE							
A079057	001					>A> PC	Jan 14, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
AMBRISENTAN - LETAIRIS						
N022081 001	RE42462	Oct 07, 2015	DS			
AMBRISENTAN - LETAIRIS						
N022081 002	RE42462	Oct 07, 2015	DS			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
ARIPIPRAZOLE - ABILIFY						
N021436 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM						
A076477 001					**>A>** PC	May 28, 2012
ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM						
A076477 002					**>A>** PC	May 28, 2012
ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM						
A076477 003					**>A>** PC	May 28, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM						
A076477 004					**>A>** PC	May 28, 2012
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX						
N050797 001	7887844	Feb 14, 2024	DP			
AZTREONAM - CAYSTON						
N050814 001					ODE	Feb 22, 2017
BIMATOPROST - LATISSE						
N022369 001	8017655	Nov 27, 2012	DS DP			
	8038988	Aug 25, 2023	DP			
BIMATOPROST - LUMIGAN						
N021275 001	8017655	Nov 27, 2012	DS DP			
BIMATOPROST - LUMIGAN						
N022184 001	8017655	Nov 27, 2012	DS DP			
BIVALIRUDIN - ANGIOMAX						
N020873 001	5196404	Aug 13, 2012	DS DP U-1040			
	5196404*PED	Feb 13, 2013				
BOCEPREVIR - VICTRELIS						
N202258 001	7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
BRIMONIDINE TARTRATE - ALPHAGAN P						
N021262 001	5424078	Jun 13, 2012		Y		
BRIMONIDINE TARTRATE - ALPHAGAN P						
N021770 001	5424078	Jun 13, 2012	DP	Y		
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 001	7967011	Aug 11, 2021	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 002	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
BUPIVACAINE - EXPAREL						
N022496 001					NP	Oct 28, 2014
BUPIVACAINE - EXPAREL						
N022496 002					NP	Oct 28, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE; NALOXONE - SUBOXONE						
N022410 001	8017150	Sep 10, 2023	DP			
BUPRENORPHINE; NALOXONE - SUBOXONE						
N022410 002	8017150	Sep 10, 2023	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL						
N022497 001	**>A>** 7674479	Jun 25, 2027	DP			
CARBAMAZEPINE - CARBAMAZEPINE						
A076697 003					PC	Nov 16, 2011
CARBAMAZEPINE - CARBATROL						
N020712 001	5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL						
N020712 002	5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL						
N020712 003	5326570	Jul 23, 2011	U-215			
CARGLUMIC ACID - CARBAGLU						
N022562 001					**>A>** ODE	Mar 18, 2017
CELECOXIB - CELEBREX						
N020998 001	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 002	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 003	5760068	Jun 02, 2015	U-672			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS						
N021441 001	7863287	Feb 28, 2027	DP			
CICLOPIROX - LOPROX						
N020519 001	7026337	Nov 21, 2016	U-714			
CICLOPIROX - LOPROX						
N021159 001	7981909	Sep 16, 2017	U-1162			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CLOBAZAM - ONFI						
N202067 001					NCE	Oct 21, 2016
					>A> ODE	Oct 21, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOBAZAM - ONFI								
N202067 002							NCE	Oct 21, 2016
							>A> ODE	Oct 21, 2018
CLOBAZAM - ONFI								
N202067 003							NCE	Oct 21, 2016
							>A> ODE	Oct 21, 2018
CLOBETASOL PROPIONATE - CLOBEX								
N021644 001	>A>	8066975	Jun 17, 2019	DP				
	>A>	8066976	Jun 17, 2019	DP				
CLOPIDOGREL BISULFATE - PLAVIX								
N020839 001		4847265	Nov 17, 2011	DS DP			M-61	May 06, 2014
		4847265*PED	May 17, 2012				PED	Nov 06, 2014
		5576328	Jan 31, 2014		U-432	Y		
		5576328*PED	Jul 31, 2014					
		6429210	Jun 10, 2019	DS DP				
		6429210*PED	Dec 10, 2019					
		6504030	Jun 10, 2019	DS				
		6504030*PED	Dec 10, 2019					
CLOPIDOGREL BISULFATE - PLAVIX								
N020839 002		4847265	Nov 17, 2011	DS DP			M-61	May 06, 2014
		4847265*PED	May 17, 2012				PED	Nov 06, 2014
		6429210	Jun 10, 2019	DS DP				
		6429210*PED	Dec 10, 2019					
		6504030	Jun 10, 2019	DS				
		6504030*PED	Dec 10, 2019					
COLCHICINE - COLCRYS								
N022352 001		7906519	Feb 17, 2029		U-1116			
		7915269	Feb 17, 2029		U-1007			
		7935731	Dec 03, 2028		U-1116			
		7964647	Oct 06, 2028		U-1007			
		7964648	Feb 17, 2029		U-1161			
		7981938	Oct 06, 2028		U-1166			
CORTICOTROPIN - H.P. ACTHAR GEL								
N008372 008							>A> ODE	Oct 15, 2017
CRIZOTINIB - XALKORI								
N202570 001	>A>	7230098	Mar 01, 2025	DS			NCE	Aug 26, 2016
		7825137	May 12, 2027		U-1179		ODE	Aug 26, 2018
		7858643	Oct 08, 2029	DS DP				
CRIZOTINIB - XALKORI								
N202570 002	>A>	7230098	Mar 01, 2025	DS			NCE	Aug 26, 2016
		7825137	May 12, 2027		U-1179		ODE	Aug 26, 2018
		7858643	Oct 08, 2029	DS DP				
CYANOCOBALAMIN - NASCOBAL								
N021642 001		7879349	Jun 01, 2024		DP U-1152			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA								
N022512 001		7866474	Aug 31, 2027		DP			
		7932273	Sep 07, 2025	DS DP				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N022512 002		7866474	Aug 31, 2027	DP			
		7932273	Sep 07, 2025	DS DP			
DALFAMPRIDINE - AMPYRA							
N022250 001		8007826	May 26, 2027	U-1030			
DAPTOMYCIN - CUBICIN							
N021572 001	**>A>**	8058238	Nov 28, 2020	DS DP			
DAPTOMYCIN - CUBICIN							
N021572 002		8003673	Sep 04, 2028	U-1180			
	>A>	8058238	Nov 28, 2020	DS DP			
DARUNAVIR ETHANOLATE - PREZISTA							
N021976 001		5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
		5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
		5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
		5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
		6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
		6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
		6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
		6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
		6335460	Aug 25, 2012	DS DP U-935			
		6335460	Aug 25, 2012	DS DP U-903			
		6335460	Aug 25, 2012	DS DP U-744			
		6335460*PED	Feb 25, 2013				
		6703403	Jun 26, 2016	U-935			
		6703403*PED	Dec 26, 2016				
		7470506	Jun 23, 2019	U-935			
		7470506*PED	Dec 23, 2019				
		7700645	Dec 26, 2026	DS DP			
		7700645*PED	Jun 26, 2027				
	>A>	RE42889	Oct 19, 2016	DP			
	>A>	RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				
DASATINIB - SPRYCEL						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
DASATINIB - SPRYCEL						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
DEFERIPRONE - FERRIPROX						
N021825 001					NCE	Oct 14, 2016
					>A> ODE	Oct 14, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE - OZURDEX						
N022315 001					**>A>** ODE	Sep 24, 2017
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
DICLOFENAC SODIUM - SOLARAZE						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
DIFLUPREDNATE - DUREZOL						
N022212 001	6114319	May 18, 2019	DP			
DORIPENEM - DORIBAX						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
DORIPENEM - DORIBAX						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 001	7915307	Aug 24, 2027	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 002	7915307	Aug 24, 2027	U-620			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N022425 001	5223510	Jul 26, 2012	DS DP U-992			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N021937 001	5922695	Jul 25, 2017	DS U-750			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP U-750			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-750			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-750			
	6043230*PED	Jan 25, 2018				
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 004	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-930			
	7790704	May 24, 2021	U-930			
	7795293	May 21, 2023	U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N202123 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS		U-257	
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP		U-257	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP			
	5977089*PED	Jan 25, 2018			U-257	
	6043230	Jul 25, 2017			U-257	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP		U-257	
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N021752 001	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	DP		U-1170	
	6043230	Jul 25, 2017	DP		U-248	
	6043230	Jul 25, 2017	DP		U-541	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-248	
EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE						
A090870 001					PC	Oct 29, 2011
EPINEPHRINE - EPIPEN						
N019430 001	**>A>** 8048035	Sep 11, 2025	DP			
EPINEPHRINE - EPIPEN JR.						
N019430 002	**>A>** 8048035	Sep 11, 2025	DP			
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 001					NPP	Feb 27, 2011
					PED	Aug 27, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 002					NPP	Feb 27, 2011
					PED	Aug 27, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N022101 001					M-86	Jun 18, 2012
					PED	Dec 18, 2012
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 001	5714504	Feb 03, 2015	DP	U-1053		
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS	U-1053		
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP	U-1053		
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS	U-1053		
	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 002	5714504	Feb 03, 2015	DP	U-1053		
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS	U-1053		
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP	U-1053		
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS	U-1053		
	7411070*PED	Nov 25, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE						
N022262 001	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N021840 001	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
N022573 001	5552394	Jul 22, 2014		U-828		
	6667050	Apr 06, 2019	DP	U-828		
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
A078965 001					PC	Sep 21, 2011
ETRAVIRINE - INTELENCE						
N022187 001	7037917	Dec 13, 2020	DS DP	U-256		
	7037917	Dec 13, 2020	DS DP	U-1016		
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				
EVEROLIMUS - AFINITOR						
N022334 001	5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					ODE	May 05, 2018
					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 002	5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					ODE	May 05, 2018
					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 003	5665772	Sep 09, 2019			I-638	May 05, 2014
					NCE	Mar 30, 2014
					ODE	May 05, 2018
					ODE	Oct 29, 2017
EVEROLIMUS - ZORTRESS						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049			
EXENATIDE SYNTHETIC - BYETTA						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
EXENATIDE SYNTHETIC - BYETTA						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
EZETIMIBE - ZETIA						
N021445 001	5846966	Sep 21, 2013	U-474			
	5846966	Sep 21, 2013	U-473			
	5846966	Sep 21, 2013	U-1172			
	7612058	Jan 25, 2022	U-1173			
	7612058	Jan 25, 2022	U-1027			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
	RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 001	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	002	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	003	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	004	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZOGABINE - POTIGA							
N022345	001					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	002					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	003					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	004					NCE	Jun 10, 2016
FAMCICLOVIR - FAMVIR							
N020363	001					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363	002					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363	003					M-98	Jan 31, 2014
FAMOTIDINE; IBUPROFEN - DUEXIS							
N022519	001	**>A>** 8067033	Jul 18, 2026	DP		NC	Apr 23, 2014
		>A> 8067451	Jul 18, 2026	DP U-1196			
FENOFIBRATE - ANTARA (MICRONIZED)							
N021695	001	7863331	Aug 08, 2020	U-1107			
		7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)							
N021695	003	7863331	Aug 08, 2020	U-1107			
		7863331	Aug 08, 2020	U-1106			
FENOFIBRIC ACID - FIBRICOR							
N022418	001	7915247	Aug 20, 2027	U-1061			
		7915247	Aug 20, 2027	U-1059			
		7915247	Aug 20, 2027	U-1000			
FENOFIBRIC ACID - FIBRICOR							
N022418	002	7915247	Aug 20, 2027	U-1061			
		7915247	Aug 20, 2027	U-1059			
		7915247	Aug 20, 2027	U-1000			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ABSTRAL							
N022510 001		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 002		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 003		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 004		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 005		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 006		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - FENTORA							
N021947 001		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 002		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 003		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 004		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 005		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - LAZANDA							
N022569 001		6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
FENTANYL CITRATE - LAZANDA							
N022569 002	**>A>**	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERUMOXYTOL - FERAHEME						
N022180 001	7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027	DP		U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027	DP		U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 007	5578610	Nov 26, 2013	DS DP		U-1160	
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-1160	
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012			U-1160	
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012			U-1160	
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS		U-1160	
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N021909 003	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N201373 002	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION						
N020786 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017	U-138			
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012	U-138			
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012	U-468			
	7135571	May 18, 2014	DS U-1159			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION						
N021704 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020	DP U-1159			
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018	DP			
FIDAXOMICIN - DIFICID						
N201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027	U-319			
FINGOLIMOD - GILENYA						
N022527 001					M-106	Jul 20, 2014
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA						
N021433 001	6315173	Dec 23, 2017	DP			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N021211 001	7446090	Aug 23, 2019	DP		D-133	Aug 22, 2014
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N021211 002	7446090	Aug 23, 2019	DP		D-133	Aug 22, 2014
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N022023 001	5691336	Mar 04, 2019	DS DP			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N022023 002	5691336	Mar 04, 2019	DS DP			
FOSPROPOFOL DISODIUM - LUSEDRA						
N022244 001	6204257	Aug 07, 2018	DS DP U-945			
	6872838	Aug 07, 2018	DS			
FULVESTRANT - FASLODEX						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
GABAPENTIN - GABAPENTIN						
A078974 001					PC	Aug 22, 2011
GABAPENTIN - GRALISE						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
GABAPENTIN - GRALISE						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN ENACARBIL - HORIZANT						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
	8026279	Nov 10, 2016	DS DP			
	>A> 8048917	Nov 06, 2022	DS DP			
GADOBUTROL - GADAVIST						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 001					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 002					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A079183 001					PC	May 14, 2011
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 001					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 002					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 003					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 004					M-102	Apr 29, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					I-635	Feb 25, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					I-635	Feb 25, 2014
HISTRELIN ACETATE - SUPPRELIN LA						
N022058 001	**>A>** 8062652	Jun 16, 2026	U-1197			
HYDROCORTISONE BUTYRATE - LOCOID						
N022076 001	7981877	Jan 23, 2025	DP			
HYDROXOCOBALAMIN - CYANOKIT						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					ODE	Feb 03, 2018
IBUPROFEN LYSINE - NEOPROFEN						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
ICATIBANT ACETATE - FIRAZYR						
N022150 001	5648333	Jul 15, 2014	DS DP U-1187		NCE	Aug 25, 2016
					ODE	Aug 25, 2018
ILOPERIDONE - FANAPT						
N022192 001	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 002	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 003	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 004	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 005	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 006	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 007	RE39198	Nov 15, 2016	DS DP U-971			
IMIQUIMOD - ZYCLARA						
N022483 001					I-636	Mar 24, 2014
IMIQUIMOD - ZYCLARA						
N022483 002					NS	Jul 15, 2014
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015	U-1125			
	5776894	Jul 07, 2015	DS DP			
INSULIN GLARGINE RECOMBINANT - LANTUS						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N021629 003	7918833	Sep 23, 2027	DP			
INSULIN RECOMBINANT HUMAN - HUMULIN R						
N018780 001					NR	Mar 25, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R PEN						
N018780 005					NR	Mar 25, 2014
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016
IXABEPILONE - IXEMPRA KIT						
N022065 001	6670384	Jan 23, 2022	DP U-960		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
IXABEPILONE - IXEMPRA KIT						
N022065 002	6670384	Jan 23, 2022	DP U-960		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
KETOCONAZOLE - KETOCONAZOLE						
A091550 001					PC	Feb 21, 2012
KETOROLAC TROMETHAMINE - ACULAR LS						
N021528 001	8008338	May 24, 2027	U-1181			

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL ODT						
N022251 001	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 002	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 003	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 004	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL XR						
N022115 001					**>A>** I-644	Apr 25, 2014
LAMOTRIGINE - LAMICTAL XR						
N022115 002					**>A>** I-644	Apr 15, 2014
LAMOTRIGINE - LAMICTAL XR						
N022115 003					**>A>** I-644	Apr 25, 2014
LAMOTRIGINE - LAMICTAL XR						
N022115 004					**>A>** I-644	Apr 25, 2014
LAMOTRIGINE - LAMICTAL XR						
N022115 005					**>A>** I-644	Apr 25, 2014
LAMOTRIGINE - LAMICTAL XR						
N022115 006					**>A>** I-644	Apr 25, 2014
					>A> I-622	Jan 29, 2013
					>A> NDF	May 29, 2012
					>A> PED	Nov 29, 2012
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LENALIDOMIDE - REVLIMID						
N021880 003	7968569	Oct 07, 2023	U-1165			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 002					M-107	Oct 08, 2014
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 005					M-107	Oct 08, 2014
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 006					M-107	Oct 08, 2014
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 007	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 008	5480656	Jan 02, 2013	DP		NP	Aug 15, 2014
	5575987	Sep 02, 2013	DP			
	5631020	May 20, 2014	DP			
	5643607	Jul 01, 2013	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
LEVETIRACETAM - LEVETIRACETAM						
A091093 001					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091093 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091261 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091285 001					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091285 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091291 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091399 001					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091399 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091430 001					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091430 002					PC	Mar 10, 2012
LEVETIRACETAM - LEVETIRACETAM						
A091557 001					PC	Mar 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - LEVETIRACETAM						
A091557 002					PC	Mar 10, 2012
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 001					I-637	Apr 29, 2014
					ODE	Apr 29, 2018
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Apr 29, 2018
					ODE	Mar 07, 2015
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Apr 29, 2018
					ODE	Mar 07, 2015
LINAGLIPTIN - TRADJENTA						
N201280 001	6303661	Apr 24, 2017	U-774		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
LOPINAVIR; RITONAVIR - KALETRA						
N021906 001	8025899	Sep 26, 2027	DP			
	8025899*PED	Mar 26, 2028				
LOPINAVIR; RITONAVIR - KALETRA						
N021906 002	8025899	Sep 26, 2027	DP			
	8025899*PED	Mar 26, 2028				
LOTEPREDNOL ETABONATE - LOTEMAX						
N200738 001					NDF	Apr 15, 2014
					PED	Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
LOVASTATIN; NIACIN - ADVICOR						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
LOVASTATIN; NIACIN - ADVICOR						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUBIPROSTONE - AMITIZA							
N021908	001	8026393	Oct 25, 2027	DP			
LUBIPROSTONE - AMITIZA							
N021908	002	8026393	Oct 25, 2027	DP			
MALATHION - OVIDE							
N018613	001	7977324	Aug 14, 2026	DP			
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N022525	001	**>A>** 8039009	Mar 24, 2029	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N022525	002	**>A>** 8039009	Mar 24, 2029	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N022525	003	**>A>** 8039009	Mar 24, 2029	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N022525	004	**>A>** 8039009	Mar 24, 2029	U-539			
MESALAMINE - LIALDA							
N022000	001					I-640	Jul 14, 2014
METFORMIN HYDROCHLORIDE - FORTAMET							
N021574	001	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - FORTAMET							
N021574	002	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE							
A090692	001					PC	Mar 28, 2012
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE							
A090692	002					PC	Mar 28, 2012
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N022024	001	7919116	Mar 20, 2018	U-973			
		7919116	Mar 20, 2018	U-1120			
		7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N022024	002	7919116	Mar 20, 2018	U-973			
		7919116	Mar 20, 2018	U-1120			
		7959946	Jul 31, 2026	DP			
METHYLNALTREXONE BROMIDE - RELISTOR							
N021964	001	6559158	Nov 03, 2017	U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR							
N021964	002	6559158	Nov 03, 2017	U-1185		NCE	Apr 24, 2013
METRONIDAZOLE - VANDAZOLE							
N021806	001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA							
N022256	001	7888342	Nov 05, 2021	U-882			
		7994220	Sep 19, 2029	U-819			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 001	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	7919483	Feb 28, 2027	U-1078			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014
MONTELUKAST SODIUM - SINGULAIR						
N021409 001	8007830	Oct 24, 2022	DP			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N022428 001	7671070*PED	Mar 29, 2020				
MUPIROCIN CALCIUM - BACTROBAN						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
NALTREXONE - VIVITROL						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N021926 001	8022095	Aug 14, 2017	DP U-867			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N021742 002	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N021742 003	6545040	Dec 17, 2021	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N021742 004	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N021742 005	6545040	Dec 17, 2021	DP U-3			
NELARABINE - ARRANON						
N021877 001	5424295	Jun 13, 2017	DS DP			
NEVIRAPINE - VIRAMUNE XR						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
NIACIN - NIASPAN						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 001	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 002	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 003	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N022068 002	7169791	Jul 04, 2023	DS DP U-836		I-627	Jun 17, 2014
					NCE	Oct 29, 2012
					ODE	Oct 29, 2014
NITROGLYCERIN - RECTIV						
N021359 001	**>A>** 7189761	May 27, 2014	DP U-1198		NP	Jun 21, 2014
OLANZAPINE - ZYPREXA ZYDIS						
N021086 001					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 002					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 003					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 004					NPP	Dec 04, 2012
					PED	Jun 04, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLOPATADINE HYDROCHLORIDE - PATANASE						
N021861 001	7977376	Feb 02, 2023	DP			
	7977376*PED	Aug 02, 2023	DP			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 002	5763483	Dec 27, 2016	DS DP U-1113			
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS DP			
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OXYCODONE HYDROCHLORIDE - OXECTA						
N202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
OXYCODONE HYDROCHLORIDE - OXECTA						
N202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
PACLITAXEL - ABRAXANE						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
PALIPERIDONE - INVEGA						
N021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 003					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE - INVEGA						
N021999 006					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N022264 001	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N022264 002	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N022264 003	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N022264 004	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N022264 005	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
PARICALCITOL - ZEMPLAR						
N020819 001	**>A>** 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
PARICALCITOL - ZEMPLAR						
N020819 002	**>A>** 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
PARICALCITOL - ZEMPLAR						
N021606 001	**>A>** 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
PARICALCITOL - ZEMPLAR						
N021606 002	**>A>** 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
PARICALCITOL - ZEMPLAR						
N021606 003	**>A>** 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE						
A091427 001					PC	Nov 01, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEMETREXED DISODIUM - ALIMTA						
N021462 001					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PEMETREXED DISODIUM - ALIMTA						
N021462 002					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PERFLUTREN - DEFINITY						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N202088 001	6149938	Jul 23, 2018	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N202088 002	6149938	Jul 23, 2018	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PLERIXAFOR - MOZOBIL						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 001					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 002					M-104	May 13, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 003					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 005					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 006					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 007					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 006	7695734	Apr 26, 2028	DP		I-623	Mar 19, 2013
					NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 007	7695734	Apr 26, 2028	DP		I-623	Mar 19, 2013
					NDF	Feb 19, 2013
PRASUGREL HYDROCHLORIDE - EFFIENT						
N022307 001	5288726	Apr 14, 2017	DS DP U-991			
PRASUGREL HYDROCHLORIDE - EFFIENT						
N022307 002	5288726	Apr 14, 2017	DS DP U-991			
RALOXIFENE HYDROCHLORIDE - EVISTA						
N020815 001	8030330	Mar 10, 2017	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001	7169780	Oct 03, 2023	DS DP			
RANOLAZINE - RANEXA						
N021526 001	6369062	May 27, 2019	DP	Y		
RETAPAMULIN - ALTABAX						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
RIBAVIRIN - COPEGUS						
N021511 001					NPP	Aug 09, 2014
RIFAXIMIN - XIFAXAN						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
RIFAXIMIN - XIFAXAN						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RITONAVIR - NORVIR							
N020659 001		5635523	Jul 30, 2013	U-190			
		5635523*PED	Jan 30, 2014				
		5674882	Jul 30, 2013	U-688			
		5674882*PED	Jan 30, 2014				
RITONAVIR - NORVIR							
N020945 001		5635523	Jul 30, 2013	U-347			
		5635523*PED	Jan 30, 2014				
		5674882	Jul 30, 2013	U-895			
		5674882*PED	Jan 30, 2014				
RITONAVIR - NORVIR							
N022417 001		5635523	Jul 30, 2013	U-688			
		5635523*PED	Jan 30, 2014				
		5674882	Jul 30, 2013	U-688			
		5674882*PED	Jan 30, 2014				
RIVAROXABAN - XARELTO							
N022406 001		7157456	Feb 08, 2021	DS DP		NCE	Jul 01, 2016
		7585860	Dec 11, 2020	DS			
		7592339	Dec 11, 2020	U-1167			
RIVAROXABAN - XARELTO							
N202439 001	**>A>**	7157456	Feb 08, 2021	DS DP		**>A>** I-643	Nov 04, 2014
	>A>	7585860	Dec 11, 2020	DS		**>A>** NCE	Jul 01, 2016
	>A>	7592339	Dec 11, 2020	U-1200			
	>A>	7592339	Dec 11, 2020	U-1167			
RIVAROXABAN - XARELTO							
N202439 002	**>A>**	7157456	Feb 08, 2021	DS DP		**>A>** I-643	Nov 04, 2014
	>A>	7585860	Dec 11, 2020	DS		**>A>** NCE	Jul 01, 2016
	>A>	7592339	Dec 11, 2020	U-1200			
	>A>	7592339	Dec 11, 2020	U-1167			
RIZATRIPTAN BENZOATE - MAXALT							
N020864 001		5298520	Jun 29, 2012	U-240			
		5298520*PED	Dec 29, 2012				
		5602162	Feb 11, 2014		Y		
		5602162*PED	Aug 11, 2014				
RIZATRIPTAN BENZOATE - MAXALT							
N020864 002		5298520	Jun 29, 2012	U-240			
		5298520*PED	Dec 29, 2012				
		5602162	Feb 11, 2014		Y		
		5602162*PED	Aug 11, 2014				
RIZATRIPTAN BENZOATE - MAXALT-MLT							
N020865 001		5298520	Jun 29, 2012	U-240			
		5298520*PED	Dec 29, 2012				
		5457895	Oct 01, 2013				
		5457895*PED	Apr 01, 2014				
		5602162	Feb 11, 2014	U-240	Y		
		5602162*PED	Aug 11, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 002	5298520	Jun 29, 2012	U-240			
	5298520*PED	Dec 29, 2012				
	5457895	Oct 01, 2013				
	5457895*PED	Apr 01, 2014				
	5602162	Feb 11, 2014	U-240	Y		
	5602162*PED	Aug 11, 2014				
ROFLUMILAST - DALIRESP						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
ROMIDEPSIN - ISTODAX						
N022393 001	4977138	Jul 06, 2012	DS DP		**>A>** ODE	Jun 16, 2018
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 001	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 002	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 003	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 004	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 005	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 006	7927624	Dec 02, 2021	DP U-20			
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 002	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 003	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 004	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 005	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROTIGOTINE - NEUPRO						
N021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
ROTIGOTINE - NEUPRO						
N021829 003	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
RUFINAMIDE - BANZEL						
N021911 001	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N021911 002	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N021911 003	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE	Nov 14, 2013
					ODE	Nov 14, 2015
RUXOLITINIB PHOSPHATE - JAKAFI						
N202192 001	**>A>** 7598257	Dec 24, 2027	DS DP U-1201		**>A>** NCE	Nov 16, 2016
					>A> ODE	Nov 16, 2018
RUXOLITINIB PHOSPHATE - JAKAFI						
N202192 002	**>A>** 7598257	Dec 24, 2027	DS DP U-1201		**>A>** NCE	Nov 16, 2016
					>A> ODE	Nov 16, 2018
RUXOLITINIB PHOSPHATE - JAKAFI						
N202192 003	**>A>** 7598257	Dec 24, 2027	DS DP U-1201		**>A>** NCE	Nov 16, 2016
					>A> ODE	Nov 16, 2018
RUXOLITINIB PHOSPHATE - JAKAFI						
N202192 004	**>A>** 7598257	Dec 24, 2027	DS DP U-1201		**>A>** NCE	Nov 16, 2016
					>A> ODE	Nov 16, 2018
RUXOLITINIB PHOSPHATE - JAKAFI						
N202192 005	**>A>** 7598257	Dec 24, 2027	DS DP U-1201		**>A>** NCE	Nov 16, 2016
					>A> ODE	Nov 16, 2018
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N022181 001	7947681	Nov 17, 2024	U-1156			
	8003126	Nov 16, 2025				
	>A> 8067416	Nov 17, 2024	U-989			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 001	7951400	Nov 30, 2028	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 002	7951400	Nov 30, 2028	DP			
SEVELAMER CARBONATE - RENVELA						
N022127 001	7985418	Oct 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 001	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 002	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 003	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
SINECATECHINS - VEREGEN						
N021902 001	7858662	Oct 02, 2026	DP U-172			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N201444 001					ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
SORAFENIB TOSYLATE - NEXAVAR						
N021923 001	7897623	Jan 12, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SPINOSAD - NATROBA						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
SUNITINIB MALATE - SUTENT						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
TADALAFIL - CIALIS						
N021368 001	6140329	Jul 11, 2016	DP U-155		I-642	Oct 07, 2014
	6140329	Jul 11, 2016	DP U-1184		I-641	Oct 07, 2014
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
TADALAFIL - CIALIS						
N021368 002					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
TADALAFIL - CIALIS						
N021368 003					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
TADALAFIL - CIALIS						
N021368 004					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 001	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 002	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 003	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 001	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	RE39593	Aug 05, 2022	DS DP U-1178			
TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3						
N019882 001	5573748	Nov 12, 2013	DP			
TELAPREVIR - INCIVEK						
N201917 001					NCE	May 23, 2016
TELBIVUDINE - TYZEKA						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
TELMISARTAN - MICARDIS						
N020850 002	7998953	Jun 06, 2020	U-1177			
	8003679	Oct 06, 2022	U-1176			
TEMSIROLIMUS - TORISEL						
N022088 001	8026276	Jan 20, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001	5922695	Jul 25, 2017	DS U-250		I-569	Aug 11, 2011
	5922695	Jul 25, 2017	DS U-256		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250		PED	Feb 11, 2012
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TESTOSTERONE - ANDRODERM						
N020489 003					NS	Oct 20, 2014
TESTOSTERONE - ANDRODERM						
N020489 004					NS	Oct 20, 2014
TESTOSTERONE - ANDROGEL						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
TESTOSTERONE - AXIRON						
N022504 001	**>A>** 8071075	Feb 19, 2017	DP U-1103			
TESTOSTERONE - FORTESTA						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
TESTOSTERONE - TESTIM						
N021454 001	7935690	Apr 21, 2023	U-1009			
	>A> 8063029	Apr 21, 2023	U-843			
THALIDOMIDE - THALOMID						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
TICAGRELOR - BRILINTA						
N022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
TIGECYCLINE - TYGACIL						
N021821 001	7879828	Feb 05, 2029	DP			
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N021745 001	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N021745 002	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N021745 003	7988998	Oct 27, 2023	DP			
TRANEXAMIC ACID - LYSTEDA						
N022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
TREPROSTINIL SODIUM - REMODULIN						
N021272 001	7999007	Mar 29, 2029	DP U-1174			

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL SODIUM - REMODULIN						
N021272 002	7999007	Mar 29, 2029	DP U-1174			
TREPROSTINIL SODIUM - REMODULIN						
N021272 003	7999007	Mar 29, 2029	DP U-1174			
TREPROSTINIL SODIUM - REMODULIN						
N021272 004	7999007	Mar 29, 2029	DP U-1174			
TRIAMCINOLONE ACETONIDE - NASACORT AQ						
N020468 001	7977045	Jul 03, 2016	DP U-896			
VANDETANIB - VANDETANIB						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VANDETANIB - VANDETANIB						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VARENICLINE TARTRATE - CHANTIX						
N021928 001					M-105	Jul 22, 2014
VARENICLINE TARTRATE - CHANTIX						
N021928 002					M-105	Jul 22, 2014
VEMURAFENIB - ZELBORAF						
N202429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		ODE	Aug 17, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VORINOSTAT - ZOLINZA						
N021991 001	7652069	Mar 04, 2023	DP			
	RE38506	Nov 29, 2012	DS DP			
ZOLEDRONIC ACID - RECLAST						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
	>A> 8052987	Mar 19, 2024	U-1199			
ZOLEDRONIC ACID - ZOMETA						
N021223 003	4939130	Sep 02, 2012	DS DP U-53			
	4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028	DP			
ZOLPIDEM TARTRATE - INTERMEZZO						
N022328 001	**>A>** 7658945	Apr 15, 2027	DP U-1194		**>A>** NP	Nov 23, 2014
	>A> 7682628	Feb 16, 2025	U-1194			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLPIDEM TARTRATE - INTERMEZZO						
N022328 002	**>A>** 7658945	Apr 15, 2027	DP U-1194		**>A>** NP	Nov 23, 2014
	>A> 7682628	Feb 16, 2025	U-1194			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm